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RESUMO 
Este trabalho teve como objetivo estudar o desempenho in vitro do plasma rico em plaquetas (PRP) com 
scaffolds de ácido hialurônico (AH) ou quitosana (CHT) como um scaffold compósito para a proliferação e 
diferenciação osteogênica de células tronco mesenquimais derivadas de tecido adiposo humano (h-
AdMSCs). O PRP é um produto autólogo obtido do sangue total (WB). O ácido hialurônico é um 
glicosaminoglicano e principal componente do fluido sinovial. A quitosana é um polissacarídeo natural 
encontrado principalmente na carapaça de crustáceos. O PRP puro (P-PRP, rico em plaquetas e pobre 
em leucócitos) foi obtido a partir da centrifugação controlada do WB, e ativado com os agonistas soro 
autólogo e cálcio. Os scaffolds foram estruturados em micropartículas ou esponjas, para atender os 
requisitos de formulações injetáveis ou sólidas, respectivamente. Nesse contexto, os seguintes scaffolds 
foram preparados e caracterizados: sólidos porosos (esponjas) de quitosana não estabilizados (PCHTs) e 
estabilizados (SPCHTs); micropartículas de quitosana-tripolifosfato de sódio (iCHT-TPPs); 
micropartículas e esponjas de ácido hialurônico autorreticulado (ACPs) e de ácido hialurônico reticulado 
com 1,4-butanodiol diglicidil éter (HA-BDDE); e esponjas e micropartículas de ACP e CHT (PECs). 
PCHTs foram preparados por congelamento e liofilização de soluções de CHT, variando a concentração 
e as condições de congelamento. As estabilizações foram realizadas pelo tratamento dos PCHTs com 
hidróxido de sódio, série de etanol ou reticulação com tripolifosfato. Os iCHT-TPPs foram preparados por 
reticulação iônica de quitosana com TPP em diferentes razões mássicas. ACPs foram obtidos por 
autoesterificação organocatalisada. HA-BDDE foi preparado por eterificação dos grupos hidroxílicos do 
HA com o epóxido BDDE. PECs foram preparados por reticulação iônica do ACP com a CHT. Para a 
preparação de scaffolds compósitos, P-PRP ativado contendo h-AdMSCs foi imediatamente pipetado 
sobre a superfície dos scaffolds. Os resultados mostraram que os scaffolds não apresentam 
citotoxicidade. Micrografias obtidas por microscopia eletrônica de varredura mostraram compatibilidade 
estrutural com as redes de fibrina formadas no interior dos poros ou na superfície de scaffolds 
compósitos. Os scaffolds compósitos estimularam o crescimento de h-AdMSCs e a diferenciação 
osteogênica. Os scaffolds compósitos também promoveram liberação gradual dos fatores de crescimento 
PDGF-AB e TGF-β1. Assim, concluímos que os scaffolds compósitos estudados neste trabalho são 
promissores para engenharia de tecidos, particularmente para a cicatrização e regeneração óssea, no 
âmbito da medicina regenerativa.  
 
Palavras-chave: Plasma rico em Plaquetas, Scaffolds, Ácido hialurônico, Quitosana, Medicina 
regenerativa. 
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ABSTRACT 
This work aimed to study the in vitro performance of platelet-rich plasma (PRP) with scaffolds of 
hyaluronic acid (HA) and/ or chitosan (CHT) as a composite scaffold for proliferation and osteogenic 
differentiation of human adipose-derived mesenchymal stem cells (h-AdMSCs). The PRP is an autologous 
product obtained from whole blood (WB). Hyaluronic acid is a glycosaminoglycan and the main 
component of the synovial fluid. Chitosan is a natural polysaccharide found mainly in the carapace of 
crustaceans. The pure PRP (P-PRP, rich in platelet and poor in leukocytes) was obtained from controlled 
centrifugation of WB, and activated with the agonists autologous serum and calcium. The scaffolds were 
structured in microparticles or sponges, to comply the requirements of injectable or solid formulations, 
respectively. In this context, the following scaffolds were prepared and characterized: chitosan porous 
solid (sponge) unstabilized (PCHTs) and stabilized (SPCHTs); chitosan-sodium tripolyphosphate 
microparticles (iCHT-TPPs); microparticles and sponges of auto-crosslinked hyaluronic acid (ACPs) and 
of hyaluronic acid crosslinked with 1,4-butanediol diglycidyl ether (HA-BDDE); and microparticles and 
sponges of ACP and CHT (PECs). PCHTs were prepared by freezing and lyophilization of CHT solutions, 
varying the concentration and freezing conditions. Stabilization was performed by treating the PCHTs with 
sodium hydroxide, an ethanol series or by crosslinking with tripolyphosphate. The iCHT-TPPs were 
prepared by ionic crosslinking of chitosan with TPP at different mass ratios. ACPs was prepared by 
organocatalyzed auto-esterification. HA-BDDE was prepared by etherification of the hydroxyl groups of 
HA with the epoxide BDDE. PECs were prepared by ionic crosslinking of ACP with CHT. For the 
preparation of composite scaffolds, activated P-PRP containing h-AdMSCs was immediately pipetted onto 
the surface of the scaffolds. The results showed that the scaffolds do not exhibit cytotoxicity. Micrographs 
obtained by scanning electron microscopy (SEM) showed structural compatibility with fibrin networks 
formed inside the pores or on the surface of scaffolds. The composite scaffolds stimulated the growth of h-
AdMSCs and osteogenic differentiation. Composite scaffolds also promoted gradual release of growth 
factors PDGF-AB and TGF-β1 and osteogenic differentiation. Thus, we conclude that the composite 
scaffolds studied in this work are promising for tissue engineering, particularly for healing and bone 
regeneration in regenerative medicine. 
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CAPÍTULO 1 – INTRODUÇÃO 
 
1.1. Apresentação 
 
O presente trabalho foi redigido na forma de capítulos, contendo uma introdução 
geral (Capítulo 1), o objetivo e uma revisão bibliográfica (Capítulo 2) direcionada para 
os principais fundamentos considerados no desenvolvimento do trabalho.  
O desempenho individual dos scaffolds estudados, assim como as metodologias, 
os resultados e as conclusões específicas estão apresentados na forma de artigos 
científicos submetidos a periódicos internacionais e na forma de uma patente cujo 
abstract também é apresentado em anexo neste trabalho. 
 
CAPÍTULO 3 – PERFORMANCE OF PRP ASSOCIATED WITH POROUS CHITOSAN 
AS A COMPOSITE SCAFFOLD FOR REGENERATIVE MEDICINE (artigo publicado 
em fevereiro de 2015 no periódico The Scientific World Journal). 
 
CAPÍTULO 4 – STABILIZATION OF POROUS CHITOSAN IMPROVES THE 
PERFORMANCE OF ITS ASSOCIATION WITH PLATELET-RICH PLASMA AS A 
COMPOSITE SCAFFOLD (artigo submetido ao periódico Materials Science and 
Engineering C: Materials for Biological Applications). 
 
CAPÍTULO 5 – IN VITRO BIOLOGICAL PERFORMANCE OF INJECTABLE 
CHITOSAN-TRIPOLYPHOSPHATE SCAFFOLDS COMBINED WITH PLATELET-
RICH PLASMA (artigo submetido ao periódico Tissue Engineering and Regenerative 
Medicine). 
 
CAPÍTULO 6 – IMPROVEMENTS IN PLATELET-RICH PLASMA PERFORMANCE BY 
ASSOCIATION WITH MICROPARTICLES OR SPONGES OF AUTO-CROSSLINKED 
HYALURONIC ACID (artigo submetido ao periódico Journal of Applied Polymer 
Science). 
 
CAPÍTULO 7 – THE STRUCTURATION OF HIGH MOLECULAR WEIGHT 
HYALURONIC ACID IN MICROPARTICLES OR SPONGES IMPROVES ITS 
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PERFORMANCE WHEN ASSOCIATED TO PLATELET-RICH PLASMA (artigo 
submetido ao periódico Trends in Biomaterials & Artificial Organs). 
 
CAPÍTULO 8 – STERILIZATION OF AUTO-CROSSLINKED HYALURONIC ACID 
STRUCTURED IN MICROPARTICLES OR SPONGES (artigo submetido ao periódico 
Biotechnology Letters). 
 
ANEXO 1 – COMPOSIÇÃO E FORMULAÇÃO DE SCAFFOLDS DE ÁCIDO 
HIALURÔNICO E QUITOSANA PARA ASSOCIAÇÃO COM PLASMA RICO EM 
PLAQUETAS E SEUS USOS EM TERAPIA REGENERATIVA somente abstract).  
 
O último capítulo (Capítulo 9) apresenta as conclusões gerais comparativas entre 
os desempenhos dos scaffolds e as sugestões para trabalhos futuros.  
 
1.2. Relevância do Trabalho 
 
O aumento da expectativa de vida, o mau funcionamento e/ ou a perda de 
tecidos causados por lesões ou por doenças, têm levado à redução da qualidade de 
vida de muitos pacientes e a um aumento do custo socioeconômico. Mesmo com o 
progresso da engenharia de tecidos e da medicina regenerativa, as terapias atuais 
ainda apresentam inúmeras limitações.  
Assim, o desenvolvimento de matrizes tridimensionais (scaffolds) combinadas 
com diferentes tipos de células e moléculas bioativas com atividades específicas tem se 
tornado uma alternativa atrativa aos tratamentos atuais. 
A obtenção de scaffolds biodegradáveis onde células específicas possam 
crescer e se multiplicar em uma estrutura similar aos tecidos é a base da engenharia de 
tecidos, que constitui um ramo da medicina regenerativa.  
O principal objetivo de um scaffold é mimetizar a matriz extracelular nativa do 
tecido desejado, permitindo adesão, migração, proliferação, diferenciação e 
manutenção do fenótipo celular. Além disso, um scaffold deve ainda promover a 
vascularização e a migração de nutrientes, e possuir taxa de degradação e 
propriedades mecânicas adequadas para suportar a formação do novo tecido (Langer & 
Vacanti, 1993; Hutmacher, 2000; Lin et al., 2009). 
Várias matrizes têm sido empregadas para a proliferação e multiplicação de 
diferentes células progenitoras, incluindo as células-tronco mesenquimais. Entretanto, a 
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maioria destas matrizes não fornece o ambiente biológico adequado para que as 
células possam proliferar e se multiplicar de forma semelhante aos sistemas in vivo. O 
desenvolvimento de um scaffold para cultivo celular que seja mecanicamente estável, 
biocompatível e biodegradável e que possa atender a especificidade das células que 
compõem os diferentes tecidos representa ainda um grande desafio para a engenharia 
de tecidos (George et al., 2008).  
Os polímeros naturais são os materiais mais atraentes para a preparação de 
scaffolds, principalmente devido às suas semelhanças com a matriz extracelular, 
versatilidade química, bom desempenho biológico, e interações celulares específicas 
(Costa-Pinto et al., 2011). 
O plasma rico em plaquetas (PRP) é um concentrado de plaquetas autólogas e 
de outros componentes do plasma capaz de liberar fatores de crescimento (FCs) e 
citocinas utilizadas na regeneração de tecidos (Anitua et al., 2012; Foster et al., 2009). 
O PRP tem sido amplamente utilizado com sucesso na prática clínica da medicina 
regenerativa (Crane & Everts, 2008; Cole et al., 2010). 
Quando ativado com soro autólogo (ser) e CaCl2, o PRP produz a rede de fibrina 
com estrutura semelhante a um gel que suporta a proliferação e diferenciação celular, 
sendo assim um scaffold natural (Marx, 2004).  
O PRP pode ser aplicado em feridas, na forma sólida ou injetável, ou pode ser 
utilizado como um suplemento em cirurgias, para promover hemostasia e acelerar a 
cicatrização através da liberação dos FCs e citocinas (Singh et al., 2014).  
Embora o PRP seja um scaffold natural eficaz, a liberação da maior parte dos 
FCs ocorre dentro da primeira hora após a ativação plaquetária. Além disso, a rede de 
fibrina não apresenta estabilidade mecânica adequada para suportar a formação do 
novo tecido (McCarrel & Fortier, 2009). 
Assim, nossa hipótese é que a associação de PRP com ácido hialurônico (AH) e/ 
ou quitosana (CHT), produza scaffolds compósitos com melhores propriedades físico-
químicas, mecânicas e biológicas, que possam promover a liberação gradual dos FCs e 
estimular a proliferação e a diferenciação celular.  
O AH é um polissacarídeo natural linear composto de repetidas unidades 
dissacarídicas de ácido D-glicurônico (GlcUA) e N-acetilglicosamina (GlcNAc) unidas 
alternadamente por ligações glicosídicas β-1,3 e β-1,4 (Ruhela et al., 2006, Meyer & 
Palmer, 1934). 
As funções e aplicações do AH na engenharia de tecidos e medicina 
regenerativa estão associadas basicamente às suas propriedades biológicas 
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favoráveis, características estruturais, e às possíveis modificações químicas do 
polímero, as quais determinam suas propriedades reológicas, de solubilidade, de 
hidratação e de reconhecimento celular específico.  
Entretanto, a rápida degradação in vivo e as propriedades mecânicas 
inadequadas do AH exigem sua modificação e/ ou estabilização para aplicações na 
medicina em especial na medicina regenerativa. 
Assim, para a preparação de um scaffold compósito de AH com prolongado 
tempo de residência in vivo e melhores propriedades mecânicas em relação ao AH 
nativo, foram utilizados o derivado autorreticulado ACP (auto-crosslinked polymers) 
completamente biocompatível e o derivado reticulado com 1,4-butanodiol diglicidil éter 
(HA-BDDE) que apresenta baixa citotoxicidade em relação a outros agentes reticulante 
disponíveis no mercado. O ACP foi preparado através de reação de autoesterificação 
organocatalisada na qual é formada uma ligação covalente entre os grupos hidroxílicos 
e carboxílicos de uma mesma cadeia e/ ou de cadeias diferentes de AH sem a adição 
de agentes reticulantes tóxicos (Bellini et al., 2001). O HA-BDDE foi preparado por 
reação de eterificação dos grupos hidroxílicos do AH com o epóxido BDDE em meio 
alcalino (Malson & Lindqvist, 1986). 
A quitosana é um polissacarídeo derivado da quitina (copolímeros β-(1→4)-2-
amino 2-desoxi-D-glicose e β-(1→4)-2-acetamida 2-desoxi-D-glicose) encontrada nas 
carapaças de crustáceos marinhos e paredes celulares de alguns fungos (Muzzarelli, 
1973; Berger et al., 2004). 
Propriedades como biodegradabilidade, biocompatibilidade, adesividade, 
capacidade de moldagem em diferentes formas e versatilidade de modificação química 
fazem com que a quitosana seja um biomaterial promissor para diversas aplicações na 
engenharia de tecidos e medicina regenerativa (Adekogbe & Ghanem, 2005; Agnihotri 
et al., 2004). 
A liofilização é a técnica mais empregada para a preparação de scaffolds de 
quitosana. Neste processo, as condições de congelamento induzem a separação de 
fase entre o sal de acetato de quitosana e a fase de cristal de gelo. A remoção de gelo 
por sublimação gera um material poroso, cujo tamanho e orientação dos poros podem 
ser controlados pela variação da temperatura e da taxa de congelamento. Na maioria 
dos casos, estes scaffolds podem conter acetato de quitosana que pode levar ao 
intumescimento e dissolução do scaffold em meio aquoso neutro. Neste caso também é 
necessária modificação ou estabilização, realizadas normalmente por reidratação ou 
reticulação (Shen et al., 2000) com hidróxido de sódio (Madihally & Matthew, 1999; 
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Manjubala et al., 2006), tripolifosfato de sódio (TPP) (Seol et al., 2004; Lee et al., 2000) 
e/ou série de etanol (Nwe et al., 2009, Reis et al., 2008). 
Embora existam inúmeros trabalhos na literatura utilizando scaffolds de AH e 
CHT, combinados ou não, para a regeneração de diferentes tecidos, estudos avaliando 
a performance in vitro destes scaffolds combinados ao PRP ainda são escassos.  
Além disso, os poucos trabalhos existentes na literatura enfatizam as aplicações 
in vitro ou in vivo desses scaffolds, ou simplesmente apresentam as suas aplicações 
clínicas ou a cinética de liberação dos FCs do PRP, sem no entanto, estudar a relação 
estrutura – função ou a combinação dos vértices do triângulo de proliferação celular: 
scaffolds, células e moléculas bioativas (Crane & Everts, 2008).  
Sendo assim, este trabalho se diferencia dos demais da literatura, pois além da 
extensa caracterização físico-química e mecânica dos scaffolds, ele correlaciona essas 
propriedades com as capacidades: condutiva dos scaffolds, indutiva do PRP e gênica 
das células tronco mesenquimais derivadas de tecido adiposo humano (h-AdMSCs) 
baseado no triângulo de proliferação celular. 
Dessa forma, neste trabalho foram preparados e caracterizados scaffolds de AH 
e/ou CHT estruturados em micropartículas ou esponjas, para atender os requisitos de 
formulações injetáveis ou sólidas, respectivamente. Estes scaffolds foram combinados 
com PRP ativado na forma de scaffolds compósitos e avaliados in vitro quanto a 
cinética de liberação de fatores de crescimento (fator de crescimento derivado de 
plaquetas (PDGF-AB) e fator de crescimento transformador β1 (TGF-β1)), proliferação 
de h-AdMSCs e diferenciação osteogênica através do marcador fosfatase alcalina 
(ALP). 
 
1.3. Objetivo 
 
O presente trabalho teve por objetivo estudar o desempenho in vitro do plasma 
rico em plaquetas ativado (aP-PRP) associado ao ácido hialurônico e/ou quitosana 
como um scaffold compósito para a proliferação e diferenciação osteogênica de células 
tronco mesenquimais derivadas de tecido adiposo humano (h-AdMSCs). 
Para atingir o objetivo mencionado, foram realizadas as seguintes etapas: 
 Preparação e caracterização do PRP; 
 Preparação e caracterização de scaffolds porosos sólidos (esponjas) de 
quitosana não estabilizados (PCHTs), variando a concentração de CHT e as 
condições de congelamento; 
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 Preparação e caracterização de scaffolds porosos sólidos (esponjas) de 
quitosana estabilizados (SPCHTs); 
 Preparação e caracterização de scaffolds injetáveis compostos de 
micropartículas de quitosana reticulada com tripolifosfato de sódio (iCHT-TPPs) 
em diferentes razões mássicas; 
 Preparação e caracterização de scaffolds de ácido hialurônico autorreticulado 
(ACPs) estruturados em micropartículas ou em esponjas. 
 Preparação e caracterização de scaffolds de ácido hialurônico reticulado com 
1,4-butanodiol diglicidil éter (HA-BDDE) estruturados em micropartículas ou em 
esponjas. 
 Preparação e caracterização de scaffolds de ACP e CHT (PECs) em diferentes 
razões mássicas, e estruturados em micropartículas ou em esponjas. 
 Avaliação de diferentes processos de esterilização na estabilidade de scaffolds 
de ácido hialurônico autorreticulado (ACPs) estruturados em micropartículas e 
em esponjas. 
 Avaliação da citotoxicidade dos scaffolds; 
 Preparação de scaffolds compósitos de aP-PRP e scaffolds de ácido hialurônico 
e/ou quitosana; 
 Avaliação da cinética de liberação de fatores de crescimentos nos scaffolds 
compósitos; 
 Avaliação in vitro da performance biológica dos scaffolds compósitos quanto a 
proliferação e diferenciação osteogênica de h-AdMSCs. 
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CAPÍTULO 2 – REVISÃO BIBLIOGRÁFICA 
 
2.1. Engenharia de Tecidos e Medicina Regenerativa  
 
O termo medicina regenerativa vem sendo utilizado muitas vezes como sinônimo 
de engenharia de tecidos, embora a medicina regenerativa frequentemente implique na 
utilização de células tronco como fonte de células (Berthiaume et al., 2011). 
Segundo Greenwood et al. (2006), “medicina regenerativa é um campo 
interdisciplinar (Figura 1) de pesquisa e aplicações clínicas, focado no reparo, 
substituição ou regeneração de células, tecidos ou órgãos visando restaurar funções 
prejudicadas por defeitos congênitos, doenças, traumas e envelhecimento e que utiliza 
a combinação de várias abordagens tecnológicas que incluem a utilização de moléculas 
solúveis, terapia gênica, terapia com células-tronco e progenitoras, engenharia de 
tecidos e reprogramação de células e de tecidos”.  
 
 
Figura 1. Disciplinas que contribuem atualmente na medicina regenerativa (Daar & 
Greenwood, 2007). 
Por outro lado, “engenharia de tecidos é definida como um campo interdisciplinar 
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que aplica os princípios da engenharia e de ciências da vida para o desenvolvimento de 
substitutos biológicos que restauram, mantém ou melhoram a função do tecido ou de 
um conjunto de órgãos” (Langer & Vacanti, 1993). Seu objetivo é superar as limitações 
dos tratamentos convencionais com base em transplantes de órgãos.  
A medicina regenerativa e a engenharia de tecidos têm se tornado campos de 
pesquisa promissores e importantes, uma vez que podem oferecer alternativas viáveis 
e menos invasivas para o reparo e regeneração de órgãos e tecidos (Vindigni et al., 
2009).  
A engenharia de tecidos é um campo relativamente novo dentro da medicina 
regenerativa, que utiliza como base o triângulo de proliferação celular proposto por 
Crane & Everts (2008) (Figura 2), o qual é composto pelas capacidades indutiva dos 
fatores de crescimento, condutiva dos scaffolds e gênica das células tronco ou 
progenitoras.  
 
 
Figura 2. Triângulo da proliferação celular (Adaptado de Barnett & Pomeroy, 2007; 
Crane & Everts, 2008). 
 
2.2. Plasma Rico em Plaquetas 
 
2.2.1. Definições 
Plasma rico em plaquetas (PRP) é um produto autólogo, preparado a partir do 
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sangue total, composto por um concentrado de plaquetas, leucócitos e proteínas, 
disperso em uma pequena fração de plasma (Marx et al., 1998; Marx, 2004). 
Plaquetas são fragmentos citoplasmáticos anucleados presentes no sangue e 
produzidos na medula óssea a partir dos megacariócitos. São os menores 
componentes do sangue, e apresentam formato irregular e diâmetro de 2-3 µm. As 
plaquetas contêm um grande número de proteínas, citocinas e outros fatores bioativos, 
tais como fatores de crescimento, que iniciam e regulam aspectos básicos da 
cicatrização de tecidos.  
Leucócitos são as células brancas do sangue, compostos de linfócitos, 
granulócitos e agranulócitos.  
Plasma é a porção fluida do sangue que contém fatores de coagulação e outras 
proteínas e íons.  
A contagem normal de plaquetas no sangue é de 150.000 a 400.000 
plaquetas/μL (Foster et al., 2009, Engebretsen et al., 2010).  
O plasma rico em plaquetas (PRP) contém uma concentração de plaquetas de 
pelo menos 1.000.000 plaquetas/ μL em 5 mL de plasma e está associado com a 
cicatrização. O PRP contém de 1,5 a 7 vezes a concentração de FCs do sangue total e 
é normalmente obtido por centrifugação diferencial (Foster et al., 2009). 
A liberação de fatores de crescimento ocorre após o processo de degranulação 
das plaquetas. As plaquetas são o primeiro tipo celular recrutado para o local da lesão e 
são responsáveis pela ativação da resposta inflamatória inicial do processo de 
cicatrização (Cole et al., 2010). 
Fatores de crescimento (FCs) são mediadores biológicos naturais que exercem 
vários efeitos sobre os processos de reparo e de regeneração. São polipeptídios 
capazes de regular diversos eventos celulares que incluem síntese de DNA, 
quimiotaxia, diferenciação e síntese de matriz extracelular. 
No PRP estes fatores de crescimento incluem 3 isômeros do fator de 
crescimento derivado de plaquetas (PDGF-αα, PDGF-ββ e PDGF-αβ), 2 isômeros do 
fator de crescimento transformador β (TGF-β1 e TGF-β2), o fator de crescimento 
endotelial vascular (VEGF), o fator de crescimento semelhante à insulina (IGF), o fator 
de crescimento de fibroblastos básico (bFGF) e o fator de crescimento epitelial (EGF) 
(Cole et al., 2010; Engebretsen et al., 2010).  
Várias técnicas para a preparação do PRP têm sido utilizadas gerando diferentes 
produtos com diferentes propriedades biológicas e aplicações.  
A classificação mais atual (Figura 3) é a estabelecida por Ehrenfest et al. (2009) 
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de acordo com o conteúdo de leucócitos e de fibrina: plasma rico em plaquetas puro (P-
PRP): plasma rico em plaquetas e leucócitos (L-PRP), fibrina rica em plaquetas pura (P-
PRF) e fibrina rica em plaquetas e leucócitos (L-PRF). 
 
 
Figura 3. Ilustração esquemática da arquitetura da matriz e das células das quatro 
categorias de concentrados de plaquetas classificados segundo Ehrenfest et al. (2009). 
P-PRP=plasma rico em plaquetas puro; L-PRP=plasma rico em plaquetas e leucócitos; 
P-PRF=fibrina rica em plaquetas pura e L-PRF=fibrina rica em plaquetas e leucócitos. 
 
2.2.2. PRP na regeneração de tecidos  
O plasma rico em plaquetas é uma terapia simples, eficiente e minimamente 
invasiva para a obtenção de FCs autólogos. Sendo uma preparação autóloga, o PRP 
tem a vantagem de evitar a transmissão de doenças e o aparecimento de reações 
imunogênicas. 
Mariani et al. (2014) demonstraram que o PRP pode ser utilizado na inibição do 
crescimento bacteriano contra diferentes patógenos, fornecendo proteção adicional 
contra possíveis contaminações bacterianas durante intervenções cirúrgicas. 
Na regeneração de tecidos, o PRP atua como um selante do tecido e como um 
carreador de fatores de crescimento, onde as plaquetas iniciam a regeneração do 
tecido através da liberação local dos FCs via degranulação de seus α-grânulos.  
As plaquetas no PRP são transportadas através de um coágulo, que contém 
moléculas de adesão celular incluindo fibronectina, fibrina e vitronectina. Na 
cicatrização de feridas, este coágulo age como uma matriz condutora ou scaffold 
natural sobre o qual as células aderem e iniciam o processo de cicatrização. 
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As plaquetas atuam no processo de hemostasia, cicatrização de feridas e re-
epitelização. Elas liberam diversos FCs que estimulam a angiogênese, promovendo 
crescimento vascular e proliferação de fibroblastos, que por sua vez proporcionam um 
aumento na síntese de colágeno (Marx, 2004). Além disso, os FCs promovem a 
proliferação celular e influenciam a diferenciação atuando diretamente na reparação e 
regeneração de tecidos (Nguyen et al., 2011) 
Nos estágios iniciais do processo de cicatrização (Figura 4), as plaquetas são 
ativadas na cascata de coagulação via colágeno endógeno, e os fatores de crescimento 
e as citocinas são liberados por estas plaquetas ativadas para auxiliar na cicatrização. 
A sequência de eventos que conduz à formação do novo tecido (quimiotaxia, migração, 
proliferação e diferenciação celular) é regulada pelos fatores de crescimento, muitos 
dos quais estão presentes no PRP (Tsay et al., 2005). 
 
 
Figura 4. Mecanismo de ação do PRP (Mishra et al., 2012). 
O processo de cicatrização, na qual os fatores de crescimento participam, 
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envolve três fases interpostas: (1) a fase inflamatória, (2) a fase de proliferação e (3) a 
fase de maturação e/ ou de remodelação.  
A fase inicial ocorre imediatamente após a lesão e envolve hemostasia e 
recrutamento de mediadores inflamatórios com duração de aproximadamente 1 
semana. A lesão tecidual ativa a ciclooxigenase-2 e leva à vasodilatação. Os FCs 
atraem os macrófagos e fibroblastos. A fase de proliferação permanece durante as 2 
semanas seguintes com formação de matriz extracelular, granulação, contração e 
reepitelização. A fase de remodelagem continua até que a produção de colágeno e do 
tecido de cicatrização seja finalizada. Esta fase pode durar até 1 ano e nela o colágeno 
tipo I substitui os proteoglicanos e a fibronectina para formar uma matriz mais forte com 
maior resistência à tração (Nguyen et al., 2011). 
Embora os mecanismos envolvidos na utilização do PRP ainda não estejam 
completamente elucidados, sua fácil aplicação na prática clínica e seu possível 
resultado benéfico tornam o PRP uma promissora ferramenta para a área médica 
(Alsousou et al., 2009). 
O plasma rico em plaquetas foi utilizado pela primeira vez por Ferrari et al. 
(1987) em cirurgia cardíaca com coração aberto como um componente de transfusão 
autólogo. Inicialmente, o PRP foi utilizado principalmente em cirurgias orais para 
promover a cicatrização do tecido e integração do implante, e controlar hemorragias 
(Anitua, 1999; Marx et al., 1998). Subsequentemente, também foi empregado em outras 
cirurgias incluindo cirurgias nos ombros (Everts et al., 2008), quadris (Everts et al., 
2007), procedimentos nas articulações dos joelhos (Sánchez et al., 2008; Ishida et al., 
2007), reconstrução de ligamentos (Radice et al., 2010) e cicatrização óssea 
(Kawasumi et al., 2008).  
Mais recentemente, o PRP com suas variantes tem sido empregado na forma 
injetável visando a cicatrização de diversos tecidos incluindo pele (Judith et al., 2010; 
Judith et al., 2012), músculos (van Ark et al., 2013), tendões (de Vos et al., 2010; Kaux 
& Crielaard, 2013), cartilagem (Kon et al., 2010; Kon et al., 2011) e osso (Jia et al., 
2011; Jiang et al., 2012).  
 
2.3. Scaffolds 
 
2.3.1. Definições 
Scaffolds são matrizes tridimensionais temporárias que funcionam como a matriz 
extracelular, organizando as células tridimensionalmente e estimulando o crescimento e 
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a formação do tecido desejado (Hutmacher, 2000).  
Os scaffolds são divididos em fluídos (injetáveis) e sólidos (convencionais), e 
podem ser fabricados em diversos formatos, os quais dependem da aplicação desejada 
e do processo de fabricação utilizado: esponjas (Amaral et al., 2006; Manferdini et al., 
2010), hidrogéis (Bhattacharyya et al., 2008, Kim et al., 2010), fibras (Yamane et al., 
2005, Iwasaki et al., 2011), membranas (Mathews et al., 2011; Mucha et al., 2012) 
micro e nano partículas (Cruz et al., 2008; Custódio et al., 2014), tubos (Venkatesan et 
al., 2012) e esferas (Shu & Zhu, 2002).  
Vários processos têm sido desenvolvidos para fabricar diferentes tipos de 
scaffolds entre eles destacam-se: evaporação de solvente/ lixiviação de partículas 
(solvent casting/ particulate leaching) (Mikos et al., 1994); espuma de gás (gas foaming) 
(Nam et al., 2000), liofilização (freeze-drying) (Madihally and Mathew, 1999); 
eletrofiação (electrospinning) (Huang et al., 2003), prototipagem rápida (rapid 
prototyping) (Peltola et al., 2008) e separação de fases termicamente induzida 
(thermally induced phase separation) (Pavia et al., 2008). 
A técnica de processamento escolhida deve obedecer, em termos gerais, aos 
seguintes critérios (Boccaccini et al., 2002):  
 O processo ou produção não deve afetar as propriedades dos materiais, isto é, a 
sua biocompatibilidade ou propriedades físico-químicas;  
 A técnica deve permitir um controle da porosidade, tamanho de poros, sua 
distribuição e interconectividade;  
 Grupos diferentes de matrizes devem exibir variações mínimas nas suas 
propriedades, quando processadas nas mesmas condições.  
As principais características que diferenciam as várias técnicas são a aplicação 
desejada e/ ou o uso de solventes; calor ou pressão; ou a utilização de aditivos 
responsáveis pela geração dos poros (Agrawal & Ray, 2001). 
 
2.3.2. Scaffolds na regeneração de tecidos 
Na engenharia de tecidos e medicina regenerativa, os scaffolds representam a 
capacidade condutiva e podem ser utilizados para transportar as células antes da sua 
implantação in vivo, ou servirem apenas como um material bioativo atraindo as células 
do tecido onde é implantado.  
Além de permitir a adesão e a migração celular dentro do suporte e promover a 
proliferação e a diferenciação celular, o scaffold deve fornecer um ambiente no qual as 
células possam manter seu fenótipo e sintetizar as proteínas e/ou outras moléculas 
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necessárias (Monteiro, 2008).  
 
2.3.3. Propriedades requeridas dos scaffolds 
Scaffolds utilizados em engenharia de tecidos e medicina regenerativa devem 
apresentar propriedades biológicas e físicas compatíveis com as condições fisiológicas 
in vitro e in vivo. Como mencionado anteriormente, a principal função dos scaffolds é 
proporcionar um suporte temporário adequado que permita os processos celulares 
necessários para a regeneração do tecido. Para isso, vários requisitos, dependentes do 
tipo de célula utilizada e do tecido a ser regenerado, devem ser considerados no 
desenvolvimento de scaffolds (Sachlos & Czernuszka, 2003). Os scaffolds devem: 
 Possuir estrutura tridimensional; 
 Possuir poros interconectados e de tamanho apropriado para favorecer a 
integridade e a vascularização do tecido; 
 Possuir porosidade que proporcione elevada área superficial para interação 
célula-scaffold; 
 Ser biodegradável e biocompatível; 
 Não apresentar nenhum componente ou subproduto de sua degradação que 
provoque reações inflamatórias ou tóxicas; 
 Apresentar superfície química que favoreça a adesão, proliferação e 
diferenciação das células; 
 Apresentar propriedades mecânicas adequadas para implantação e 
manipulação; 
 Ter bioatividade satisfatória para explorar o processo de reparação natural do 
tecido; 
 Ser facilmente fabricado em uma variedade de formas e tamanhos. 
Além dos requisitos necessários para a preparação dos scaffolds sólidos, os 
scaffolds fluidos devem apresentar as seguintes propriedades (Hou et al., 2004): 
 Injetabilidade; 
 Solidificação sob condições brandas; 
 Coesividade; 
 Força mecânica e resistência a forças in situ; 
 Possibilidade de incorporação de moléculas bioativas. 
Do ponto de vista clínico, a utilização de scaffolds fluidos é muito interessante, 
pois minimiza o desconforto do paciente, o risco de infecção, a formação de cicatrizes e 
o custo do tratamento já que não requer intervenção cirúrgica para sua implantação 
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(Hou et al., 2004).  
O material fluido pode preencher de forma homogênea o defeito ou ponto de 
reparo, pode incorporar vários agentes terapêuticos, e, finalmente, não exige 
procedimento cirúrgico invasivo para sua implantação (Gutowska et al., 2001). 
Além disso, a alta hidratação destes materiais mimetiza a matriz extracelular 
sendo, portanto, ideais para a proliferação e diferenciação celular. 
 
2.3.4. Materiais utilizados na fabricação de scaffolds 
A seleção dos materiais para a produção dos scaffolds é uma das etapas mais 
importantes e vários materiais têm sido propostos para sua fabricação, entre eles estão 
os metais, os polímeros de origem natural ou de origem sintética, os materiais 
cerâmicos e os compósitos.  
Embora os materiais metálicos e cerâmicos tenham contribuído para muitos 
avanços na área médica, principalmente na substituição de tecidos ortopédicos, eles 
apresentam duas importantes desvantagens para a aplicação em engenharia de 
tecidos: não são biodegradáveis e a processabilidade destes materiais é bastante 
limitada (Liu & Ma, 2004).  
Os polímeros biodegradáveis são considerados os materiais ideais para a 
produção destas matrizes e podem ser divididos em naturais e sintéticos.  
Os polímeros biodegradáveis naturais podem ser obtidos de fontes animais ou 
vegetais. São idênticos ou semelhantes às substâncias já encontradas no corpo e, 
portanto, a probabilidade de toxicidade ou de estimular uma reação inflamatória crônica 
é reduzida. Estes materiais também têm, geralmente, atividade biológica inerente, 
proporcionando assim sinalização para células sem a necessidade de adição de fatores 
exógenos. Eles também são susceptíveis a enzimas presentes no organismo e, 
portanto, são inerentemente biodegradáveis, sendo possível controlar suas taxas de 
degradação através de modificações químicas.  
No entanto, são frequentemente imunogênicos e sua manipulação e/ ou 
processamento são muito mais difíceis que a de polímeros sintéticos devido a sua 
complexidade.  
Além disso, o processo de extração desses materiais a partir de um tecido 
muitas vezes altera sua estrutura natural. Outra desvantagem é a variabilidade natural 
dos materiais derivados de fontes animais (Mann, 2003).  
Assim, a escolha do material para a produção dos scaffolds deve levar em 
consideração as vantagens e desvantagens desses materiais bem como a aplicação 
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pretendida. 
A seguir são apresentadas as principais caraterísticas dos biomateriais, ácido 
hialurônico e quitosana, utilizados neste trabalho para preparar os scaffolds compósitos 
estudados. 
 
2.3.4.1. Ácido hialurônico (AH) 
O AH é um biopolímero viscoelástico linear, composto de repetidas unidades 
dissacarídicas de ácido D-glicurônico (GlcUA) e N-acetilglicosamina (GlcNAc) unidas 
alternadamente por ligações glicosídicas β-1,3 e β-1,4 (Figura 5), encontrado 
naturalmente nos tecidos conjuntivos de mamíferos (Kuo et al., 2000) e produzido por 
bactérias do gênero Streptococcus (Pires et al., 2010). 
Devido a suas propriedades físicas, o AH tem funções no preenchimento de 
espaços, na lubrificação, na absorção de choque e na exclusão de proteínas. Além 
disso, suas propriedades bioquímicas incluem a modulação da resposta inflamatória 
das células, a interação com os proteoglicanos da matriz extracelular e a captura de 
radicais livres (Monheit & Coleman, 2006). Estudos também mostraram que o AH ligado 
a proteínas e a receptores específicos desempenha importante papel na embriogênese, 
na transdução de sinais, na motilidade celular e está ainda associado ao câncer e a 
metástase (Kogan et al., 2007). 
 
 
n = número de repetições de unidades dissacarídicas 
Figura 5. Estrutura molecular do ácido hialurônico.  
 
Sendo assim, o ácido hialurônico tem sido amplamente aplicado nas áreas 
médicas e cosméticas, principalmente em cirurgias oftálmicas (Balazs, 1983); em 
terapias para o controle da artrite (Balazs & Denlinger, 1993), implante de próteses; 
cicatrização de feridas; prevenção de adesão de tecidos (Garg & Hales, 2004) e 
preenchimento dérmico (Holmström & Ricici, 1967). Além disso, devido a suas 
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propriedades físico-químicas e funções biológicas, o ácido hialurônico e seus derivados 
modificados também têm sido amplamente utilizados na administração de fármacos 
(Kim et al., 2005; Hahn et al., 2006) e na engenharia de tecidos (Ohri et al., 2004; West 
et al., 1985). 
As funções e aplicações do ácido hialurônico (AH) estão associadas 
basicamente às suas características estruturais e às possíveis modificações químicas 
do polímero, as quais determinam suas propriedades reológicas, de solubilidade, de 
hidratação e de reconhecimento celular específico. 
O AH é não-imunogênico, biocompatível e biodegradável, e por isso, possui 
diversas aplicações como biomateriais. Entretanto, sua aplicação na preparação de 
scaffolds requer prévia modificação do polímero visando melhorar suas propriedades 
mecânicas e químicas, e principalmente aumentar seu tempo de residência nos tecidos 
(biodisponibilidade). Como o AH natural apresenta um tempo de residência de 1 a 2 
dias e a maioria das aplicações médicas desse biopolímero requer um tempo de 
residência maior, modificações químicas do AH tem se tornado essenciais na 
preparação de produtos para aplicações médicas e cosméticas (Romagnoli & 
Belmontesi, 2008, Monheit & Coleman, 2006). 
A molécula de AH apresenta quatro grupos funcionais que podem ser 
modificados quimicamente: carboxílico, hidroxílico, acetamida e o terminal reduzido do 
polímero (Figura 6). Além disso, as ligações glicosídicas também podem ser 
hidrolisadas para formar cadeias menores ou oligossacarídeos. 
 
 
Figura 6. Grupos de modificação química da molécula de AH: (1) carboxílico, (2) 
hidroxílico, (3) acetamida, (4) Terminal Reduzido do Polímero (Adaptado de Garg & 
Hales, 2004). 
Além das modificações do AH através da adição de moléculas em sua cadeia 
(conjugação), o AH pode também ser modificado através de reticulação.  
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A reticulação do AH fornece moléculas maiores e mais estáveis, com 
biocompatibilidade similar à do AH não modificado. O polímero pode ser reticulado 
através de ligações covalentes irreversíveis (reticulação química), ou através da 
formação de várias ligações iônicas reversíveis (reticulação física). 
A reticulação pode ser realizada através da exposição direta do AH ao agente 
reticulante, ou através da reação de um derivado de AH altamente reativo 
primariamente sintetizado com o agente reticulante em uma reação secundária.  
A maioria dos métodos reportados na literatura para reticular o AH emprega 
reagentes polifuncionais tais como bis-epoxidos, carbodiimidas, dihidrazidas e divinil 
sulfona (Band, 1998). Entretanto, os agentes reticulantes mais comuns normalmente 
apresentam elevada citotoxicidade, a qual limita sua aplicação nas áreas médica e 
cosmética.  
A seguir serão discutidas brevemente as reações de modificações químicas do 
AH utilizadas neste trabalho. 
 
 Modificação do grupo carboxílico por amidação com iodeto de 2-cloro-1-
metilpiridínio (CMPI). Magnani et al. (2000) descreveram a reação de amidação usando 
CMPI como o agente de ativação dos grupos carboxílicos do AH. Esta reação é 
normalmente realizada em dimetilformamida (DMF) ou dimetilsulfóxido (DMSO), um 
solvente orgânico anidro, para minimizar a hidrólise do CMPI. Inicialmente, o 
hialuronato de sódio é convertido no sal de tetrabutilamônio (TBA) para permitir a sua 
solubilização no solvente orgânico. Para formar as ligações cruzadas entre as cadeias 
de AH, CMPI reage com o grupo carboxílico do HA, forma um intermediário piridíneo e 
libera o íon cloreto, o qual é neutralizado pelo tetrabutilamônio. Trietilamina neutraliza o 
íon iodeto liberado (Figura 7). Quando nenhuma amina é adicionada ao meio reacional, 
a esterificação ocorre entre o intermediário AH-CMPI ativado e os grupos hidroxílicos 
de uma mesma cadeia ou de cadeias diferentes de AH, formando uma ligação éster 
entre as cadeias de AH. Neste caso, temos uma reação de autoesterificação na qual é 
formado o derivado autorreticulado de ácido hialurônico (ACP = auto-crosslinked 
polymers) (Della Valle, 1994; Della Valle & Romeo, 1989). Os grupos carboxílicos do 
AH ativados por CMPI também podem reagir com um grupo carboxílico não ativado, 
porém o anidrido resultante é instável e subsequentemente reage com um grupo 
hidroxílico formando a mesma ligação éster. A desvantagem desse método é a 
necessidade de uma etapa adicional para a preparação do TBA-AH e de ter que ser 
realizado em um solvente orgânico que requer um processo de purificação longo. 
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Figura 7.  Preparação de ACP por autoesterificação organocatalisada usando o 
intermediário ativado AH-CPMI (Schanté et al., 2011).  
 
Na reação de autoesterificação organocatalisada é formada uma ligação 
covalente entre os grupos hidroxílicos e carboxílicos de uma mesma cadeia e/ ou de 
cadeias diferentes de AH, formando assim lactonas ou ligações ésteres 
intermoleculares. Nos derivados ACP, os grupos carboxílicos do AH estão 
completamente ou parcialmente esterificados. No caso de ésteres parcialmente 
esterificados, os grupos carboxílicos remanescentes podem ainda ser totalmente ou 
parcialmente esterificados com álcoois mono- ou polivalentes, formando assim grupos 
ésteres externos; podem permanecer livres e/ou serem salinizados com bases 
metálicas ou orgânicas (Bellini et al., 2001). 
A reticulação por autoesterificação da molécula de AH é uma excelente 
alternativa para preparação de derivados reticulados completamente biocompatíveis e 
que apresentam prolongado tempo de residência in vivo e/ ou melhores propriedades 
mecânicas em relação ao AH nativo.  
Embora sejam utilizados compostos orgânicos como os solventes e os 
catalisadores da reação, as etapas de lavagem do produto final mantêm sua 
biocompatibilidade (Bellini et al., 2001, Collins & Birkinshaw, 2007). 
A principal vantagem da formação das ligações ésteres sem a adição de agentes 
reticulantes tóxicos em relação a outros métodos de reticulação é ausência de 
moléculas estranhas inseridas nas cadeias de AH. Sendo assim, durante o processo de 
degradação do ACP in vivo, somente AH nativo é gerado.  
Além disso, o ACP pode ser preparado com vários graus de reticulação, os quais 
permitem adequar suas propriedades para inúmeras aplicações. 
 
 Modificação do grupo hidroxílico por formação de ligações éter utilizando 
epóxidos. Malson & Lindqvist (1986) patentearam a reticulação de AH utilizando 1,4-
butanodiol-diglicidíl éter (BDDE) em uma solução 0.25 M NaOH. A reação consiste da 
abertura do anel epóxido para formar ligações éter com os grupos hidroxílicos do AH 
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(Figura 8). Quando AH é submetido a valores de pH (pH> 13) acima do pKa dos grupos 
hidroxílicos do AH (pKa~10), estes são desprotonados e se tornam mais do 
nucleofílicos que os grupos carboxílicos desprotonados. Os epóxidos, portanto, reagem 
preferencialmente com os grupos hidroxílicos para formar ligações éter.  
No entanto, quando o pH é menor do que o valor de pKa do grupo hidroxílico, 
uma quantidade menor de grupos hidroxílicos é desprotonada e os grupos carboxílicos 
aniônicos tornam-se predominantes, promovendo assim a formação da ligação éster. 
Isto tem sido demonstrado por De Belder & Malson (1986), que realizaram a reticulação 
de AH com BDDE em condições ácidas (pH 2-4,5).  
Atualmente, BDDE é usado na preparação da maioria dos hidrogéis de AH 
reticulados disponíveis no mercado. Além da síntese fácil, a degradação dos produtos 
de AH-BDDE não demonstram citotoxicidade e os compostos epóxidos são hidrolisados 
em dióis simples (Nishi et al., 1995). 
 
 
Figura 8. Ácido hialurônico reticulado com BDDE em meio alcalino (Malson & Lindqvist, 
1986).  
2.3.4.2. Quitosana  
Quitosana (CHT) é um polissacarídeo derivado da quitina (copolímeros β-(1→4)-
2-amino 2-desoxi-D-glicose e β-(1→4)-2-acetamida 2-desoxi-D-glicose), encontrada em 
abundância na natureza, principalmente na carapaça de crustáceos. A quitosana pode 
ser obtida a partir da quitina por meio de desacetilação alcalina, podendo também estar 
naturalmente presente em alguns fungos pertencentes aos gêneros Mucor e 
Zygomicetes (Silva et al., 2006). 
A Figura 9 representa a estrutura química parcial da quitosana. 
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Figura 9. Estrutura molecular da quitosana. 
Os principais parâmetros que influenciam as características da quitosana são a 
sua massa molar (MM) e seu grau de desacetilação (GD), o qual representa o conteúdo 
de unidades desacetiladas. Em geral, o produto N-desacetilado da quitina só passa a 
ser considerado quitosana quando o GD se torna igual ou superior a 60%, percentagem 
a partir da qual o biopolímero se torna solúvel em soluções ácidas diluídas. O grau de 
desacetilação é um parâmetro muito importante, pois é capaz de influenciar as 
características químicas, físicas e biológicas do biopolímero.  
Do ponto de vista químico, o GD da quitosana exerce influência sobre algumas 
de suas propriedades, tais como hidrofilicidade, capacidade de reticulação na presença 
de determinados agentes reticulantes, solubilidade e viscosidade (Gonsalves et al., 
2011).  
Na sua forma cristalina, a quitosana é normalmente insolúvel em solução aquosa 
acima de pH 7, no entanto, em ácidos diluídos (pH<6.0), os grupos amino livres 
protonados da glicosamina facilitam a solubilidade da molécula (Madihally & Matthew, 
1999). 
Nos últimos anos, pesquisadores das áreas médica e farmacêutica têm 
demonstrado grande interesse na utilização de quitosana devido principalmente a suas 
propriedades intrínsecas. A quitosana é um polímero biocompatível, devido à sua 
metabolização por certas enzimas humanas como a lisozima, sendo considerado, 
portanto, biodegradável (Nordtveit et al., 1996; Muzzarelli, 1997). Além disso, devido à 
sua carga positiva em pH fisiológico, a quitosana é também bioadesiva (He et al., 1998; 
Calvo et al., 1997; Bertram & Bodmeier, 2006), o que aumenta sua retenção no local da 
aplicação. A quitosana também promove a cicatrização de feridas (Antonov et al., 2008; 
Dai et al., 2011) e tem efeito antimicrobiano (Muzzarelli et al., 1990; Liu et al., 2001; Li 
et al., 2013). Finalmente, a quitina é muito abundante, e a produção da quitosana é de 
baixo custo e ecologicamente interessante (Berger et al., 2004).  
Além destas propriedades, estudos recentes mostraram que a quitosana e seus 
derivados são candidatos promissores a scaffolds principalmente devido à facilidade de 
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modificação química, possibilidade de ser moldada em várias formas (membranas, géis, 
esferas, esponjas, micro- e nanopartículas) e à sua elevada afinidade às 
macromoléculas in vivo. 
A versatilidade química da quitosana resulta principalmente da presença dos 
grupos amino em sua estrutura. Apesar da maioria das modificações químicas da 
quitosana ocorrer em seus grupos amino C-2, as hidroxilas em C-3 e C-6 das unidades 
estruturais do biopolímero também são susceptíveis a reações.  
A natureza química da quitosana fornece possibilidades para as modificações 
covalentes e iônicas, as quais também permitem a modulação das propriedades 
mecânicas e biológicas dos biomateriais produzidos, ampliando seu espectro de 
aplicação na engenharia de tecidos e medicina regenerativa. (Gonsalves et al., 2011). 
 
2.3.4.3. Complexos Polieletrolíticos de Ácido Hialurônico e Quitosana  
Complexos polieletrolíticos (PECs) são complexos poliméricos formados pela 
reação entre polímeros de cargas opostas. A formação e as propriedades dos PECs 
dependem da razão das cargas aniônicas e catiônicas dos polímeros, do grau de 
neutralização, da força iônica e da valência dos íons na solução eletrolítica. Os PECs 
preparados a partir polímeros naturais, tais como ácido hialurônico e quitosana, têm a 
vantagem de serem não tóxicos e bioabsorvíveis (Kim et al., 2004a; Kim et al., 2004b). 
Como dito anteriormente, o ácido hialurônico tem sido amplamente utilizado 
como scaffolds na cicatrização de feridas e na regeneração de tecidos, entretanto, a 
elevada densidade de cargas negativas do AH pode reduzir a adesão celular e interferir 
nos processos biológicos envolvidos na regeneração tecidual limitando sua aplicação 
(Ren et al., 2005; Correia et al., 2011). Uma boa alternativa para contornar esta 
limitação é combinar o AH com policátions tais como a quitosana.  
Testes in vitro mostraram que os PECs formados de CHT e AH podem ser 
utilizados como um material de suporte para o transplante de condrócitos autólogos e/ 
ou como scaffolds para a engenharia de tecidos, principalmente de tecidos da 
cartilagem (Sechriest et al., 1999). 
Correia et al. (2011) prepararam scaffolds de CHT com diferentes concentrações 
de AH (1, 5, 10%) por liofilização. Os scaffolds de CHT-AH não apresentaram 
citotoxicidade e promoveram adesão celular. Além disso, a incorporação de AH até uma 
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concentração de 5% melhorou as propriedades físico-químicas e biológicas dos 
scaffolds de CHT, favorecendo a adesão de condrócitos, proliferação celular e a 
produção de cartilagem, quando comparados aos scaffolds de CHT e a outras razões 
CHT-AH. 
Scaffolds porosos de AH e CHT foram preparados por Coimbra et al. (2011) 
visando regeneração de polpa dentária. Estudos in vitro mostraram que as células 
tronco mesenquimais (MSCs) aderiram e proliferaram sobre a superfície do scaffold, o 
que demonstrou a biocompatibilidade e não citotoxicidade do biomaterial.  
Majima et al. (2007) prepararam fibras de CHT com 0,1 % de ácido hialurônico 
que foram utilizadas como scaffolds para a engenharia de tecidos de ligamentos e 
tendões. Ensaios in vivo mostraram baixa toxicidade e baixa indução da inflamação. 
Além disso, ensaios in vivo mostraram que as propriedades mecânicas do ligamento ou 
do tendão engenheirado podem conferir maior estabilização das articulações.  
Lee et al. (2003) prepararam esponjas de AH-CHT em vários pHs por liofilização 
e avaliaram seu efeito de cicatrização de feridas na pele de ratos Wistar com ou sem o 
agente antimicrobiano sulfadiazina de prata. Os resultados mostraram a proliferação de 
fibroblastos na ferida e uma redução significativa de agentes infecciosos.  
 
2.4. Células Tronco Mesenquimais  
 
Células tronco mesenquimais são células indiferenciadas tradicionalmente 
encontradas na medula óssea. No entanto, as MSCs podem também ser isoladas a 
partir de outros tecidos, incluindo o tecido adiposo (h-AdMSCs).  
Atualmente, as h-AdMSCs são as células mais utilizadas na medicina 
regenerativa devido principalmente à facilidade de obtenção de grandes quantidades de 
células. 
As h-AdMSCs podem ser facilmente obtidas através de lipoaspiração, que é um 
método mais barato e menos invasivo que o procedimento de punção realizado para a 
obtenção das MSCs derivadas da medula óssea.  
Além disso, a frequência de h-AdMSCs no tecido adiposo (5000 células/g de 
gordura) é muito maior em relação às MSCs da medula óssea (100-1000 células/g) 
(Chavez-Munoz et al., 2013; Lin et al., 2008). 
Morfologicamente, as h-AdMSCs são fibroblastoides, com formato fusiforme. 
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Quando submetidas a diferentes estímulos, as h-AdMSCs apresentam potencial 
para se diferenciarem, in vitro ou in vivo, em células de tecidos mesodérmicos, como os 
adipócitos, as cartilagens, os ossos e o músculo esquelético; e não mesodérmicos, 
como os hepatócitos, as células pancreáticas endócrinas, os neurônios, os hepatócitos 
e as células endoteliais vasculares, possibilitando assim um vasto campo de aplicações 
na medicina regenerativa (Yarak & Okamoto, 2010) 
As h-AdMSCs também compartilham algumas características importantes das 
MSCs adultas, incluindo plasticidade, alto potencial proliferativo, capacidade de secretar 
moléculas protetoras bioativas e capacidade para modular a resposta imune (Bailey et 
al., 2010).  
Apesar das h-AdMSCs e PRP apresentarem propriedades benéficas para os 
processos celulares utilizados na regeneração de tecidos, estudos utilizando a 
combinação de h-AdMSCs e PRP ainda são escassos.  
A seguir são citados os principais trabalhos da literatura utilizando a combinação 
de PRP e h-AdMSCs, sem a presença de scaffolds. 
Baseados na avaliação clínica por ultrassonografia, Guercio et al. (2014) 
verificaram que a combinação de PRP e AdMSCs é uma terapia promissora para o 
tratamento de lesões em tendões de cavalos de competição.  
Pak et al. (2013) mostraram que terapias com h-AdMSCs/ PRP podem ser 
consideradas seguras quando utilizadas na forma de injeções percutâneas locais para o 
tratamento de diferentes condições ortopédicas.  
Em estudos realizados por van Pham et al. (2013), PRP promoveu a proliferação 
de h-AdMSCs e a diferenciação condrogênica. Além disso, estes autores observaram 
que PRP combinado com h-AdMSCs melhorou a cicatrização da cartilagem das 
articulações em modelos murinos quando comparados com PRP sem a presença de 
células. 
O efeito da liberação de FC do PRP e de BMP-2 (proteína morfogênica óssea) 
encapsulada em microesferas na proliferação e diferenciação osteogênica de h-
AdMSCs foi verificado por Chen et al. (2012). Para isso, estes autores prepararam 5 
compósitos: h-AdMSCs/ plasma pobre em plaquetas (PPP); h-AdMSCs/ PRP; BMP-2/ 
PPP; h-AdMSCs/BMP/PRP e h-AdMSCs/ BMP-2/ PPP. Os resultados mostraram que a 
liberação controlada de BMP-2 em combinação com o PRP é melhor do que uma única 
administração de PRP ou de BMP-2 na diferenciação osteogênica de h-AdMSCs. 
Kakudo et al. (2008) verificaram que concentrações menores que 20% de PRP 
ativado promovem significantemente a proliferação de h-AdMSCs. 
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2.5. Scaffolds Compósitos 
 
Embora o PRP seja uma fonte de FCs plaquetários, a liberação da maior parte 
desses fatores de crescimento ocorre dentro da primeira hora após a ativação 
plaquetária, apesar da liberação continuar durante todo o período de viabilidade das 
plaquetas (7 dias) (McCarrel & Fortier, 2009) 
Hokugo et al. (2005) mostraram que nenhuma regeneração óssea foi observada 
com o tratamento usando PRP livre, devido a sua rápida excreção do sítio de aplicação. 
Além disso, segundo Rossi et al. (2013), a eficácia dos FCs no processo de 
regeneração depende também da forma como esses FCs são disponibilizados no 
tecido lesionado.  
Assim, a liberação gradual dos FCs tem sido considerada benéfica nas terapias 
utilizando PRP.  
Em adição, na preparação do PRP, ocorre a formação de uma rede de fibrina, 
scaffold natural, decorrente da ativação das plaquetas e decomposição do fibrinogênio. 
No entanto, a rede de fibrina formada é frágil e possui viscoelasticidade e viscosidade 
limitadas pelo endurecimento das fibras sob altos níveis de cisalhamento, além de 
sofrer degradação rápida no meio biológico. 
Para proteger os FCs contra proteólise, prolongando assim sua atividade in vivo 
e melhorar a estabilidade da rede de fibrina do PRP, Tabata (2003) sugeriu combinar as 
funções dos scaffolds com a tecnologia de liberação controlada. 
Entretanto, trabalhos utilizando PRP associado a scaffolds visando potencializar 
a utilização dos FCs do PRP ainda são escassos.  
O desenvolvimento de scaffolds adequados para a utilização eficaz do PRP é 
ainda um grande desafio para a engenharia de tecidos.  
Embora vários trabalhos tenham descrito as propriedades físico-químicas, 
mecânicas e biológicas, e/ou as aplicações clínicas de diferentes scaffolds de quitosana 
e ácido hialurônico, ainda existem poucos trabalhos usando a combinação desses 
scaffolds com PRP, ou seja, utilizando scaffolds compósitos.  
Além disso, somente o trabalho descrito por Rossi et al. (2013) utilizou os três 
vértices da proliferação celular, usando scaffolds de quitosana, PRP e fibroblastos 
como fonte de células.  
Os principais trabalhos da literatura que descrevem a utilização de scaffolds 
compósitos de AH e CHT, que foram utilizados como base para este trabalho são 
descritos a seguir.  
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Ouyang et al. (2013) patentearam diferentes scaffolds compósitos de quitosana 
solúvel combinada com PRP para a reparação de tecidos, usando trombina e/ ou CaCl2 
como agonistas.  
Esponjas de glutamato de quitosana e de hialuronato de sódio combinadas com 
lisado de plaquetas e preparadas por liofilização utilizando glicina como crioprotetor, 
foram usadas por Rossi et al. (2013) como matrizes para a incorporação de FCs 
derivados do PRP. Os resultados de crescimento celular para fibroblastos obtidos para 
as esponjas de CHT e de AH foram similares aos valores encontrados para o lisado de 
plaquetas fresco.  
Kutlu et al. (2012) prepararam compósitos de quitosana/ PRP por 2 métodos 
diferentes: PRP foi adicionado ao gel de quitosana antes da liofilização e PRP foi 
embebido no scaffold liofilizado. Estes autores demonstraram que scaffolds de 
quitosana, especialmente na forma de géis, podem ser apropriados carreadores para o 
PRP fornecendo liberação controlada dos fatores de crescimento.  
Uma terapia de etapa única para o tratamento de defeitos osteocondrais de 
coelhos utilizando fragmentos autólogos de cartilagem e scaffolds compostos de ácido 
hialurônico (AH), cola de fibrina humana e PRP foi proposta por Marmotti et al. (2012). 
Esses autores observaram que os fragmentos de cartilagem autólogos em AH/ cola de 
fibrina/ PRP fornecem uma fonte eficiente de células e permitem uma melhor reparação 
do defeito. A cola de fibrina, no entanto, dificultou o processo de cicatrização nos 
coelhos.  
Fathi (2012) demonstrou que a utilização de PRP sozinho ou em combinação 
com AH acelerou a cicatrização de feridas em coelhos adultos comparado ao AH livre 
usado como controle. 
A eficácia do uso de PRP e da viscossuplementação com injeções intra-
articulares de AH para o tratamento de lesões degenerativas da cartilagem do joelho e 
osteoartrite foram comparadas por Kon et al. (2011). Injeções autólogas de PRP 
mostraram maior eficácia e maior duração que as injeções de AH na redução da dor e 
dos sintomas; e recuperação da função articular. Melhores resultados foram 
conseguidos em pacientes mais jovens e em degenerações da cartilagem menos 
intensas, enquanto que um pior resultado foi obtido em articulações mais degeneradas 
e em pacientes mais idosos, em quem os resultados foram semelhantes aos da 
viscossuplementação. 
He et al. (2010) estudaram a ativação e a adesão plaquetária em scaffolds de 
quitosana e quitosana-heparina combinados com PRP. Eles observaram, in vitro, que 
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os scaffolds de quitosana-heparina quando combinados com PRP apresentam 
supressão da adesão e ativação das plaquetas em relação com os scaffolds de 
quitosana/PRP. 
O efeito de PRP, de esponjas de quitosana e da combinação deles, na 
regeneração óssea de defeitos cranianos de coelhos foi investigado por Oktay et al. 
(2010). Para isso, eles criaram e enxertaram 4 defeitos cranianos, com um diâmetro de 
4,5 mm com os 3 grupos. Os coelhos foram mortos entre a quarta e oitava semana, e 
os defeitos foram analisados histologicamente. Maior formação óssea foi observada no 
grupo contendo PRP com preenchimento completo do defeito com osso trabecular. Os 
defeitos que foram preenchidos somente com esponjas de quitosana mostraram uma 
quantidade limitada de osso, e a presença de tecido fibroso.  
Uma nova abordagem terapêutica para estimular a regeneração de feridas 
complexas em membros inferiores, com base em um tratamento composto de PRP e 
curativo de AH foi avaliada por Cervelli et al. (2011). Após um único tratamento, os 
autores observaram que o tempo médio de re-epitelização foi de 8,1 semanas em 
73,3% dos pacientes tratados com o PRP-AH versus 30% dos pacientes tratados 
apenas com AH. 
Um compósito injetável de fosfato tricálcico/ quitosana (FTC/CHT) e PRP para a 
reconstrução de defeitos de tíbias de cabras foi preparado por Bi et al. (2010). Esses 
autores mostraram que a adição de PRP aumentou a biocompatibilidade e a 
osteocondutividade do FTC/CHT sem comprometer sua força mecânica e injetabilidade. 
Chang et al. (2009) mostraram que compósitos preparados pela associação de 
PRP ativado e microesferas de CaSO4/ quitosana, preparadas utilizando campo 
eletrostático de alta tensão, melhoraram a regeneração óssea em torno dos alvéolos 
orais de porcos.  
A possibilidade de utilizar quitosana como substituto da trombina durante a 
preparação PRP foi avaliada por Shen et al. (2006). Os resultados obtidos por estes 
autores mostraram aumento na adesão e da agregação de plaquetas, além de maiores 
concentrações de fatores de crescimento do PRP após utilização da quitosana, 
sugerindo que quitosana e/ ou seus derivados podem substituir a trombina em 
preparações do PRP. 
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Abstract. This study aimed to evaluate the in vitro performance of activated platelet-rich 
plasma associated with porous sponges of chitosan as a composite scaffold for 
proliferation and osteogenic differentiation of human adipose tissue-derived 
mesenchymal stem cells. The sponges were prepared by controlled freezing (−20, −80, 
or −196°C) and lyophilization of chitosan solutions (1, 2, or 3% w/v). The platelet-rich 
plasma was obtained from controlled centrifugation of whole blood and activated with 
calcium and autologous serum. The composite scaffolds were prepared by embedding 
the sponges with the activated platelet-rich plasma. The results showed the 
performance of the scaffolds was superior to that of activated platelet-rich plasma alone, 
in terms of delaying the release of growth factors and increased proliferation of the stem 
cells. The best preparation conditions of chitosan composite scaffolds that coordinated 
the physicochemical and mechanical properties and cell proliferation were 3% (w/v) 
chitosan and a −20°C freezing temperature, while −196°C favored osteogenic 
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differentiation. Although the composite scaffolds are promising for regenerative 
medicine, the structures require stabilization to prevent the collapse observed after five 
days. 
 
3.1. Introduction 
 
In tissue engineering, a scaffold is a three-dimensional matrix for the stimulation 
of cell proliferation and the formation of new tissue. To achieve this goal, scaffolds must 
meet some specific requirements such as mimicking the native extracellular matrix 
(ECM) of the target tissue; allowing cell attachment, migration, proliferation, and 
differentiation and maintenance of the target phenotype; promoting vascularization and 
nutrient delivery; and having a biodegradation rate and mechanical properties that are 
adequate to support the formation of the new tissue (Langer & Vacanti, 1993). 
According to Crane & Everts (2008), tissue regeneration is based on a 
proliferation triangle composed of the three fundamental elements: cells, growth factors 
(GFs) and scaffolds, which are in a close relationship through their capabilities. Thus, 
scaffolds provide the conductive matrix for supporting the genic capability of progenitor 
cells mediated by the inductive capability of GFs (Chen et al., 2002). Optimal conditions 
for tissue regeneration must come from the interaction of the properties of those 
elements. 
The cell responses to the surface chemistry of scaffolds depend on their 
hydrophobicity, protein adsorption, surface charge, and roughness, softness, and 
stiffness. Additionally, the porous architecture characterized by the pore size, porosity, 
connectivity, and tortuosity plays important roles, as described and discussed by Chang 
& Wang (2011). Therefore, bringing together all these properties in solid scaffolds is an 
enormous technological challenge.  
The fibrin matrix is the natural scaffold formed from the coagulation cascade in 
the healing process. Under injury, thrombin cleaves the soluble plasma protein 
fibrinogen into peptide fragments, yielding insoluble fibrin peptides that aggregate and 
form fibrils. A fibrin network is then formed, which entraps platelets and other blood 
components (Bensaïd et al., 2003; Weisel & Nagaswami, 1992). Calcium acts as a 
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cofactor of thrombin, modulates the elongation of fibers during polymerization by 
promoting lateral branching, and functions in clot stability (Falvo et al., 2010; Ryan et al., 
1999). Calcium and thrombin also activate platelets, allowing the release of GFs and 
cytokines. Therefore, the fibrin matrix provides an optimized medium for cell proliferation 
and healing.  
Based on these features, platelet-rich plasma (PRP) has been widely used in 
regenerative medicine. PRP is an autologous product prepared from whole blood by 
separating the red blood cells and concentrating the platelets and other components of 
plasma. However, although viscoelastic, the fibrin matrix alone lacks stability to be 
efficient when regenerative medicine is the goal.  
To mimic the natural healing process and improve the stability of the fibrin matrix, 
we propose in this work the use of the fibrin network from activated PRP with porous 
chitosan as a composite scaffold for tissue regeneration.  
Our hypothesis is that the chemical nature of the chitosan surface supports the 
fibrin network by electrostatic attachment, thus prolonging its stability, without changing 
the paracrine affinity of mesenchymal cells to fibrin fibers. As a consequence, the 
composite scaffold must improve cell proliferation and tissue differentiation compared to 
PRP alone.  
Related works showed the effects of chitosan on blood coagulation through the 
strong adhesion of platelets to the surface of chitosan particles, as well as chitosan 
(0.1–1mg/mL) incorporated with PRP to enhance the release of PDGF-AB and TGF-𝛽1 
from platelets (Kojima et al., 2004; Okamoto et al., 2003). Shen et al. (2006) 
demonstrated that chitosan could be an appropriate substitute for thrombin, as an 
agonist in PRP preparation. Chang et al. (2009) showed that growth factors could 
sustain release until 12 h at approximately 1 ng/mL from chitosan/CaSO4/PRP 
microspheres after activation with thrombin. Kutlu et al. (2012) showed that scaffolds 
prepared by the freeze-drying of PRP added to chitosan gel (2% w/v) were more 
effective than chitosan sponges soaked with PRP on controlled GF release. Oktay et al. 
(2010) applied PRP-embedded chitosan sponges to defects and showed a histological 
tendency toward increased bone formation. Mathews et al. (2011) demonstrated that 
chitosan enhanced mineralization by upregulating the genes associated with 
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mineralization and calcium-binding proteins.  
Chitosan is a polysaccharide derived from chitin (copolymers β-(1→4)-2-amino-2-
deoxy-D-glucose and β-(1→4)-2-acetamido 2-deoxy-D-glucose) found in the shells of 
marine crustaceans and insects and the cell walls of some fungi (Muzzarelli, 1973; 
Berger et al., 2004).  
In the last ten years, considerable attention has been given to chitosan-based 
materials in the field of tissue engineering (Nwe et al., 2009; Martins et al., 2014). The 
beneficial properties of chitosan have been proven, such as biodegradability (Nordtveit 
et al., 1996; Koga, 1998), biocompatibility (Molinaro et al., 2002; Rücker et al., 2006), 
antibacterial activity (Muzzarelli et al., 1990; Li et al., 2013), cell adhesion (He et al., 
1998; Bertram & Bodmeier, 2006), and wound healing properties (Antonov et al., 2008; 
Dai et al., 2011). Moreover, the chemical nature of chitosan gives many possibilities for 
ionic and covalent modifications that allow for the modulation of the mechanical and 
biological properties of biomaterials (Agnihotri et al., 2004; Adekogbe & Ghanem, 2005).  
Regarding the technological aspects, chitosan can be easily processed in diverse 
forms in the absence of toxic solvents, such as films (Mucha et al., 2012), sponges 
(Madihally & Matthew, 1999; Amaral et al., 2006), fibers (Majima et al., 2007), beads 
(Shu & Zhu, 2002), hydrogels (Tan et al., 2009), and microparticles/nanoparticles 
(Lavertu et al., 2006). Furthermore, chitosan supports sterilization (Rao & Sharma, 
1995), is abundant in nature, and requires only low-cost processing in nonaggressive 
ecological conditions before being used as a raw material (Berger et al., 2004).  
Freeze-drying is the most common and simplest method to produce porous 
chitosan scaffolds. The freezing process provides the nucleation of ice crystals from 
solution and further growth along the lines of thermal gradients. Exclusion of the 
chitosan acetate salt from the ice crystal phase and subsequent ice removal by 
lyophilization generate a porous material (Cardea et al., 2010; Costa-Pinto et al., 2011).  
Madihally & Matthew (1999) reported that the pore size of chitosan scaffolds 
produced by lyophilization can be controlled within the range of 1–250 𝜇m. A more 
uniform and interconnected pore structure can be obtained when lower freezing 
temperatures are used. Furthermore, the pore orientation is related to the geometry of 
the moldings used and can also be controlled by changing thermal gradients during 
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freezing (Shen et al., 2000).  
The microstructure, crystallinity, and mechanical strength of the porous chitosan 
matrix also can be controlled by the chitosan concentration, molecular weight, and 
deacetylation degree (Madihally & Matthew, 1999; Nettles et al., 2002).  
In this work, the effects of PRP association were studied regarding to the porous 
structure of solid sponges, which were produced by varying chitosan concentration and 
freezing conditions. The biological performance of association was evaluated in terms of 
growth factor release kinetics, proliferation, and osteogenic differentiation of seeded 
human adipose tissue-derived mesenchymal stem cells (h-AdMSCs). 
 
3.2. Experimental 
 
3.2.1. Materials 
Chitosan (average molecular weight [Mw] = 4 × 105 Da, degree of deacetylation = 
83± 4%) was purchased from Polymar (Fortaleza, CE, Brazil) and purified according to 
the protocol described by Nasti et al. (2009). Other chemicals were of reagent grade and 
were used without any further purification. All biological experiments were performed 
with human adipose tissue-derived stem mesenchymal cells (h-AdMSCs) and approved 
by the Ethics Committee of the Medical Sciences School of the University of Campinas 
(UNICAMP; CAAE: 0972.0.146.000-11). The donors were healthy individuals aged 
between 30 and 40 years old who were previously assessed through clinical 
examinations. 
 
3.2.2. Methods 
3.2.2.1. Preparation of Porous Chitosan Scaffolds (PCHTs) 
PCHTs were prepared by freezing at a controlled temperature of a chitosan 
solution previously poured in 24-well culture plates (TPP, polystyrene, diameter = 15.4 
mm) to give them a cylindrical shape, followed by lyophilizing in lyophilizer L101 
(Liobras, São Carlos, SP, Brazil) at a temperature of approximately −30°C for 48 hours.  
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Effects of Chitosan Concentration. Chitosan solutions with concentrations of 1, 2, 
or 3% (w/v) were prepared by dissolution in 0.2 mol.L−1 acetic acid for 24 hours at room 
temperature. The solutions were frozen at −20°C for 24 hours and lyophilized. 
 
Effects of Freezing Conditions. Chitosan solution (3% w/v) was prepared as 
previously described. The solution was frozen at −20°C in a freezer for 24 hours; −80°C 
in an ultrafreezer for 24 hours; or −196°C by immersion in liquid N2; and lyophilized. 
 
3.2.2.2. Characterization of Porous Chitosan Scaffolds (PCHTs) 
Morphology and Pore Size. The morphology of PCHTs was evaluated by 
scanning electron microscopy (SEM) using an LEO 440i Electron Microscopy/Oxford 
(Cambridge, England) operated at 5 kV accelerating voltage. The scaffolds were gold-
coated using a sputter coater POLARON SC7620, VG Microtech (Uckfield, England) for 
180 s at a current of 3 mA. Pore size (𝑛 = 20) was measured using software Image J 
1.47t. 
 
Mechanical Properties. Mechanical compression tests of PCHTs (𝑛 = 3) were 
performed using a Universal Testing Machine, MTS model 810-Flex Test 40 (MTS 
Systems Corporation, Eden Prairie, MN, USA) up to 60% strain, according to Correia et 
al. (2011). The testing machine was equipped with a 1.5 kN load cell, and the loading 
rate was 5 mm/min. Young’s modulus was calculated in the initial linear section of the 
stress-strain curve, when the strain was lower than 10%.  
 
Degradation in PBS. The degradation profile of the PCHTs in PBS at 37°C was 
performed by the gravimetric method described by Tang & Spector (2007) through 
measurements of loss weight. 
 
Water Sorption. The water sorption was determined by swelling of PCHTs 
(previously weighted) in PBS (LB Laborclin, Pinhais, PR, Brazil) at pH 7.4 for 24 hours 
at 37°C. The swollen PCHTs were weighed after the removal of excess water by 
keeping the surfaces on a filter paper. The swelling ratio (SR) was also calculated using 
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Equation (1): 
 
𝑆𝑅 =
𝑤𝑠
𝑤𝑑
                                                                                                                        Equation (1) 
 
where 𝑤𝑠 and 𝑤𝑑 are the weights of the scaffolds in the swelled state and the dry state, 
respectively.  
 
Porosity. The porosity (𝜀) of the PCHTs was determined according to the protocol 
used by Wang et al. (2003) and calculated by Equation (2): 
 
𝜀 (%) =  
𝑉𝑚−(
𝑤𝑚
𝜌
)
𝑉𝑚
 𝑥 100                                                                                              Equation (2) 
 
where 𝑉𝑚 is the total volume of PCHTs (cm3), 𝜌 is the density of nonporous CHT (1.342 
g/cm3), and 𝑤𝑚 is the weight of sponge (g). Values are expressed as the mean ± 
standard deviation (𝑛 = 3). 
 
Cell Compatibility. The compatibility was carried out by exposing PCHTs to h-
AdMSCs followed by cultivation at 37°C for 24 hours and evaluation by MTT assay (3-
[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyltetrazolium bromide) (MTT, Molecular Probes) 
according to a modified Mosmann method (1983). The MTT assay is a colorimetric test 
based on the reduction of yellow tetrazolium salt into a purple formazan product in 
presence of cells (Gümüdereliolu & Aday, 2011). 
 
3.2.2.3. PRP Preparations 
PRP Concentration. P-PRP (plasma rich in platelets and poor in leukocytes) was 
prepared according to Perez et al. (2013). Briefly, whole blood (WB) was collected into 
3.5 mL vacuum tubes (Vacuette, Campinas, SP, Brazil) containing sodium citrate 3.2% 
(w/v) as an anticoagulant. WB was initially centrifuged in a Rotina 380R centrifuge 
(Hettich Zentrifugen, Tuttlingen, Germany) at 100 ×g for 10 minutes at 25°C. After the 
formation of three layers (a bottom layer composed mainly of red blood cells (RBCs); an 
upper layer composed of plasma, platelets, and some WB cells; and an intermediate 
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layer, or buffy coat, composed mostly of WB cells), only the upper layer was collected to 
obtain PPRP. The concentration of platelets, WB cells, and RBCs in WB and P-PRP 
were determined using the ABX Micros ES 60 hematology analyzer (HORIBA ABX 
Diagnostics, Montpellier, France). 
 
P-PRP Activation. Activated P-PRP (𝑎P-PRP) was obtained by adding 
autologous serum (Ser) and 10% (w/v) CaCl2 solution as agonists using the following 
proportions: agonist/P-PRP = 20% (v/v), Ser/CaCl2 volumetric ratio = 9. Autologous 
serum was prepared by collecting 5 mL of WB in tubes without anticoagulant. After 30 
minutes to form clots, WB was centrifuged at 2000 ×g for 10 minutes (Perez et al., 
2014). 
 
3.2.2.4. The Composite Scaffolds (𝑎P-PRP/PCHTs) 
Preparation. 𝑎P-PRP/PCHTs was prepared for embedding by dripping 𝑎P-PRP, 
immediately after activation, into PCHTs. The preparation was carried out in 48-well 
microplates using a ratio of 200 µL of 𝑎P-PRP to 10–20 mg of PCHTs. 
 
Release of GFs. The release of platelet-derived growth factor AB (PDGF-AB) and 
transforming growth factor β1 (TGF-β1) was performed after 1 hour of gelation of 𝑎P-
PRP associated with PCHTs in the presence of the culture medium (Dulbecco’s 
Modified Eagle’s Medium (DMEM-LG) (Gibco, Grand Island, NY, USA) with low glucose 
concentration). The culture medium (1.5 mL) was added to 𝑎P-PRP/PCHTs in 48-well 
microplates, which were maintained in an incubator with 5% CO2 throughout the assays. 
The total volume of culture medium was withdrawn at 3, 6, 12, 24, and 72 hours, and the 
same volume of fresh medium was replaced without removing the hydrogels from the 
wells. The samples were stored at −80°C for further characterization. The 
concentrations of the released GFs PDGF-AB and TGF-β1 were measured using 
enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, Minneapolis, MN, 
USA) according to the manufacturer’s instructions and specifications. 
 
h-AdMSCs Proliferation. The cultivation of h-AdMSCs was carried out in 24-well 
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tissue culture plates by adding 1 mL DMEM to the seeded composite scaffolds (𝑛 = 4). 
The composite scaffolds seeded were maintained at 37°C for 10 days. Cell proliferation 
was quantified using the thiazolyl blue tetrazolium bromide (MTT) assay. At 3, 5, 7, and 
10 cultivation days, the composite scaffolds were removed and transferred to 24-well 
plates. MTT (1 mL of 1 mg/mL) was then added, and the cultivation proceeded at 37°C 
for 4 hours. The MTT solution was then discarded, and 1 mL of DMSO was added to 
dissolve the purple formazan crystals. The samples were shaken at 120 rpm for 30 min 
to ensure homogeneous dissolution of the formazan dye, and then 200 µL of each 
sample was transferred to a 96-well plate. Optical density was measured at 595 nm 
using a microplate reader (Filter Max F5, Molecular Devices). The isolation and pre-
cultivation of h-AdMSCs as well as the cell seeding were performed as described below. 
 
h-AdMSCs Isolation and Pre-cultivation. Human subcutaneous adipose tissue 
that was initially acquired from liposuction surgery was washed with sterile PBS, 
separated into fractions of 10 g, digested with 20 mg of collagenase type 1A and 
maintained in 20 mL of DMEM-LG containing 10% BSA (bovine serum albumin) and 10 
µL of gentamicin for 30 min in a 37°C bath. After complete digestion, the reaction was 
quenched with 10 mL fetal bovine serum (FBS) and immediately centrifuged for 15 min 
at 1500 rpm. The supernatant was discarded, and the pellet was suspended in 10 mL 
DMEM-LG with 10% FBS. After pre-cultivation for 24 h, the culture medium was 
changed every 3 days; after the fourth passage, the cells were characterized by 
immunophenotyping (data not shown) using flow cytometry and according to their 
adipogenic, osteogenic, and chondrogenic differentiation and then used in the 
subsequent experiments. 
 
h-AdMSCs-Seeding. The pre-cultured h-AdMSCs were trypsinized and 
resuspended in P-PRP to a final cell concentration of 1 × 104 cells/mL. P-PRP 
containing h-AdMSCs was activated and immediately embedded to the PCHTs in a 24-
well tissue culture plate, using 200 µL of h-AdMSCs + 𝑎P-PRP per 10–20 mg of PCHTs. 
The composite scaffolds with h-AdMSCs were kept at room temperature for 45 minutes 
for consolidation of the fibrin network. Pure PRP was used as control. 
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3.2.2.5. Images of the h-AdMSCs-Seeded Composite Scaffolds 
The images of the cell-seeded composite scaffolds were obtained by scanning 
electron microscopy after 5 days of h-AdMSCs proliferation. The cell-seeded composite 
scaffolds were fixed in a solution of 4% paraformaldehyde and 2.5% glutaraldehyde in 
phosphate buffer, pH 7.4, for 2 hours. The samples were than dehydrated in ethanol for 
15 min intervals in aqueous 50%, 70%, 95%, and 100% ethanol solutions (2x) and dried 
at the critical point dryer BAL-TEC CPD 030 (Schalksmühle, Germany). After gold 
coating (Sputter Coater POLARON, SC7620, VG Microtech), the cell-seeded composite 
scaffolds were visualized with a SEM (Leo440i, LEO) with an accelerating voltage of 20 
kV. 
 
3.2.2.6. Induction of Osteogenic Differentiation 
h-AdMSCs seeded in the composite scaffolds were induced to differentiate into 
the osteogenic lineage by providing the osteogenic medium containing DMEM-LG 
supplemented with 10% FBS, 1% β-glycerol-phosphate (Sigma-Aldrich, St. Louis, MO, 
USA), 1% L-ascorbic acid (Sigma-Aldrich, St. Louis, MO, USA), 1% dexamethasone 
(Sigma-Aldrich, St. Louis, MO, USA), and 1% penicillin/streptomycin solution (Gibco, 
Grand Island, NY, USA). The medium was changed every 7 days. 
 
Evaluation of Differentiation. Differentiation was evaluated by measuring the 
alkaline phosphatase activity (ALP) on day 14. The supernatant (200 µL) was collected 
and mixed with the same volume of p-nitrophenyl phosphate (SIGMAFAST p-nitrophenyl 
phosphate tablets, Sigma, Saint Louis, MO, USA) as substrate and incubated at room 
temperature for 30 minutes. Absorbance was read immediately at 405 nm. 
 
3.2.2.7. Statistical Analysis 
Each experiment was carried out in triplicate unless otherwise specified. All 
results are presented as the mean ± standard deviation (SD).The experimental data 
from all the studies were analyzed using Analysis of Variance (ANOVA). Statistical 
significance was set to 𝑃 value ≤ 0.05. 
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3.3. Results and Discussion 
 
3.3.1. Experimental Design 
In this study, we prepared novel composite scaffolds by association of PRP with 
the 3D-porous structure of chitosan. First, different 3D-porous structures of chitosan 
(PCHTs) were prepared by freeze-drying by varying the CHT concentration and freezing 
conditions (temperature and freezing rate). Second, the microstructure and mechanical 
properties of the PCHTs were characterized and evaluated for cell compatibility. The 
surface chemistry, hydrophilicity, and positive charge of –NH2 groups in acidic medium 
were maintained unaltered.  
The composite scaffolds (𝑎P-PRP/PCHTs) were obtained by embedding the 
PCHTs with immediately activated P-PRP in a 24-well microplate. The release of the 
GFs (PDGF-AB and TGF-β1) from the composite scaffolds was evaluated in DMEM 
culture medium. Afterwards, pre-cultured h-AdMSCs were added to PRP before 
activation in order to obtain cell-seeded composite scaffolds. In vitro examination of h-
AdMSCs proliferation kinetics was performed over 10 days by using the cell-seeded 
composite scaffolds in DMEM. Additionally, osteogenic differentiation was evaluated by 
ALP activity measurements after 14 days. Thus, we verified the correlation between the 
structure and function of PCHTs by controlling the concentration and freezing conditions 
of chitosan solution. 
 
3.3.2. Effects of Freezing Conditions and Chitosan Concentration on 
PCHTs 
3.3.2.1. Images of Porous Structure 
Figures 10(a) – 10(c) show images of the porous structure from controlled 
freezing at −20°C by varying the concentration of the chitosan solution (1, 2, or 3%) and 
subsequent lyophilization. The images show highly porous structures with rounded 
pores that interconnected, regardless of CHT concentration. Differences in chitosan 
molecular weight, deacetylation degree, and purity make difficult comparisons even for 
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similar treatment. Madihally & Matthew (1999) showed a higher pore interconnectivity 
degree and more open pores for 1% (w/w) chitosan concentration for a similar 
deacetylation degree, but other properties were not characterized. 
  
(a) (b) 
   
(c) (d) (e) 
Figure 10. SEM micrographs of PCHTs. Cross-sectional morphologies of (a) PCHTs 1% 
(−20°C); (b) PCHTs 2% (−20°C); (c) PCHTs 3% (−20°C); (d) PCHTs 3% (−80°C); and 
(e) PCHTs 3% (−196°C). Original magnification is ×100 and the scale bar represents 
200 µm. 
 
Freezing conditions produced a more prominent effect on the morphology of the 
pores [Figures 10(d) – 10(e)] attributed the variations in the freezing rate used to 
achieve the temperatures evaluated. In contrast with rounded pores at −20°C (3% CHT) 
[Figure 10(c)], we observed pores with leaf structure at −80°C [Figure 10(d)], while 
smaller and elongated open pores were produced at −196°C [Figure 10(e)]. In all cases, 
the pores were uniformly distributed and radially oriented and had a high degree of 
interconnectivity. 
The pore structures allow uniform cell spatial distribution throughout the scaffold, 
facilitating homogeneous tissue formation. Moreover, the differences in pore 
morphologies obtained are suitable to several cell linage and type of tissue to be 
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regenerated. 
 
3.3.2.2. Characterization of PCHTs 
Physicochemical and Mechanical Properties. Table 1 shows physicochemical 
characterization of the PCHTs. At −20°C, the mean diameter of rounded pores could be 
controlled around the 300–400 µm, regardless of the CHT concentration, although there 
is a large distribution. 
However, the elongated pores from Figures 10(d) – 10(e) were markedly 
decreased with freezing conditions from 2615 µm (−80°C) to 280 µm (−196°C) because 
crystal growth and hence pore size are functions of both heat and mass transfer rates, 
determined by the temperature and freezing rate. At −80°C, the observed differences in 
pore shape and size suggest parallel ice crystal growth, which in turn was caused by the 
strongly one-dimensional nature of the thermal gradients established during freezing, as 
discussed by Madihally & Matthew (1999). 
The diverse nature of tissue architectures requires scaffolds with optimal pore 
sizes, such as 5 µm for neovascularization (Brauker et al., 1995), 5–15 µm for fibroblast 
ingrowth (Klawitter & Hulbert, 1971), 20 µm for the ingrowth of hepatocytes (Yang et al., 
2001), 200–900 µm for osteoconduction (Salgado et al., 2004), and 20–125 µm for 
regeneration of adult mammalian skin (Yannas et al., 1989). 
According to these data, the rounded pores obtained at −20°C or elongated at 
−196°C are adequate for bone tissue, although other properties could also influence the 
choice. Moreover, because human adipose tissue-derived mesenchymal stem cells (h-
AdMSCs) exhibit a spindle-like shape and are 80–100 µm in diameter and ∼200 µm in 
length (Chavez-Munoz et al., 2013), the range of pore sizes in our PCHTs allows cells to 
migrate freely into the scaffolds, favoring the formation of a new tissue. 
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Table 1. Physicochemical characterization of PCHTs. 
CHT 
concentration 
(%) 
Freezing 
temperature 
(°C) 
Swelling ratio 
(n=3) 
Pore size  
(µm)  
(n=20) 
Porosity  
(%)  
(n=3) 
Young’s Moduli 
(MPa)  
(n=3) 
1 -20 6.5 ± 0.4 425 ± 102 97.1 ± 0.3 0.037 ± 0.002 
2 -20 5.5 ± 0.9 418 ± 113 94.7 ± 0.8 0.5 ± 0.1 
3 -20 4.7 ± 0.9 336 ± 138 93.1 ± 0.5 1.1 ± 0.1 
3 -80 5.1 ± 0.9 2615 ± 600* 91.7 ± 0.3 0.28 ± 0.01 
3 -196 6.4 ± 0.6 280 ± 62* 92.5 ± 0.1 1.01 ± 0.05 
*mean longitudinal size.  
 
The porosity is also an important aspect of cell migration and proliferation, 
guiding and promoting the formation of new tissue. Porosity is defined as the percentage 
of void space in a solid and is a morphological property independent of material (Léon y 
Léon, 1998). A porosity higher than 90% and pore interconnectivity are basic 
requirements for scaffolds in tissue engineering because they affect the diffusion of 
physiological nutrients and gases to and the removal of metabolic waste and byproducts 
from cells that have penetrated the scaffold (Leong et al., 2003; Liu & Ma, 2004). 
Moreover, the porosity often compromises the mechanical and structural stability of the 
scaffolds and must be evaluated in accordance with the application and degradation rate 
of materials utilized (Loh & Choong, 2013).  
The porosity values of PCHTs scaffolds ranged from 91.0 to 97.0% (Table 1), 
which are adequate for TE, independent of CHT concentration or freezing conditions. 
However, the porosity decreased with increasing chitosan concentration. The highest 
porosity was provided from 1% chitosan solution, but there was not a direct relationship 
with freezing conditions. The PCHTs prepared at −80°C showed a significantly lower 
porosity even with higher pore size, probably due to their leaf structure. 
To guide tissue regeneration, scaffolds should also have sufficient mechanical 
strength during in vitro culturing to maintain the spaces required for cell in-growth and 
matrix elaboration (Leong et al., 2003). Moreover, their mechanical properties should be 
similar to the properties of tissues generated to provide an adequate structural support 
in the stage of healing (Cheung et al., 2007). 
Scaffolds for the regeneration of hard tissue must exhibit a mechanical modulus 
in the range of 10–1,500 MPa, while scaffolds for soft tissues must exhibit a mechanical 
modulus in the range of 0.4–350 MPa (Hollister, 2005). 
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In this work, we observed a drastic decrease in Young’s modulus (Table 1) with a 
decrease in CHT concentration. Better mechanical properties were found for a CHT 
concentration of 3%.  
The PCHTs 3% (w/v) prepared at −80°C showed lower mechanical strength than 
those prepared at −20°C and −196°C with the same CHT concentration, which could be 
attributed to its leaf structure and pore size. There was no significant difference (𝑃 < 
0.05) in mechanical properties for PCHTs 3% (w/v) frozen at −20°C or −196°C. Thus, 
the range of Young’s moduli found for PCHTs suggests their application for soft tissue 
engineering. For hard tissues, these scaffolds must be crosslinked and/or reinforced by 
the addition of fillers. 
The water absorption capacity (swelling ratio) of the scaffolds affects cell growth 
indirectly (Enrione et al., 2010). The hydration of the scaffolds is a necessary step for 
cell incorporation and proliferation. 
PCHTs scaffolds showed a high swelling capacity in PBS (pH 7.4) regardless of 
chitosan concentration and freezing conditions, allowing for rapid hydration when culture 
medium was added. 
 
Degradation in PBS. Scaffold degradation is also an important parameter for the 
formation of new tissue. The scaffold degradation rate must be tuned appropriately with 
the growth rate of the new tissue in such a way that by the time the injury site is 
completely regenerated, the scaffold is completely degraded (Salgado et al., 2004). 
Degradation can occur through mechanisms that involve physical or chemical processes 
and/or biological processes that are mediated by biological agents, such as enzymes 
(Langer & Vacanti, 1993).  
Here, we evaluated in vitro the profile degradation of PCHTs in PBS (pH 7.4) at 
37°C; we supposed that degradation occurred by solubilization due to the presence of 
residual acetate molecules. 
Figure 11 shows the degradation profile of PCHTs. 
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Figure 11. The weight loss of scaffolds with time in PBS at 37°C as a percentage of the 
original weight of the scaffold (𝑛 = 3). The data are plotted with the mean ± standard 
error. (■) PCHTs 1% (−20°C); (●) PCHTs 2% (−20°C); (▲) PCHTs 3% (−20°C); (□) 
PCHTs 3% (−80°C); and (Ο) PCHTs 3% (−196°C). 
We observed the highest weight loss, approximately 45%, for PCHT 1% (−20°C) 
after 7 days, while for PCHTs 2% (−20°C), 3% (−20°C), and 3% (−196°C) weight loss 
was approximately 35% after 3 days. The PCHTs 3% (−80°C) showed the lowest weight 
loss (~20%), probably due to their leaf structure retaining lower concentration of acetate 
molecules. 
Our results suggest that the PCHTs need further stabilization, to ensure the 
balance between tissue regeneration and degradation rate of the scaffold. 
 
3.3.2.3. Cell Compatibility 
Figure 12 shows the cell compatibility of h-AdMSCs cultured in the presence of 
PCHTs, as assayed by MTT. The results revealed no potential cytotoxicity in 24 hours 
for the scaffolds according to the standard values (PTC). 
However, we observed lower proliferation of h-AdMSCs on PCHTs prepared with 
chitosan concentration of 3% (w/v) compared to the negative control. 
Nevertheless, the PCHTs are potentially useful for in vivo applications regardless 
of CHT concentration and freezing conditions. 
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Figure 12. Proliferation of h-AdMSCs exposed to the PCHTs scaffolds after 24 hours of 
cultivation. Negative control (NTC) = DMEM with 10%FBS; positive control (PTC) 
=DMEM with phenol 0.5%. Mean ± standard deviation 𝑛 = 3. The population means are 
significantly different from positive control at *𝑃 < 0.05. 
 
3.3.3. Characterization of the Composite Scaffolds 
3.3.3.1. Images of the Cell-Seeded 𝑎P-PRP/PCHTs 
SEM characterization (Figure 13) of the 𝑎P-PRP/PCHTs on the 5th day of culture 
showed fibrin networks covering the pores and surface of PCHTs, as a consequence of 
the interaction of fibrin fibers and CHT. This interaction supported cell proliferation by 
improving the mechanical strength of the fibrin network, in addition to providing 
additional surface area to cell adhesion, proliferation and differentiation. 
   
(a) (b) (c) 
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(d) (e) (f) 
Figure 13. Scanning electron microscopic images of 𝑎P-PRP/PCHTs after 5 days of 
cultivation of h-AdMSCs. (a) 𝑎-PRP; (b) 𝑎P-PRP/PCHTs 1% (−20°C); (c) 𝑎P-
PRP/PCHTs 2% (−20°C); (d) 𝑎P-PRP/PCHTs 3% (−20°C); (e) 𝑎P-PRP/PCHTs 3% 
(−80°C); and (f) 𝑎P-PRP/PCHTs 3% (−196°C). Original magnification is ×5,000 and the 
scale bar represents 3 µm. 
. 
 
3.3.3.2. Growth Factor Release 
Figure 14 shows PDGF-AB and TGF-β1 release kinetics from 𝑎P-PCHTs 
determined by ELISA. 
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(c) (d) 
Figure 14. Release profiles of growth factors from 𝑎P-PRP in porous chitosan scaffolds 
as a function of [(a), (b)] chitosan concentrations and [(c), (d)] freezing conditions. (■) 
PCHTs 1% (−20°C); (●) PCHTs 2% (−20°C); (▲) PCHTs 3% (−20°C); (□) PCHTs 3% 
(−80°C), (O) PCHTs 3% (−196°C), and (Δ) P-PRP activated with Ca+2/thrombin (used 
as control); TGF-β1 [(a), (c)]; and PDGF-AB [(b), (d)]. The concentration of platelets in 
P-PRP was 472,250 pq/mm3. Activated P-PRP alone was used as control. 
 
The curves show diffusion profiles, indicating no collapse of the porous structure 
of chitosan scaffolds during the course of the assays, regardless of the CHT 
concentration and freezing conditions.  
PDGF-AB released from PCHTs ended within 24 hours of incubation, whereas 
TGF-β1 tended to continue after 72 hours. 
A controlled release of TGF-β1 and PDGF-AB was achieved for all CHT 
concentrations, related to the scaffolds of activated P-PRP only. The slowest release 
was observed for a chitosan concentration of 3%. 
In contrast, for the PCHTs 3% freezing at −80°C and −196°C, we observed a 
controlled release of TGF-β1, but a strong burst release of PDGF-AB. 
Thus, PCHTs prepared with 3% CHT at −20°C provided a controlled release of 
PDGF-AB and TGF-β1 and can be an efficient vehicle for release of GFs from PRP. 
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3.3.3.3. h-AdMSCs-Seeded Proliferation  
Figure 15 shows the proliferation profile of h-AdMSCs cultured in 𝑎P-
PRP/PCHTs. 
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(a) (b) 
Figure 15. Proliferation kinetic profiles of h-AdMSCs seeded in 𝑎P-PRP/PCHTs. (a) 
CHT concentration and (b) freezing conditions. (■) PCHTs 1% (−20°C); (●) PCHTs 2% 
(−20°C); (▲) PCHTs 3% (−20°C); (□) PCHTs 3% (−80°C), (O) PCHTs 3% (−196°C), and 
(Δ) P-PRP activated with Ca+2/thrombin (control). The concentration of platelets in P-
PRP was 374,000 pq/mm3. Activated P-PRP alone was used as control. 
 
The cell number per well determined after 3 days exceeded the number of 
seeded cells (1.4 × 104 cells/well) in all the 𝑎P-PRP/PCHTs, meaning that the cells kept 
in the matrices retained their viability, regardless of the CHT concentration and freezing 
conditions.  
The cell number per well of 𝑎P-PRP/PCHTs prepared with 1, 2, and 3% (w/v) of 
chitosan [Figure 15(a)] showed significant differences (𝑃 < 0.05) compared to control 
(𝑎P-PRP). Therefore, PCHTs must have stabilized fibrin networks as we initially 
hypothesized.  
However, regarding freezing condition, no significant variations for 𝑎P-
PRP/PCHTs prepared at −80°C or −196°C and 𝑎P-PRP were observed [Figure 15(b)]. In 
all cases, cell viability decreased after 7 days, probably due to collapse of the structure. 
We also observed that the exponential phase of the cultures [Figure 15(a)] 
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started after the maximum release of GFs (Figure 14), and the decline phase matched 
the largest weight loss of the PCHTs (Figure 11). 
 
3.3.3.4. Induction of Osteogenic Differentiation 
Osteogenic differentiation of h-AdMSCs was investigated 14 days after cell 
seeding. ALP, an early marker of osteogenic differentiation, was determined, and the 
results are shown in Figure 16. The expression of ALP activity showed no significant 
difference (𝑃 < 0.05) with CHT concentration. However, higher osteogenic differentiation 
was obtained with 𝑎P-PRP/PCHTs 3% (−196°C). 
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Figure 16. ALP activities of cells cultured on 𝑎P-PRP/PCHTs scaffolds prepared with 
different CHT concentrations and freezing conditions (statistically significant differences 
from blank, 𝑛 = 3, *𝑃 < 0.05). Blank = the reagents used in the assay only. The 
concentration of platelets in whole blood donors (average of 2 donors) was 163,500 
pq/mm3. After preparation of the PRP, the platelets were concentrated approximately 
1.74 times, with an average final concentration of 303,000 pq/mm3. 
 
3.4. Conclusions 
 
Composite scaffolds were prepared with porous chitosan and 𝑎-PRP. The 
performance of the composite scaffolds was superior to 𝑎P-PRP alone, indicating that 
the porous chitosan stabilized the fibrin network, supporting our initial hypothesis. 
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Chitosan concentration and freezing conditions influenced the physicochemical and 
biological properties of the scaffolds. On the average, physicochemical, mechanical, and 
h-AdMSCs proliferation improved by the use of 3% (w/v) chitosan and −20°C freezing 
temperature, while −196°C favored osteogenic differentiation. Additional stabilization of 
the porous structure is needed for applications in regenerative medicine. 
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Abstract. This study offers innovative perspectives for optimizing of scaffolds based on 
correlation structure-function aimed the regenerative medicine. Thus, we evaluated in 
vitro the performance of stabilized porous chitosan (SPCHTs) associated with activated 
platelet-rich plasma (aP-PRP) as a composite scaffold for the proliferation and 
osteogenic differentiation of human adipose-derived mesenchymal stem cells (h-
AdMSCs). The porous structure of chitosan (PCHT) was prepared similarly to solid 
sponges by controlled freezing (-20°C) and lyophilization of a 3% (w/v) chitosan solution. 
Stabilization was performed by treating the PCHT with sodium hydroxide (TNaOH), an 
ethanol series (TEtOH) or by crosslinking with tripolyphosphate (CTPP). The aP-PRP 
was obtained from the controlled centrifugation of whole blood and activated with 
autologous serum and calcium. Imaging of the structures showed fibrin networks inside 
and on the surface of SPCHTs as a consequence of electrostatic interactions. SPCHTs 
were non-cytotoxic, and the porosity, pore size and Young’s modulus were 
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approximately 96%, 145 µm and 1.5 MPa for TNaOH and TEtOH and 94%, 110 µm and 
1.8 MPa for CTPP, respectively. Stabilization maintained the integrity of the SPCHTs for 
at least 10 days of cultivation. SPCHTs showed controlled release of the growth factors 
TGF-β1 and PDGF-AB. Although generating different patterns, all of the stabilization 
treatments improved the proliferation of seeded h-AdMSCs on the composite scaffold 
compared to aP-PRP alone, and differentiation of the composite scaffold treated with 
TEtOH was significantly higher than for non-stabilized PCHT. We conclude that the 
stabilized of porous chitosan scaffolds improved the in vitro performance of PRP and 
have potential in regenerative medicine.  
 
Keywords: Regenerative medicine; scaffolds; chitosan; platelet-rich plasma; growth 
factors. 
 
4.1. Introduction 
 
Platelet-rich plasma (PRP) is an autologous product from whole blood (WB) 
comprised primarily of a high concentration of platelets dispersed in plasma (P-PRP) but 
that can also include concentrated leukocytes (L-PRP) (Ehrenfest et al., 2009). 
Currently, PRP therapy has been used in various medical specialties and has been 
responsible for several successful outcomes. Various clinical uses including sports 
medicine, orthopedics and the recovery of musculoskeletal injuries have been reported 
recently (Lana et al., 2014). 
Activated PRP (aPRP) releases growth factors (GFs) and various cytokines from 
platelets and leukocytes as well as stimulating the decomposition of fibrinogen in fibrin 
fibers, which arrange themselves in a network structure that supports cell proliferation 
and differentiation (Marx, 2004). Therefore, tissue repair occurs from a cascade of 
multiple reactions mediated by GFs (Jacobson et al., 2008), in which cytokines play an 
important role (Kanaji et al., 2011). 
Preparation of PRP first involves the separation of red blood cells and the 
concentration of platelets and other components of WB. Usually, separation is 
performed by centrifugation, and activation is promoted by thrombin and calcium. 
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Adequate centrifugation conditions and multiple spins must be used to obtain a high 
yield of platelets and preserve integrity (Perez et al., 2013). The architecture of the fibrin 
network is determined by the activation conditions (Perez et al., 2014) and plays an 
important role in GF release and cell proliferation.  
Crane & Everts (2008) described tissue regeneration based on the triangle of 
proliferation, which represents cooperation between genic, conductive and inductive 
capabilities, using the cells, scaffold and GFs as basic elements. PRP is beneficial to 
tissue regeneration because it acts as an inducer and conductive matrix (scaffold) for 
cell proliferation. Furthermore, aPRP influences the paracrine activity of mesenchymal 
cells (MSCs), which is an important mechanism determining their efficacy in 
regenerative therapies (Liu et al., 2002; Hom et al., 2007). 
In regenerative PRP therapies, we would consider first generation therapies to be 
PRP alone, followed by the second generation of PRP associated with bone marrow 
cells, and finally a third generation using PRP and h-AdMSCs. However, the 
performance of the fibrin network as a scaffold in regeneration requires further attention. 
Structural stability is an important issue because MSCs needs the maintenance of a 3-
dimensional fibrin architecture for proliferation, migration and differentiation.  
Some of the available literature suggests that the association of PRP with 
chitosan is beneficial to osteogenic regeneration (Ouyang et al., 2013; Rossi et al., 
2013; Kutlu et al., 2013; Bi et al., 2010; Oktay et al., 2010; Chang et al., 2009; Shen et 
al., 2006; Kojima et al., 2004; Okamoto et al., 2003). 
In our previous studies, we observed the association of aP-PRP with PCHTs 
controlled the release of GFs and also improved the in vitro proliferation and 
differentiation of h-AdMSCs compared to aP-PRP only. However, the PCHTs collapsed 
after five days of cell cultivation and required stabilization.  
Porous chitosan scaffolds are produced primarily by a freezing process, which 
provides the nucleation of ice crystals from solution and further growth along the lines of 
thermal gradients. Exclusion of the chitosan acetate salt from the ice crystal phase and 
subsequent ice removal by lyophilization generates a porous material. After freeze-
drying, the acetate molecules are in solid form in the scaffold cavities as ions bound to 
the cationic amine groups in the chitosan. When the acetate is not removed or 
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neutralized, the scaffold will swell rapidly and ultimately dissolve upon rehydration in a 
neutral aqueous medium, requiring stabilization of the scaffold.  
Stabilization using multiple methods has been studied, including rehydration and/ 
or crosslinking (Shen et al., 2000), immersion in sodium hydroxide (Madihally & Mathew, 
1999; Manjubala et al., 2006), tripolyphosphate (Seol et al., 2004; Lee et al., 2000) and/ 
or an ethanol series (Nwe et al., 2009; Reis et al., 2008). Neutralization with NaOH 
removes acid remnants and regenerates the NH2 groups on the chitosan, yielding a 
hydrophilic surface. The stabilization occurs by inhibition of the repulsion between 
chitosan chains and the formation of hydrogen bonds, hydrophobic interactions and 
chitosan crystallites (Noriega & Subramanian, 2011). An adequate NaOH concentration 
must be applied to maintain the shape and volume of the chitosan scaffold during the 
cell culture period (Nwe et al., 2009). 
Stabilization with an ethanol series occurs because CHT decreases in solubility 
as the polarity of mixed solvents decreases, and affects not only the solubility of CHT 
but also the elasticity of the hydrogel (Sano et al., 1999). 
Cationic chitosan can be crosslinked by multivalent counterions such as 
tripolyphosphate to form an intermolecular and/or intramolecular network structure. The 
reactions occurs through the ionic interaction between the NH3+ protonated groups of 
chitosan and the negatively charged counterions of TPP, including the OH- and P3O105- 
ions coexisting in the TPP solution (Bhumkar & Pokharkar, 2006). 
In this work, we extended previous findings by studying the effects of PCHT 
stabilization on the performance of the composite scaffold aP-PRP/SPCHT. Stabilization 
was performed by treating PCHT with sodium hydroxide (TNaOH), an ethanol series 
(TEtOH) or by crosslinking with tripolyphosphate (CTPP). The in vitro performance of 
the composite scaffolds was evaluated based on physicochemical and biological 
properties, and these results are important to optimize composite scaffolds for use in 
implants or for wound healing.  
 
4.2. Materials and Methods 
 
73 
 
4.2.1. Materials 
Chitosan (average molecular weight [Mw] = 4 x 105 Da, degree of deacetylation = 
83 ± 4%) was purchased from Polymar® (Fortaleza, CE, Brazil) and purified according 
to a protocol described by Nasti et al. (2009). Other chemicals were reagent grade and 
were used without any further purification. PRP was prepared from whole blood (WB) of 
donors, who were healthy individuals aged between 30 and 40 years old and previously 
assessed through their clinical examinations. The human adipose tissue-derived 
mesenchymal stem cells, h-AdMSCs, were provided by Umbilical Cord Blood Bank of 
Haematology and Hemotherapy Center of University of Campinas. All biological 
experiments were approved by the Ethics Committee of the Medical Sciences School of 
the University of Campinas (UNICAMP; CAAE: 0972.0.146.000-11). 
 
4.2.2. Methods 
4.2.2.1. Preparation of porous chitosan (PCHT) 
PCHT was prepared from a chitosan solution 3% (w/v) prepared by dissolving 
chitosan in 0.2 mol.L-1 acetic acid. To obtain a cylindrical shape, the solution was added 
to the wells of a 24 well culture plate (TPP®, polystyrene, diameter=15.4 mm). The 
sponge-like porous structure was generated by freezing at -20°C for 24 hours and 
lyophilizing in a lyophilizer Liobras L101 (Liobras, São Carlos, SP, Brazil) at a 
temperature of approximately -30°C for 48 hours.  
 
4.2.2.2. Stabilization of PCHT  
PCHT was stabilized by treatment with dilute NaOH (TNaOH), an ethanol series 
(TEtOH) or by crosslinking with tripolyphosphate (CTPP) (Madihally & Matthew, 1999). 
All of these treatments began with the slow immersion of PCTS in specific aqueous 
solutions, some of which were followed by washing. For TNaOH, 0.05 mol.L-1 NaOH 
solution was used, and the PCHT was equilibrated for ~10 min and then washed twice 
with water and twice with phosphate buffered saline (pH 7.4). TEtOH treatment was 
performed by immersing the PCHT in absolute ethanol for ~1 h, then immersing 
sequentially in 70% and 50% (v/v)  ethanol for ~30 min each. For CTPP treatment, the 
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PCHT was immersed in 5% (w/v) TPP solution, equilibrated for ~2 h and then washed 
twice with water and twice with phosphate buffered saline (pH 7.4). The final mass ratio 
in the stabilized scaffold of CHT/TPP was 2:1. The stabilized PCHT (SPCHTs) were 
frozen at -20°C and lyophilized at a temperature of approximately -30°C for 48 hours 
again.  
 
4.2.3. Characterization of SPCHTs 
4.2.3.1. Chemical modification 
Infrared spectrometry (FT-IR) was used to identify the chemical modifications in 
the SPCHT scaffolds. Infrared spectra of PCHTs were obtained using an Infrared 
Spectrometer Fourier Transform (FT-IR) Thermo Scientific Nicolet Model 6700 (Thermo 
Fisher Scientific, Waltham, MA, USA) in the spectral range of 4000–675 cm-1. 
Measurements were made in ATR mode with the SMART OMNI-SAMPLER accessory 
in the spectral range between 4000-675 cm-1 at a resolution of 4 cm-1 and 64 scans. 
ATR-IR(chitosan): 3500–3000 (ν OH and NH2), 2875 (νCH), 1645 (amide I), 1550 (amide II) 
1380, 1067, 1020 cm−1 (Nasti et al., 2009). 
 
4.2.3.2. Morphology and pore size 
The morphology of the SPCHTs was evaluated by scanning electron microscopy 
(SEM) using a LEO 440i Electron Microscopy/Oxford (Cambridge, England) operated at 
5 kV accelerating voltage The scaffolds were gold-coated using a sputter coater 
POLARON SC7620, VG Microtech (Uckfield, England) for 180 s at a current of 3 mA. 
Pore size (n=20) was measured using an Image J 1.47t.  
 
4.2.3.3. Swelling profile 
The swelling profile in function of time of the SPCHTs was determined by swelling 
freeze-dried scaffolds of known weight in phosphate buffered saline (PBS) (LB 
Laborclin, Pinhais, PR, Brazil) at pH 7.4 and 37°C. The swelling ratio (SR) was 
calculated using Equation (1): 
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𝑆𝑅 =
𝑤𝑠
𝑤𝑑
                                                                                                                        Equation (1) 
 
in which 𝑤s and 𝑤d are the weights of the scaffolds at the swelling state and the dry 
state, respectively. 
4.2.3.4. Porosity 
Porosity (𝜀) of the SPCHTs was measured according to the protocol used by 
Wang et al. (2003), and calculated using Equation (2):  
 
ε (%) =  
Vm−(
Wm
ρ
)
Vm
𝑥 100                                                                                     Equation (2) 
 
in which 𝑉m is the total volume of CHT scaffolds (cm3), ρ is the density of the non-porous 
chitosan scaffold (1.342 g/cm3) and 𝑤m is the weight of scaffold (g). Values are 
expressed as the mean ± standard deviation (n=3). 
 
4.2.3.5. Mechanical resistance 
Mechanical compression tests of the SPCHTs (n=3) were performed using a 
Universal Testing Machine, MTS model 810-Flex Test 40 (MTS Systems Corporation, 
Eden Prairie, MN, USA) at up to 60% of strain, according to Correia et al. (2011). The 
testing machine was equipped with a 1.5 kN load cell, and the loading rate was 5 
mm/min. The Young’s modulus was calculated in the initial linear section of the stress–
strain curve, when the strain was lower than 10%.  
 
4.2.3.6. Degradation in phosphate buffered saline 
Degradation of SPCHTs was examined by the weight loss of previously weighed 
SPCHTs (𝑤o), which was monitored as a function of incubation time in PBS at 37°C. At 
specified time intervals, PCHTs were removed from the PBS and weighed (𝑤t). The 
weight loss ratio is defined in Equation (3) (Tan et al., 2009). 
 
weight loss (%) =
(w0−wt)
w0
𝑥 100                                                                        Equation (3) 
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4.2.3.7. Cell compatibility 
The compatibility of the SPCHTs was performed by exposing h-AdMSCs to 
SPCHTs followed by cultivation at 37°C for 24 hours and evaluation by MTT (3-[4,5-
dimethyl-thiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay (MTT, Molecular Probes), 
according to a modified Mosmann method (1983). The MTT assay is a colorimetric test 
based on the reduction of yellow tetrazolium salt into a purple formazan product in the 
presence of cells (Gümüşderelioğlu & Aday, 2011). 
 
4.2.4. Preparation of pure platelet-rich plasma (P-PRP) 
P-PRP, which is rich in platelets and poor in leukocytes, was prepared according 
to Perez et al. 2013. Briefly, whole blood (WB) was collected in 3.5 mL vacuum tubes 
(Vacuette®, Campinas, SP, Brazil) containing sodium citrate 3.2% (w/v) as an 
anticoagulant. WB was initially centrifuged in a Rotina 380R centrifuge (Hettich® 
Zentrifugen, Tuttlingen, Germany) at 100xg for 10 minutes at 25ºC. After the formation 
of three layers: a bottom layer of red blood cells (RBCs); an upper layer of plasma, 
platelets and some WBCs; and an intermediate layer, or buffy coat, composed mostly of 
WBCs; only the upper layer was collected as P-PRP. The concentration of platelets, 
WBCs and RBCs in WB and P-PRP was determined using the ABX Micros ES 60 
hematology analyzer (HORIBA ABX Diagnostics, Montpellier, France). 
 
4.2.5. Preparation of activated P-PRP (aP-PRP) 
aP-PRP was prepared by activation of P-PRP using autologous serum (Ser) and 
10% (w/v) CaCl2 solution as agonists in the following proportions: agonist/P-PRP=20% 
(v/v); Ser/CaCl2 volumetric ratio=9. Autologous serum was prepared by collecting 5 mL 
of WB in tubes without anticoagulant. After 30 minutes of clot formation, WB was 
centrifuged at 2000xg for 10 minutes (Perez et al., 2014).  
 
4.2.6. Preparation of composite scaffold (aP-PRP/SPCHTs) 
aP-PRP/SPCHTs were prepared by dripping aP-PRP, immediately after 
activation, onto SPCHTs. The preparation was carried out in 48-well microplates using 
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200 µL of aP-PRP/10-20 mg of PCHTs. 
 
4.2.7. h-AdMSCs isolation and pre-cultivation 
Human subcutaneous adipose tissue initially acquired from liposuction surgery 
was washed with sterile PBS, separated into 10 g samples, digested with 20 mg of 
collagenase type 1A and maintained in 20 mL of DMEM-LG containing 10% bovine 
serum albumin (BSA) and 10 µL of gentamicin for 30 min in a 37°C bath. After complete 
digestion, the reaction was quenched with 10 mL fetal bovine serum (FBS) and 
immediately centrifuged for 15 min at 1500 rpm. The supernatant was discarded, and 
the pellet was suspended in 10 mL DMEM-LG with 10% FBS. After pre-cultivation for 24 
h, the culture medium was changed every 3 days and after the fourth passage, the cells 
were characterized by immunophenotyping using flow cytometry and adipogenic, 
osteogenic and chondrogenic differentiation (data not shown), then were used in the 
subsequent experiments. 
 
4.2.8. h-AdMSCs-seeding in the composite scaffolds 
The pre-cultured h-AdMSCs were trypsinized and re-suspended in P-PRP to a 
final cell concentration of 1 x 104 cells/ mL. P-PRP containing h-AdMSCs was activated 
and immediately embedded in the SPCHTs in a 24-well tissue culture plate using 200 µL 
of h-AdMSCs+aP-PRP/10-20 mg of SPCHTs. The composite scaffolds seeded were 
with h-AdMSCs and incubated at room temperature for 45 minutes for the consolidation 
of the fibrin network. aP-PRP was used as the control.  
 
4.2.9. Characterization of the composite scaffold  
4.2.9.1. Release of GFs 
The release of platelet-derived growth factor AB (PDGF-AB) and transforming 
growth factor β1 (TGF-β1) was assessed after 1 hour gelation of aP-PRP associated to 
SPCHTs in the presence of the culture medium (Dulbecco's Modified Eagle's Medium 
(DMEM-LG) (Gibco, Grand Island, NY, USA) with low glucose concentration). The 
culture medium (1.5 mL) was added to aP-PRP/SPCHTs in 48 well microplates, which 
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were maintained in an incubator with 5% CO2 for the duration of the assays. The total 
volume of culture medium was removed at 3, 6, 12, 24 and 72 hours, and the same 
volume of fresh medium was replaced without removing the hydrogels from the wells. 
The samples were stored at -80ºC for further characterization. The concentration of the 
released GFs PDGF-AB and TGF-β1 were measured using enzyme-linked 
immunosorbent assay (ELISA) kits (R&D Systems, Minneapolis, MN, USA) according to 
the manufacturer’s instructions and specifications.  
 
4.2.9.2. Images of the cell-seeded composite scaffolds 
The images of cell-seeded composite scaffolds were obtained by scanning 
electron microscopy after 5 days of h-AdMSCs proliferation. The cell-seeded composite 
scaffolds were fixed in a solution of 4% paraformaldehyde and 2.5% glutaraldehyde in 
phosphate buffer, pH 7.4, for 2 hours. The samples were then dehydrated in ethanol for 
15 min intervals in aqueous 50%, 70%, 95% and 100% ethanol solutions (2x) and dried 
at the critical point dryer BAL-TEC CPD 030 (Schalksmühle, Germany). After gold 
coating (Sputter Coater POLARON, SC7620, VG Microtech), the cell-seeded composite 
scaffolds were visualized with a scanning electron microscope (Leo 440i LEO) with an 
accelerating voltage of 20 kV. 
 
4.2.9.3. h-AdMSCs proliferation 
The cultivation of h-AdMSCs was performed in 24-well tissue culture plates by 
adding 1 mL of the DMEM culture medium to the seeded composite scaffolds (n=4) and 
controlling the temperature at 37°C for 10 days. Cell proliferation was quantified by MTT 
assay. After 3, 5, 7 and 10 days of cultivation, the composite scaffolds were removed 
and transferred to 24-well plates. Then, MTT (1 mL of 1 mg/mL) was added, and the 
cultivation proceeded at 37°C for 4 hours. The MTT solution was discarded, and 1 mL of 
DMSO was added to dissolve the purple formazan crystals. The samples were shaken 
at 120 rpm for 30 min to ensure homogeneous dissolution of the formazan dye, and then 
200 µL of each sample was transferred to a 96-well plate. The optical density was 
measured at 595 nm using a microplate reader (FilterMax F5 Molecular Devices).  
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4.2.9.4. Induction of osteogenic differentiation 
h-AdMSCs-seeded in the composite scaffolds were induced to differentiate into 
the osteogenic lineage by providing osteogenic medium containing DMEM-LG 
supplemented with 10% FBS, 1% β-glycerol-phosphate (Sigma-Aldrich, St. Louis, MO, 
USA), 1% L-ascorbic acid (Sigma-Aldrich, St. Louis, MO, USA), 1% dexamethasone 
(Sigma-Aldrich, St. Louis, MO, USA) and 1% Penicillin/Streptomycin solution (Gibco, 
Grand Island, NY, USA). The medium was changed every 7 days.  
 
4.2.9.5. Alkaline phosphatase activity (ALP) 
The level of alkaline phosphatase (ALP) activity in h-AdMSCs was determined on 
day 14. The supernatant (200 μL) was collected and mixed with 200 μL of the substrate 
p-nitrophenyl phosphate (SIGMAFAST™ p-nitrophenyl phosphate tablets, Sigma, Saint 
Louis, MI, USA) and incubated at room temperature for 30 minutes. Absorbance was 
read immediately on a spectrophotometer at 405 nm. 
 
4.2.10. Statistical analysis 
Each experiment was performed in triplicate unless otherwise specified. All of the 
results are presented as the mean ± standard deviation (SD). The experimental data 
from all of the studies were analyzed using Analysis of Variance (ANOVA). Statistical 
significance was set to p-value ≤ 0.05. 
 
4.3. Results and discussion 
 
4.3.1. Modifications and surface chemistry  
The FTIR spectra of the SPCHTs from the various treatments is shown in Figure 
17. The FTIR spectra of non-treated scaffolds (NTPCHTs) were included as controls. 
FTIR spectra of SPCHTs/TNaOH and SPCHTs/TEtOH showed no significant 
modification of the chemical structure of chitosan compared to the NTPCHTs, which 
showed peaks at 1550 cm−1 and 1400 cm−1 corresponding to asymmetric and symmetric 
carboxylate ion stretching, characteristic of the presence of acetate ions in the chitosan 
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acetate salt and suggesting incomplete deacetylation of chitosan (Noriega & 
Subramanian, 2011; Demarger-Andre & Domard, 1994). Therefore, the chemical groups 
of SPCHTs/TNaOH and SPCHTs/TEtOH exposed to PRP and h-AdMSCs during in vitro 
assays are –NH3+ and –OH from the chitosan chain, which favor osteoblast 
differentiation (Chang & Wang, 2011). 
The formation of an intermolecular complex between the–NH3+ group of chitosan 
and the P3O10-5 of TPP in the SPCHTs/CTPP was characterized by the presence of the 
P=O and P-O groups at the frequencies of 1100 cm-1 and 1232 cm-1, respectively (Mi et 
al., 1999). In this case, the crosslinking decreased the positive charge on the chitosan 
exposed to PRP and h-AdMSCs during the in vitro assays. However, there is increased 
scaffold hydrophilicity due to the presence of –OH and P=O groups from TPP that favor 
cell spreading, proliferation and differentiation (Chang & Wang, 2011). 
Thus, the stabilized scaffolds prepared in this work show chemical surfaces 
favorable for cell processes required for tissue regeneration as well as being suitable for 
the adhesion and support of the fibrin network from PRP, which has a negative charge. 
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Figure 17. ATR-FTIR spectra of SPCHTs/TNaOH, SPCHTs/TEtOH, SPCHTs/CTPP and 
NTPCHTs. 
 
4.3.2. Physicochemical and mechanical properties of SPCHTs 
In addition to surface chemistry, physicochemical and mechanical properties such 
as porous structure, Young’s modulus, swelling and degradation over time play 
important roles in the performance of scaffolds. It is known that the microstructural 
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characteristics such as pore size and distribution, porosity and pore shape have 
prominent influences on cell intrusion, proliferation and function in tissue engineering 
(Ma et al., 2003). When PRP is associated, the microstructure might also induce 
activation as well as support the fibrin network on the internal and external surfaces. 
These properties in conjunction are shown in Figure 18, for an easier comparison of the 
SPCHTs. 
The micrographs obtained by SEM [Figure 18(a)] showed three-dimensional 
structures with visually interconnected pores in all cases. Scaffolds with open and 
interconnected pores are essential for cell nutrition, proliferation and migration 
promoting the vascularization and formation of new tissues (Loh & Choong, 2013). 
However, the surface chemistry provided by the treatments produced significant 
differences in the scaffolds.  
The Young’s modulus values [Figure 18(b)] were similar for SPCHT/TNaOH and 
SPCHT/TEtOH, approximately 1.4 MPa, but significantly larger than NTPCHTs (1.1 
MPa). SPCHT/CTPP exhibited the highest mechanical resistance (1.8 MPa) due to the 
physical crosslinking, as expected. 
Regardless of the type of treatment, the mean pore diameter [Figure 18(b)] could 
be controlled around 100-200 µm. Tiğli et al. (2007) also obtained a pore size in the 
range of 100 µm. Although controversial, several researchers have suggested optimal 
pore structures for the regeneration of specific tissues. Pore sizes of 100–400 µm and 
200–350 µm have been suggested for bone tissue regeneration and osteoconduction, 
respectively (Oh et al., 2007). 
The smallest pores from TPP treatment are from crosslinking and entanglement 
of the chains of chitosan.  
According to Ma et al. (2003), an additional freeze-drying can induce the fusion of 
some smaller pores to generate larger ones, or the slight collapse of the scaffold of the 
structure might reduce pore size. Therefore, in our scaffolds, the collapse effect was 
more prominent than fusion because the pores were smaller for all treatments. In 
addition, this effect seemed to be homogeneous in the structures.  
According to Liu & Ma (2004), high porosity of scaffolds (such as ≥ 90%) is 
important for any tissue engineering applications, including bone. 
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Porosity was similar for SPCHT/TNaOH and NTPCHT. A significant reduction in 
porosity and pore size was observed after rehydration and new lyophilization for 
SPCHT/CTPP. Final porosities were in the range of 93-97% [Figure 18(c)]. These 
values agree with those reported by Amaral et al. (2006) for similar scaffolds.  
The water uptake property of the raw materials primarily influences the 
maintenance of the chitosan scaffolds’ shape. Deformations in the structure affect cell 
proliferation and migration. The SPCHTs/TNaOH and SPCHTs/TEtOH [Figure 18(d)] 
exhibited rapid swelling in PBS pH 7.4 within 5 minutes. After 24 h their SR values were 
11 ± 1 and 14 ± 3, respectively, indicating extremely hydrophilic structures with the 
capacity to accommodate in their 3D structure large amounts of saline solution. 
SPCHTs/CTPP showed smaller SR in 24 hours (5.9 ± 0.4) because the crosslinking that 
reduces the functional groups that hydrogen bond with water and decreased the pore 
size and porosity. NTPCHT rehydrated in a neutral aqueous medium after 24 hours of 
rapid swelling and ultimately dissolved, indicating that the lyophilized structure was 
composed of soluble chitosan acetate. 
The swelling was stabilized after 7.5 hours and increased in the following order: 
SPCHTs/TEtOH> SPCHTs/TNaOH> SPCHTs/CTPP. It was not possible to measure the 
swelling of NTCHTs after 7 days due to the fragility of its structure. 
Degradation profiles were similar over 30 days. These results indicated that the 
treatments reduced the solubility of chitosan, providing stability to the scaffolds 
compared to NTCHTs. The high weight loss (approximately 40%) of SPCHTs/TNaOH 
and SPCHTs/TEtOH likely occurs due to the presence of residual chitosan acetate that 
can cause rapid swelling and subsequently dissolution in a neutral aqueous medium.  
Both processes, degradation and swelling, occur simultaneously and compete 
with other. 
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Figure 18. Physicochemical and mechanical properties of the PCHTs. (a) Photographs 
and SEM micrographs of the cross-section of the scaffolds. Original magnification is 
×100 and the scale bar represents 200 µm. (b) Young’s moduli and pore size; (c) 
Porosity (*The means difference are significant at level at p<0.05); (d) Swelling profile in 
PBS pH 7.4 at 37°C; (e) Degradation profile in PBS pH 7.4 at 37°C expressed as weight 
loss. Values are the mean ± standard deviation. (■) SPCHTs/TNaOH; (●) 
SPCHTs/TEtOH; (▲) SPCHTs/CTPP and (□) NTPCHTs. 
 
The freeze-drying technique limits the pores to medium sizes and the mechanical 
properties of the porous structures even after cross-linking (Costa-Pinto et al., 2011). 
Therefore, the physicochemical characterization suggests that the SPCHTs might 
* 
* 
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be useful for bone regeneration. Stabilization provided pore sizes in the range of 100-
150 µm and porosities higher than 90%. In addition, they prevented the collapse of the 
structures after at least 10 days in PBS at pH 7.4 with swelling capacity. However, 
mechanical resistance was low, requiring further treatments for application in regions 
exposed to high shear. 
 
4.3.3. Biological properties of SPCHTs 
SEM characterization [Figure 19(a)] of the aP-PRP/PCHTs composite scaffolds 
after 5th days of culture indicated cell attachment and a fibrin network inside the pores 
and on the surface of SPCHTs. aP-PRP was used as control. 
The cell compatibility, as assayed by MTT, of h-AdMSCs cultured in the presence 
of SPCHTs is shown in [Figure 19(b)]. This assay is widely used to determine cellular 
toxicity, viability and proliferation (Gümüşderelioglu & Aday, 2011). The results revealed 
no potential cytotoxicity over 24 hours for the SPCHTs according to the standard values 
(PCT). However, we observe reduced viability compared to the negative control toxicity 
(NCT) for SPCHTs/TNaOH and SPCHTs/CTPP.  
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Figure 19. (a) SEM images of cells on aP-PRP/SPCHTs after 5 days of culture. Scale 
bars indicate 3 µm (magnification = 5,000x). (b) The compatibility of h-AdMSCs that 
were exposed to SPCHTs. Negative control (NTC) = DMEM with 10% FBS; positive 
control (PTC) = DMEM with phenol 0.5%. Mean ± standard deviation n = 3. The 
population means are significantly different from the positive control at *p<0.05. (c) 
Proliferation profile of h-AdMSCs cultured in aP-PRP/SPCHTs as a function of time. aP-
PRP and NTPCHTs were used as controls. Platelets were concentrated in aP-PRP at 
approximately 1.84 times the basal value. The average concentration was 393,000 
pq/mm3. (d) PDGF-AB release profile from aP-PRP/SPCHTs. Platelets were 
concentrated in aP-PRP at approximately 2.09 times the basal value. The average 
concentration was 472,250 pq/mm3. (e) TGF-β1 release profile from aP-PRP/PCHTs. 
Platelets were concentrated in aP-PRP at approximately 2.09 times the basal value. The 
average concentration was 472,250 pq/mm3. (f) ALP activity of cells cultured on 
SPCHTs (statistically significant differences from blank, n=3, *p<0.05). NTPCHTs is the 
control group, blank = the reagents used in the assay only. Platelets were concentrated 
in aP-PRP at approximately 1.79 times the basal value. The average concentration was 
280,500 pq/mm3. (Δ) aP-PRP and (□) NTPCHT were both used as controls; (●) 
SPCHTs/TEtOH; (■) SPCHTs/TNaOH, and (▲) SPCHTs/CTPP.  
The cell number per well as a function time for aP-PRP/ SPCHTs [Figure 19(c)] 
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showed that the number of viable cells determined after 3 days exceeded the number of 
seeded cells (1.4 x 104 cells/well) in all of the composite scaffolds, indicating that the 
cells grown in the matrices retained their viability, regardless of the treatment. The 
results also indicated cell proliferation was significantly higher (p<0.05) for the aP-
PRP/SPCHTs compared to the control aP-PRP. Cultivation in aP-PRP/SPCHTs/TNaOH 
showed faster cell proliferation, and the stationary phase was reached in 5th days, 
whereas for aP-PRP/SPCHTs/CTPP the proliferation shows a nearly linear increasing 
profile. In aP-PRP/SPCHTs/TEtOH, the cells had a longer lag phase (5 days) followed 
by an exponential phase in the subsequent period.  
TEtOH has the added advantage of allowing direct sterilization of samples in 70% 
ethanol; however, after treatment, the scaffolds should be equilibrated with culture 
medium or PBS for several hours prior to any cell seeding or in vivo implantation activity 
(Oh et al., 2007).  
Cultivation in aP-PRP/NTPCHT reached the exponential phase in 5th days and 
decreased sharply afterward due to the collapse of the non-stabilized structure.  
The curves of Figure 19(d) and 19(e) show PDGF-AB and TGF-β1 release 
kinetics from aP-PRP/SPCHTs with aP-PRP and aP-PRP/NTPCHTs used as controls. 
The curves show diffusive controlled profiles, indicating no collapse of the porous 
structure of chitosan scaffolds over the duration of the assays. The differences in the 
profiles are due to interactions of the GFs with the surface groups generated by the 
various stabilizing treatments.  
The ALP activity of h-AdMSCs assayed after 14 days of cultivation is shown in 
Figure 19(f). The ALP activity of the cells cultured on aP-PRP/SPCHTs and aP-
PRP/NTPCHTs scaffolds showed significant differences from the control (p<0.05), 
suggesting that the composite scaffolds favored osteogenic differentiation. Moreover, 
the differentiation of the composite scaffold treated with TEtOH was significantly higher 
than for non-stabilized PCHT. 
 
4.4. Conclusions 
 
Composite scaffolds of stabilized porous chitosan and activated P-PRP were 
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prepared and characterized. The stabilization of the porous chitosan was accomplished 
by using various treatments. In general, the composite scaffolds controlled the release 
of growth factors and improved proliferation of h-AdMSCs that were seeded compared 
to activated P-PRP. Osteogenic differentiation evaluated by ALP marker was favored by 
the stabilization provided mainly by the ethanol series treatment. These findings are 
important for optimizing composite scaffolds for applications in regenerative medicine.  
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Abstract: This study aimed to evaluate the in vitro biological effectiveness of chitosan-
sodium tripolyphosphate microparticles in combination with activated platelet-rich 
plasma as an injectable composite scaffold for growth factor release, cell proliferation 
and osteogenic differentiation. The microparticles were prepared by vortexing the 
chitosan and TPP solutions. The ionic crosslinking of chitosan with TPP was made at 
mass ratios of 2:1, 5:1, and 10:1 at pH 4.0. Pure platelet-rich plasma (P-PRP) was 
obtained via the controlled centrifugation of whole blood. The composite scaffolds were 
prepared by adding the microparticles to immediately activated P-PRP. The results 
showed that the microparticles enhanced the physicochemical and mechanical 
properties of aP-PRP. The proliferation of human adipose-derived mesenchymal stem 
cells was lower than in aP-PRP but significant at a 2:1 chitosan:TPP mass ratio. 
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Osteogenic differentiation was stimulated at all studied mass ratios, as indicated by the 
ALP activity. These results offer perspectives for optimizing the composite scaffold, and 
to prove its potential as an injectable scaffold in regenerative medicine. 
 
Keywords: Chitosan; tripolyphosphate; platelet-rich plasma; injectable scaffolds; 
composite. 
 
5.1. Introduction 
 
Due to their minimally invasive implantation procedures, injectable scaffolds have 
being widely investigated and are considered promising in tissue engineering (Kretlow et 
al., 2007). 
From the clinical perspective, the use of injectable scaffolds is advantageous 
because it minimizes patient discomfort, the risk of infection and scarring, and the cost 
of treatment (Hou et al., 2004). Furthermore, injectable scaffolds can homogeneously fill 
the defect or repair point and can incorporate cells and various therapeutic agents such 
as growth factors prior to injection (Gutowska et al., 2001).  
From the biomaterial perspective, adequate injectable scaffolds must be nontoxic, 
biodegradable, and sterilizable. Moreover, they must solidify under mild conditions, 
show mechanical strength and resistance to in situ forces and allow for the incorporation 
of bioactive molecules. 
Various types of biodegradable materials have been proposed for the preparation 
of injectable scaffolds used in tissue engineering. Considerable attention has been given 
to chitosan-based materials, primarily due to their similarities with the extracellular 
matrix, chemical versatility, good biological performance, and specific cellular 
interactions (Costa-Pinto et al., 2011).  
Chitosan scaffolds has been prepared as hydrogels by physical association 
(Berger et al., 2004), coordination with metal ions (Brack et al., 1997) and chemical 
crosslinking (Hennink & Van Nodtrum, 2002). However, the use of chemical crosslinking 
agents are a major obstacle to scaffolds fluids due to their toxicity to the cells. Thus, 
tripolyphosphate (TPP) and genipin have become attractive alternatives to chitosan 
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crosslinking (Bhumkar & Pokharkar, 2006; Ibezim et al., 2010; Harris et al., 2010; 
Karnchanajindanun et al., 2010).  
The electrostatic interaction between chitosan and TPP leads to the formation of 
biocompatible crosslinked chitosan hydrogels, which could be used as injectable 
scaffolds in micro- and/or nanoparticles in non-surgical treatments.  
Platelet-rich plasma (PRP) is an autologous concentrate of platelets and other 
components of plasma that is capable of releasing the growth factors and cytokines 
used in tissue regeneration (Anitua, 1999; Foster et al., 2009). PRP has been 
successfully used in regenerative medicine (Crane & Everts, 2008; Cole et al., 2010). 
When activated, aP-PRP produces a fibrin network with a gel-like structure that 
supports cell proliferation and differentiation (Marx, 2004). Efforts have been made to 
improve the stability and rheological properties of the fibrin network. 
In our previous studies, we have shown that porous chitosan sponges stabilized 
by crosslinking with TPP had adequate physicochemical properties for tissue 
engineering uses. Moreover, in combination with aP-PRP, the sponges supported the 
fibrin network, increased its stability, delayed the release of PDGF-AB and TGF-β1 
compared to aP-PRP alone, and allowed the proliferation and differentiation of h-
AdMSCs.  
 In the present work, we extended our previous findings by evaluating the 
performance of the combination of chitosan microparticles and activated P-PRP as a 
composite scaffold. Our hypothesis is that the crosslinked microparticles will also 
improve the properties of aP-PRP alone, with the benefits of an injectable formulation. 
 
5.2. Materials and Methods 
 
5.2.1. Materials 
Chitosan (average molecular weight [Mw] = 4 x 105 Da, degree of deacetylation = 
83 ± 4%) was purchased from Polymar® (Fortaleza, Brazil) and purified according to the 
protocol described by Nasti et al. (2009). Other chemicals were reagent grade and were 
used without any further purification. All biological experiments were performed with 
human adipose-derived mesenchymal stem cells (h-AdMSCs) and approved by the 
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Ethics Committee of the Medical Sciences School of the University of Campinas 
(UNICAMP; CAAE: 0972.0.146.000-11). The donors were healthy individuals between 
30 and 40 years old and were previously assessed through their clinical examinations. 
 
5.2.2. Preparation of injectable scaffolds of chitosan-sodium 
tripolyphosphate (iCHT-TPPs) 
The injectable scaffolds (iCHT-TPPs) prepared in this work are composed of 
hydrogels of chitosan microparticles that were ionically crosslinked with TPP. Initially, a 
chitosan solution 2.5% (w/v) was prepared by dissolution in acetic acid 5% (w/v). TPP 
solution was prepared as a 5% (w/v) solution in Milli-Q water. The solutions were mixed 
at mass ratios CHT-TPP of 2:1, 5:1 and 10:1 and vortexed for 5 minutes to obtain the 
microparticles. The crosslinking was carried out at 25°C for 24 hours at pH 4. The 
hydrogels were washed three times with water and phosphate buffered saline (PBS) (LB 
Laborclin, Pinhais, PR, Brazil) at pH 7.4 and centrifuged at 10,000 rpm for 10 minutes. 
 
5.2.3. Physicochemical Characterization  
5.2.3.1. Chemical modification.  
The ionic crosslinking was characterized by Fourier-transform infrared (FTIR) in a 
Thermo Scientific Nicolet model 6700 (Thermo Scientific Nicolet™, Waltham, MA, USA). 
Measurements were made in the ATR mode with accessory SMART OMNI-SAMPLER, 
in the spectral range of 4000-675 cm-1 resolution of 4 cm-1 and 64 scans. Pure chitosan 
was used as control. 
ATR-IR (chitosan): 3500–3000 (ν OH and NH2), 2875 (νCH), 1645 (amide I), 
1550 (amide II) 1380, 1067, 1020 cm−1 (Nasti et al., 2009). 
 
5.2.3.2. Crosslink density Flory-Rehner calculations.  
Crosslink density was evaluated by measuring the volumetric swelling and using 
a simplified version of the Flory-Rehner equation (Flory & Rehner, 1943), according to 
Collins & Birkinshaw (2008). The value used for chitosan–water interaction parameter 
(χ) was 0.5917 (Jin & Song, 2006). 
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5.2.3.3. Particle diameter measurements 
The mean diameter of the particles was evaluated by laser light scattering in a 
Mastersizer S particle size analyzer, model Long Bench-MAM 5005 (Malvern 
Instruments, Worcestershire, UK). The particle size analysis was performed with the 
hydrogels dispersed in water. The standard deviation was calculated from five 
measurements of the mean diameter. 
 
5.2.3.4. Rheology measurements.  
Rheological measurements were performed in steady and oscillatory regimes at 
25°C, using a parallel plate geometry of 20 mm. Steady shear measurements were 
obtained at shear rates of 0.1-50 s-1. Oscillatory measurements were conducted in the 
linear region, at a stress of 1.188 Pa and in the frequency range of 0.01 to 10 Hz. All 
rheological measurements were performed on a rheometer Haake RheoStress 1 
(Haake, Karlsruhe, Germany).  
 
5.2.3.5. Extrusion force.  
Initially the iCHT-TPPs were loaded in 1-mL plastic syringes with 30-gauge 
needles. Subsequently, the force required to extrude was measured using a MTS 810 
Servo-hydraulic Universal Testing Machine (MTS Systems Corporation, Eden Prairie, 
MN, USA) (Load Cell 1.5 kN) at 25°C at a 5.0 mm/ min extrusion rate. 
 
5.2.3.6. Swelling ratio (SR).  
The microparticles were weighed after swelling in phosphate buffered saline 
(PBS) at pH 7.4, and their dry weight was determined by drying under vacuum (1 
mmHg) at 25°C after 3 days. SR was calculated using the Equation (1): 
 
SR =  
ws
wd
                                                                                                            Equation (1) 
 
where ws and wd are the weights of the scaffolds at the swelling state and the dry state, 
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respectively. 
5.2.3.7. Degradation in phosphate buffered saline.  
The degradation of iCHT-TPPs was examined with respect to weight loss. The 
weight loss of the initially weighed iCHT-TPPs (wo) was monitored as a function of 
incubation time in PBS at 37°C. At specified time intervals, iCHT-TPPs were removed 
from the PBS and weighed (wt). The weight loss ratio was defined as in Equation (2) 
(Tan et al., 2009). 
 
weight loss (%) =
(w0−wt)
w0
𝑥 100                                                                        Equation (2) 
 
5.2.4. Biological characterization 
5.2.4.1. Cell compatibility.  
The compatibility of the iCHT-TPPs was carried out by exposure to h-AdMSCs 
and cultivation at 37°C for 24 hours. The cell compatibility was evaluated using a 
modified MTT (3-[4,5-dimethyl-thiazol-2-yl]-2,5-diphenyltetrazolium bromide) assay 
(MTT, Molecular Probes®, São Paulo, SP, Brazil) (Mossmam, 1983). The MTT assay is 
a colorimetric test that is based on the reduction of yellow tetrazolium salt into a purple 
formazan product in presence of cells (Gümüşderelioğlu & Aday, 2011).  
 
5.2.5. Preparation of pure platelet-rich plasma (P-PRP) 
P-PRP, a PRP type that is rich in platelets and poor in leukocytes, was prepared 
according to Perez et al. (2013). Briefly, whole blood (WB) was collected into 3.5 mL 
vacuum tubes (Vacuette®, Campinas, SP, Brazil) containing sodium citrate 3.2% (w/v) 
as an anticoagulant. WB was initially centrifuged in a Rotina 380R centrifuge (Hettich® 
Zentrifugen, Tuttlingen, Germany) at 100 xg for 10 minutes at 25°C. After the formation 
of three layers (a bottom layer composed primarily of red blood cells (RBCs); an upper 
layer composed of plasma, platelets and some WBCs; and an intermediate layer, or 
buffy coat, composed primarily of WBCs), only the upper layer was collected to obtain P-
PRP. The concentrations of platelets, WBCs and RBCs in WB and in P-PRP were 
determined using the ABX Micros ES 60 hematology analyzer (HORIBA ABX 
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Diagnostics, Montpellier, France). 
5.2.5.1. Activation of P-PRP (aP-PRP) 
aP-PRP was prepared via the activation of P-PRP with autologous serum (Ser) 
and 10% (w/v) CaCl2 solution as agonists using the following proportions: agonist/P-
PRP=20%; Ser/CaCl2 volumetric ratio=9. Autologous serum was prepared by collecting 
5 mL of WB in tubes without anticoagulant. After 30 minutes of clot formation, WB was 
centrifuged at 2000 xg for 10 minutes.  
 
5.2.6. Preparation of composite scaffold (aP-PRP/iCHT-TPPs) 
aP-PRP/iCHT-TPPs was prepared by embedding by dripping aP-PRP, 
immediately after activation, into iCHT-TPPs. The preparation was carried out in 48-well 
microplates using 200 µL of aP-PRP/ 100-200 mg of iCHT-TPPs. 
 
5.2.7. Characterization of aP-PRP/iCHT-TPPs 
 
5.2.7.1. Release of GFs 
The release of platelet-derived growth factor AB (PDGF-AB) and transforming 
growth factor β1 (TGF-β1) was performed after a 1 hour gelation of aP-PRP associated 
to iCHT-TPPs in the presence of the culture medium Dulbecco's Modified Eagle's 
Medium with low glucose concentration (DMEM-LG, Gibco, Grand Island, NY, USA). 
The culture medium (1.5 mL) was added to aP-PRP/iCHT-TPPs in 48-well microplates, 
which were maintained in an incubator with 5% CO2 throughout the assays. The total 
volume of culture medium was withdrawn at 3, 6, 12, 24 and 72 hours, and the same 
volume of fresh medium was replaced without removing the hydrogels from the wells. 
The samples were stored at -80°C for further characterization. The concentrations of the 
released GFs PDGF-AB and TGF-β1 were measured using enzyme-linked 
immunosorbent assay (ELISA) kits (R&D Systems, Minneapolis, MN, USA) according to 
the manufacturer’s instructions and specifications.  
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5.2.8. h-AdMSCs isolation and pre-cultivation 
Human subcutaneous adipose tissue, initially acquired from liposuction surgery, 
was washed with sterile PBS, separated into fractions of 10 g, digested with 20 mg of 
collagenase type 1A and maintained in 20 mL of DMEM-LG containing 10% BSA 
(bovine serum albumin) and 10 µL of gentamicin for 30 min in a bath at 37°C. After 
complete digestion, the reaction was quenched with 10 mL fetal bovine serum (FBS) 
and immediately centrifuged for 15 min at 1500 rpm. The supernatant was discarded, 
and the pellet was suspended in 10 mL DMEM-LG with 10% FBS. After pre-cultivation 
for 24 h, the culture medium was changed every 3 days; after the fourth passage, the 
cells were characterized by immunophenotyping using flow cytometry and by 
adipogenic, osteogenic and chondrogenic differentiation (data not shown) and were then 
used in the subsequent experiments. 
 
5.2.9. Culture of h-AdMSCs-seeding in the composite scaffolds 
The pre-cultured h-AdMSCs were trypsinized and resuspended in P-PRP to a 
final cell concentration of 1 x 104 cells/mL. P-PRP containing h-AdMSCs was activated 
and immediately embedded into the iCHT-TPPs in a 24-well tissue culture plate, using 
200 µL of h-AdMSCs+aP-PRP/100-200 mg of iCHT-TPPs. The composite scaffolds with 
h-AdMSCs were kept at room temperature for 45 minutes for the consolidation of the 
fibrin network. Activated PRP was used as a control.  
 
5.2.9.1. h-AdMSCs proliferation  
The cultivation of h-AdMSCs was carried out in 24-well tissue culture plates by 
adding 1 mL of the culture medium DMEM to the seeded composite scaffolds (n=4). The 
seeded composite scaffolds was maintained at 37°C along 10 days. Cell proliferation 
was quantified using the thiazolyl blue tetrazolium bromide (MTT) assay. At cultivation 
days 3, 5, 7 and 10, the composite scaffolds were removed and transferred to 24-well 
plates. MTT (1 mL of 1 mg/mL) was then added, and the cultivation proceeded at 37°C 
for 4 hours. The MTT solution was then discarded, and 1 mL of dimethylsulfoxide 
(DMSO) was added to dissolve the purple formazan crystals. The samples were shaken 
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at 120 rpm for 30 min to ensure the homogeneous dissolution of the formazan dye, and 
200 µL of each sample was then transferred to a 96-well plate. Optical density was 
measured at 595 nm using a microplate reader (FilterMax F5 Molecular Devices). 
5.2.9.2. Images of the cell-seeded composite scaffolds 
The images of cell-seeded composite scaffolds were obtained by scanning 
electron microscopy after 5 days of h-AdMSCs proliferation. The cell-seeded composite 
scaffolds were fixed in a solution of 4% paraformaldehyde and 2.5% glutaraldehyde in 
phosphate buffer, pH 7.4, for 2 hours. The samples were than dehydrated in ethanol for 
15-min intervals in aqueous 50%, 70%, 95% and 100% ethanol solutions (2x) and dried 
using the critical point dryer BAL-TEC CPD 030 (BAL-TEC®, Schalksmühle, Germany). 
After gold coating in Sputter Coater POLARON SC7620 (VG Microtech, Ringmer, UK), 
the cell-seeded composite scaffolds were visualized using a scanning electron 
microscope Leo440i (LEO Electron Microscopy/Oxford, Cambridge, UK) with an 
accelerating voltage of 20 kV. 
 
5.2.9.3. Induction of osteogenic differentiation 
h-AdMSCs-seeding composite scaffolds were induced to differentiate into the 
osteogenic lineage by providing the osteogenic medium containing DMEM-LG 
supplemented with 10% FBS, 1% β-glycerol-phosphate (Sigma-Aldrich, St. Louis, MO, 
USA), 1% L-ascorbic acid (Sigma-Aldrich, St. Louis, MO, USA), 1% dexamethasone 
(Sigma-Aldrich, St. Louis, MO, USA) and 1% Penicillin/Streptomycin solution (Gibco, 
Grand Island, NY, USA). The medium was changed every 7 days.  
 
5.2.9.4. Alkaline phosphatase activity (ALP) 
The alkaline phosphatase (ALP) activity produced by h-AdMSCs was determined 
on day 14. Here, 200 μL of the supernatant was collected and mixed with 200 μL of p-
Nitrophenyl phosphate (SIGMAFAST™ p-Nitrophenyl phosphate Tablets, Sigma, Saint 
Louis, MI, USA) as substrate and subsequently incubated at room temperature for 30 
minutes. Absorbance was read immediately on a spectrophotometer at 405 nm.  
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5.2.10. Statistical analysis 
Each experiment was carried out in triplicate unless otherwise specified. All 
results are presented as the mean ± standard deviation (SD). The experimental data 
from all of the studies were analyzed using Analysis of Variance (ANOVA). Statistical 
significance was set at a p-value ≤ 0.05. 
 
5.3. Results and discussion 
 
5.3.1. Crosslinking in the injectable scaffolds of chitosan-sodium 
tripolyphosphate (iCHT-TPPs). 
According to Bhumkar and Pokharkar (2006), chitosan (pKa 6.3) may be 
crosslinked with TPP (pKa 9.7) by two different pH-dependent mechanisms (Figure 20). 
The ionic crosslinking occurs at low pH values by a reaction between NH3+ 
groups of chitosan and P3O10-5 of TPP [Figure 20(a)]. The deprotonation mechanism 
occurs at high pH values using the OH- groups of TPP that are present in solution 
[Figure 20(b)]. In this work, the pH of the reaction mixture was maintained at pH 4, which 
favored the ionic crosslinking mechanism.  
 
 
 
 
(A) (B) 
Figure 20. Interaction of chitosan with TPP by (a) ionic crosslinking or (b) deprotonation. 
 
The FTIR spectra of pure chitosan and iCHT-TPPs 2:1 are shown in Figure 21. 
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Pure chitosan was characterized by bands at 3449 cm–1 attributed to the –NH2 
and –OH groups’ stretching vibration and the band of amide I at 1639 cm–1 (Bhumkar & 
Pokharkar, 2006).  
The ionic crosslinking between the –NH3+ group of chitosan and P3O10-5 of TPP in 
iCHT-TPPs (2:1) was characterized by the presence of the P=O and P-O groups at the 
frequencies of 1100 cm-1 and 1232 cm-1, respectively (Mi et al., 1999).  
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Figure 21. FTIR spectrum of pure chitosan and iCHT-TPPs 2:1. 
 
5.3.2. Physicochemical and mechanical properties of iCHT-TPPs.  
The water absorption capacity (swelling properties) of scaffolds must be carefully 
controlled to allow handling during cell implantation and promote cell growth. When 
hydrated, the scaffolds became fragile being deformed and/ or broken with the 
application of small forces. Thus, a balance between the viscoelastic and swelling 
properties is essential to maintain the integrity of scaffolds and support the cell 
proliferation and differentiation.  
Table 2 shows the physicochemical and rheological properties of iCHT-TPPs 
prepared by varying the CHT-TPP mass ratio. The iCHT-TPPs showed a high swelling 
capacity (SR), allowing for fast hydration when culture medium was added. Moreover, 
SR decreased with the degree of crosslinking because of the decreased availability of 
functional groups to hydrogen bonds with water.  
Flory-Rehner calculations were used to determine the effective crosslink density (Ve) 
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and the molecular weight between crosslinks (Mc). The decrease of the CHT-TPP mass 
ratio increased Ve, as expected (Flory & Rehner, 1943). Moreover, we observed lower 
Mc values, indicating higher entanglement of chains.  
We also estimated the charge ratio (R+/-) of iCHT-TPPs according to Rädler et al. 
(1998). The values of R+/- were negative for iCHT-TPPs 2:1 and positive for iCHT-TPPs 
5:1 and 10:1. Therefore, the increase in the crosslinking degree decreased the positive 
charge of chitosan in the complex. These modifications to the charge ratio may change 
the interactions with the fibrin network and alter the electrostatic interaction with growth 
factors.  
The microparticles in iCHT-TPPs had a mean diameter in the range of 150 to 220 
µm, which was proportional to the CHT-TPP mass ratio. These diameters are within the 
adequate range for an injectable application (<700 µm) (Kablik et al., 2009). 
 
Table 2. Physicochemical and mechanical properties of iCHT-TPPs. 
Physicochemical properties 
Mass ratio CHT:TPP SR Ve (mol.cm-3) Mc  (g.mol-1) R+/- Particle diameter (µm) 
2:1 
5:1 
10:1 
22 ± 1 
31 ± 1 
44 ± 1 
2.4 x 10-4 
1.3 x 10-4 
7.5 x 10-5 
5110 
9450 
16669 
0.7 
1.8 
3.6 
152 ± 4 
205 ± 3 
215 ± 4 
Rheological properties 
Mass ratio CHT:TPP G’ in 1 Hz (Pa) n tan δ Extrusion force (N) 
2:1 
5:1 
10:1 
522 
333 
72 
0.04 
0.15 
0.32 
0.134 
0.174 
0.276 
12.6 ± 0.9 
10.8 ± 0.4 
11.1 ± 0.8 
SR=swelling ratio; 
Ve=Effective crosslink density; 
Mc=Molecular weight between crosslinks; 
R+/-=charge ratio; 
G’=elastic moduli; 
G”=viscous moduli; 
tan δ=G”/G’; 
n= flow behavior index. 
 
The rheological data (Table 2) show that the iCHT-TPPs exhibited behavior that 
is typical of so-called weak gels, irrespective of their mass ratios, as analyzed by the 
storage (G’) and loss moduli (G”). The moduli had low frequency dependence, and tan δ 
>0.1 (Ikeda & Nishimari, 2001; Clark & Ross-Murphy, 1987). 
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We also observed an increase in the G’ values with the number of crosslinks or 
entanglements (high Ve and low Mc), which indicated stiffer gels.  
In addition, the values of tan δ indicated an increment in gel strength with an 
increase in Ve. Regardless of the CHT-TPP mass ratio, iCHT-TPPs showed G’ values 
that are adequate (<700 Pa) for injectable application (Kablik et al., 2009).  
Considering the Ostwald de Waele power law (η=K.γn-1), the flow indices (n) of 
iCHT-TPPs showed a viscoelastic behavior that was dependent on mass ratio. The 
pseudoplastic behavior is an important parameter in injectable applications, where the 
flow viscosity should be lower than the rest viscosity. 
In addition to the beneficial rheological properties and microparticle size, the 
injectable scaffolds must have an extrusion force to allow for their easy injection through 
an appropriately sized needle and thereby prevent side effects such as pain (Kablik et 
al., 2009). 
 In iCHT-TPPs, we measured extrusion forces between 10 and 12 N, which were 
adequate (<20 N) for injectable applications (De Melo & Marijnissen-Hofste, 2012; 
Öhrlund, 2010). No modifications were observed in the extrusion force with the degree 
of crosslinking, particle size and distribution, as reported by Bentkover (2009). 
Figure 22 shows the loss weight of iCHT-TPPs after incubation in PBS, pH 7.4, at 
37°C. The microparticles can be considered stable for 30 days, irrespective of the CHT-
TPP mass ratio. The maximum loss weight was approximately 4%, for CHT-TPP 2:1.  
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Figure 22. Degradation profile of iCHT-TPPs in PBS pH 7.4 at 37°C. (■) iCHT-TPPs 
2:1; (●) iCHT-TPPs 5:1 and (▲) iCHT-TPPs 10:1. 
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5.3.3. Biological characterization 
Figure 23 shows the PDGF-AB and TGF-β1 release kinetics from aP-PRP/iCHT-
TPPs.  
The curves shows predominantly diffusive profiles, indicating no collapse of the 
scaffold structure at the time of the assays. Controlled GF release was achieved from 
aP-PRP/iCHT-TPPs compared with aP-PRP alone. The maximum PDGF-AB release 
was obtained at 24 hours [Figure 23(a)], whereas a concentration plateau was not 
observed for TGF-β1 at 72 hours [Figure 23(b)].  
In addition to the barrier of the structures, the interactions of GF and scaffolds 
play an important role in the release. According to Hokugo et al. (2005) and De Cock et 
al. (2012), because GFs are generally basic proteins, in physiological conditions, they 
interact ionically with negatively charged surfaces.  
In this work, we observed a slower release in the PDGF-AB for the scaffold aP-
PRP/iCHT-TPPs mass ratio 2:1 compared with aP-PRP, suggesting electrostatic 
interactions with negative charges of the scaffold. At physiological pH, PDGF-AB bore a 
net positive charge (isoelectric point 9.8-10.5) (De Cock et al., 2012). 
For TGF-β1, a slower release was observed for the scaffolds aP-PRP/iCHT-TPPs 
at mass ratios of 5:1 and 10:1 compared with aP-PRP. Because TGF-β1 has the 
isoelectric point of 8.2, which is near the physiological pH (7.4), the positive charges of 
the scaffolds had a smaller influence on controlled release (Wang et al., 2011).  
In this case, we hypothesized that the slower release was primarily due to the 
interaction of the negative fibrin network and the positive scaffold, which entrapped the 
GF molecules.  
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(a) (b) 
Figure 23. Growth factor release profiles from aP-PRP combined with CHT-TPP 
scaffolds. (a) PDGF-AB and (b) TGF-β1. (Δ) PRP activated with Ca+2/serum used as 
control; (■) aP-PRP/iCHT-TPPs 2:1; (●) aP-PRP/iCHT-TPPs 5:1 and (▲) aP-PRP-iCHT-
TPPs 10:1. The concentration of platelets in whole blood donors (average of 2 donors) 
was 234,250 pq/mm3. After preparation of the P-PRP, the platelets were concentrated 
approximately 2.09 times, with an average final concentration of 472,250 pq/mm3. 
 
Scanning electronic microscopy (Figure 24) of aP-PRP showed a tangled network 
that was similar to the extracellular matrix. The microparticles were entrapped by the 
fibrin network, which provided an additional matrix for h-AdMSCs adherence and 
proliferation. 
  
aP-PRP aP-PRP/iCHT-TPPs 2:1 
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aP-PRP/iCHT-TPPs 5:1 aP-PRP /iCHT- TPPs 10:1 
Figure 24. Scanning electron microscopic images of aP-PRP and aP-PRP/iCHT-TPPs 
after 5 days of cultivation of h-AdMSCs.  
 
The proliferation of h-AdMSCs cultured in the presence of iCHT-TPPs, as 
assayed by MTT is shown in Figure 25(a). In all of the prepared mass ratios, the iCHT-
TPPs had a higher proliferation compared with the positive control, which indicated 
compatibility.  
The proliferation kinetic profiles in presence of PRP [Figure 25(b)] showed a long 
lag phase (~7 days) for aPRP and aP-PRP/iCHT-TPPs at 2:1 and 5:1.  
The proliferation of h-AdMSCs was lower than aP-PRP in the composite scaffolds 
at 2:1 and 5:1 mass ratios, whereas no proliferation was observed at 10:1 aP-
PRP/iCHT-TPPs.  
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(a) (b) 
Figure 25. (a) % of NTC as a measurement of the compatibility of h-AdMSCs that were 
exposed to the iCHT-TPPs. Negative control (NTC) = DMEM with 10% FBS; positive 
control (PTC) = DMEM with phenol 0.5%. The population means are significantly 
different from positive control at *p<0.05. (b) Proliferation profile of h-AdMSCs cultured 
in aP-PRP/iCHT-TPPs scaffolds as a function of time. Activated PRP was used as 
control. (Δ) aP-PRP; (■) aP-PRP/iCHT-TPPs 2:1; (●) aP-PRP/iCHT-TPPs 5:1 and (▲) 
aP-PRP/iCHT-TPPs 10:1. The concentration of platelets in whole blood donors (average 
of 2 donors) was 215,375 pq/mm3. After preparation of the P-PRP, the platelets were 
concentrated approximately 1.79 times, with an average final concentration of 383,500 
pq/mm3. Mean ± standard deviation n = 3. 
 
Figure 26 shows significant ALP activity in the aP-PRP/iCHT-TPPs, indicating 
stimulation of osteoblast differentiation. It is known that ALP enzymatic activity is 
essential for mineralization. Differences among the structures could not be inferred 
because ALP activity was determined in the culture medium and thus did not include the 
concentrations inside the gels. This may have also contributed to the lower values of 
ALP activities of the composite scaffolds compared with aP-PRP, due to the higher 
viscosity, which delayed the release of ALP. 
* 
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Figure 26. ALP activities of h-AdMSCs cultured on composite scaffolds (*statistically 
significant differences from blank, n=3, p<0.05). Blank = the reagents used in the assay 
only). The concentration of platelets in whole blood donors (average of 2 donors) was 
214,000 pq/mm3. After preparation of the P-PRP, the platelets were concentrated 
approximately 2.31 times, with an average final concentration of 473,500 pq/mm3.  
 
5.4. Conclusions 
 
We have demonstrated that the injectable composite scaffolds (aP-PRP/iCHT-
TPP) promoted the controlled release of PDGF-AB and TGF-β1 from platelets primarily 
during the first 10 h. Although the physicochemical and rheological properties of iCHT-
TPP increased the stability of the fibrin network, a significant proliferation of AdMSCs 
was observed only for the composite scaffold containing 2:1 chitosan:TPP. However, the 
osteogenic differentiation was promoted in all mass ratios. Thus, the injectable 
composite scaffolds could be optimized to demonstrate their potential for regenerative 
medicine applications.  
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Abstract. The association of platelet-rich plasma (PRP) to fluid hyaluronic acid (HA) has 
yielded beneficial outcomes in vivo in orthopedic applications. However, aside from 
needing to repeat the applications, the literature is not conclusive about the 
improvements to efficiency or long-lasting effects related to PRP alone. Auto-crosslinked 
hyaluronic acid (ACP) may introduce benefits to the stability of fibrin network from 
activated PRP (aP-PRP) and to the mechanical properties of fluid HA. The main 
advantage of ACP is not introducing foreign molecules to the formulation. This study 
was undertaken to investigate in vitro association of aP-PRP and ACPs as composite 
scaffolds for growth factors release, the proliferation of human adipose-derived 
mesenchymal stem cells (h-AdMSCs) and differentiation by osteogenic marker alkaline 
phosphatase (ALP). ACP was prepared by organocatalyzed auto-esterification and 
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structured into microparticles or sponges to create injectable or solid scaffolds, 
respectively. The structured ACP were not cytotoxic and had better mechanical 
properties than does fluid HA. PRP was obtained by centrifuging whole blood without 
the buffy-coat layer (P-PRP). Autologous serum and calcium were used for P-PRP 
activation. Most of PDGF-AB (platelet-derived growth factor AB) and TGF-β1 
(transforming growth factor β-1) was released from aP-PRP alone or from the composite 
scaffolds in the first 10 hours. The release occurred in concert with the degradation time 
of the structured ACPs. The composite scaffolds improved h-AdMSCs proliferation and 
promoted ALP activity suggesting potential osteogenic differentiation. Therefore, aP-
PRP combined with ACP is a promising biomaterial for further biological studies and 
applications in regenerative medicine.  
 
Keywords: auto-crosslinked hyaluronic acid; controlled release; microparticles; PDGF-
AB; platelet-rich plasma; sponges; TGF-β1.  
 
6.1. Introduction 
Platelet-rich plasma (PRP) is a platelets concentrate prepared from whole blood, 
which is able to release growth factors following induced activation (Anitua 1999; Foster 
et al., 2009). PRP have been widely applied in various regenerative therapies and its 
beneficial effects has been proven mainly in cartilage regeneration, wound healing and 
sports medicine (Crane & Everts, 2008; Civinini et al., 2011; Kon et al., 2011; Amable et 
al., 2013). 
Since the 1990s, when clinical application of PRP began, three generations of 
formulations can be identified: the first generation applied PRP only; the second-
generation included bone marrow cells in PRP; and the third and current generation 
uses PRP and human adipose derived mesenchymal stem cells (h-AdMSCs). It has 
been reported that AdMSCs are comparable to bone marrow-derived MSCs (BM-MSCs) 
with respect to multi-lineage potential, growth kinetics, and cells senescence (de Ugarte 
et al., 2003). 
Recently, PRP has been used in combination to high molecular weight HA aimed 
to ensure better stability of the fibrin network, control release of GF and decrease pain 
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related to inflammation caused by injury in the application of PRP (Pak, 2012; de 
Angelis et al., 2012; Chen et al., 2014; Fathi, 2012; de Boulle et al., 2013). 
Pak (2012) has described different methods and pharmaceutical compositions 
comprising PRP, h-AdMSCs, HA and CaCl2 for the treatment, preventions or alleviation 
of bone and cartilage diseases.  
De Angelis et al. (2012) have treated patients with wound dehiscence and tendon 
exposure, showing that PRP combined with fluid hyaluronic acid (fHA) enables a more 
rapid regeneration of damaged tissues. 
Recently, Chen et al. (2014) demonstrated synergic effects of the anabolic 
actions of PRP-fHA on cartilage regeneration and the inhibition of osteoarthritis 
inflammation. Cytokine-induced degeneration was reduced through the recovery of 
chondrogenic signaling. 
The benefits of using platelet-rich plasma and hyaluronic acid when used alone or 
in combination on wound healing were evaluated by Fathi (2012). This author observed 
that the use of PRP alone or in combination with HA accelerate wound healing, while the 
use of low concentration of HA alone presents no improvement of wound healing in 
comparison with normal one. 
However, the need for repeated applications of free HA in vivo has directed the 
studies for the use of biocompatible crosslinked derivatives (de Boulle et al., 2013; 
Collins & Birkinshaw, 2013; Stern et al., 2000).  
Preliminary studies from our group have shown that the addition of divinyl sulfone 
(DVS) crosslinked HA microparticles to activated P-PRP (aP-PRP) improves the 
mechanical properties of the natural fibrin networks by increasing its viscoelasticity and 
eliminating strain hardening (unpublished data). Furthermore, the HA microparticles 
stimulate h-AdMSCs proliferation on the thin fibers (~65 nm) of the fibrin network. 
However, the long-term effects of DVS-crosslinked HA microparticles remain unclear, 
and the release of the chemical crosslinkers causes inflammatory outcomes (Prasadam 
et al., 2013). 
Thus, auto-crosslinked polysaccharide (ACP) represents an interesting strategy 
for improving the stability of HA. ACP polymers are inter- and intra-molecular esters of 
HA for which some of the carboxyl groups have been esterified with hydroxyl groups of 
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the same and/ or different molecules, thus forming a mixture of lactones and inter-
molecular ester bonds (Mensitieri et al., 1996). 
The main advantage for ACP is the formation of ester bonds without the addition 
of toxic crosslinking agents. As no foreign molecules are used to create the crosslink, 
the gel is de-esterified upon degradation and hyaluronic acid is liberated. HA is a 
naturally occurring molecule that has a biological role and is eliminated through a known 
metabolic pathway (Mensitieri et al., 1996). 
Furthermore, ACP can be prepared with various degrees of crosslinking by 
modulating the reaction conditions, which allow the adaption of its mechanical and/or 
rheological properties for many applications (de Laco et al., 1998)  
ACP has been widely used on the prevention of postsurgical adhesions (de Laco 
et al., 1998; Belluco et al., 2001; Koçak et al., 1999; Yerushalmi et al., 1994). However, 
as far as we know, the application of ACP as scaffolds is still scarce.  
Solchaga et al. (2005) demonstrated that porous sponges of ACP® seeded with 
chondrocytes or osteoblasts improve the cartilage and bone regeneration in 
osteochondral defects of rabbits compared to HYAFF®-11 (a benzyl ester of HA that is 
completely esterified). The degradation time of ACP® led to rapid bone formation while 
the slow degradation of HYAFF®-11 prolonged the presence of cartilage and delayed 
endochondral bone formation. 
The present work extends the previous findings by investigating the association 
of activated aP-PRP and ACP structured in microparticles or sponges as a composite 
scaffold for growth factors (GFs) release, the proliferation of h-AdMSCs and osteogenic 
differentiation in vitro. Our hypothesis is that the composite scaffolds will improve 
proliferation and differentiation of h-AdMSCs by providing better structural and 
mechanical properties compared to fHA or aP-PRP alone.  
This study might offer promising approaches for further biological applications 
and should provide alternatives in orthopedic treatments. 
 
6.2. Experimental  
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6.2.1. Materials 
HA in sodium form (MW = 2 x 106 Da) was obtained from Spec-Chem Ind. 
(Nanjing, China). All other reagents were purchased from Synth® (Diadema, SP, Brazil) 
unless specified otherwise. PRP was prepared from whole blood (WB) of donors, who 
were healthy individuals aged between 30 and 40 years old and previously assessed 
through their clinical examinations. The human adipose tissue-derived mesenchymal 
stem cells, h-AdMSCs, were provided by Umbilical Cord Blood Bank of Haematology 
and Hemotherapy Center of University of Campinas. All biological experiments were 
approved by the Ethics Committee of the Medical Sciences School of the University of 
Campinas (UNICAMP; CAAE: 0972.0.146.000-11). 
 
6.2.2. Methods 
6.2.2.1. Preparation of HA-TBA 
An aqueous solution of 0.5% (w/v) sodium hyaluronate (Na-HA) was stirred in 
strongly acidic ion exchange resin Dowex® 50-8WX-400 mesh (Sigma-Aldrich, St. Louis, 
MO, USA) for 8 hours. The suspension was centrifuged in a Rotina 380R centrifuge 
(Hettich® Zentrifugen, Tuttlingen, Germany) at 10,000 rpm for 10 minutes to remove the 
resin and neutralized with tetrabutylammonium hydroxide (TBA-OH) 0.2 mol.L-1 (Vetec®, 
Duque de Caxias, Rio de Janeiro, Brazil) to form the quaternary ammonium salt of HA 
(HA-TBA). The solution was then frozen and lyophilized in lyophilizer Liobras L101 
(Liobras, São Carlos, SP, Brazil) for 48 hours (Khetan & Burdick, 2010). 
 
6.2.2.2. Preparation of ACP 
The auto-crosslinked HA (ACP) was prepared by an autoesterification reaction 
according to the protocol described by Bellini et al. (2001) (Figure 27). HA-TBA with a 
molecular weight of approximately 2 x 106 Da and corresponding to 10 mEq of 
monomeric units was solubilized in 50 mL of dimethylsulfoxide (DMSO) at 25°C. 
Triethylamine (0.5 mEq) was added and the resulting solution was agitated for 30 
minutes. A solution of 2-chloro-1-methyl pyridinium iodide (CMPI) (0.5 mEq) (Sigma-
Aldrich, St. Louis, MO, USA) in 15 mL of DMSO was slowly added drop by drop over 1 
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hour and the mixture was kept at 30°C for 15 hours. A solution of sodium chloride 2.5% 
(w/v) was then added and the resulting mixture was poured slowly into 150 mL of 
acetone, maintaining continual agitation. The formed precipitate was centrifuged at 
10,000 rpm for 10 minutes, washed three times in 100 mL of 5:1 acetone: water and 
three times with 100 mL of acetone and vacuum-dried for 24 hours at 30°C.  
 
Figure 27. Auto-crosslinking reaction using CMPI-activated HA intermediate (Schanté et 
al., 2011). 
 
6.2.2.3. Characterization of ACP 
ACP was characterized by Fourier-transform infrared (FTIR) in a Thermo 
Scientific Nicolet model 6700 (Thermo Scientific Nicolet™, Waltham, MA, USA). 
Measurements were made in the ATR mode with accessory SMART OMNI-SAMPLER, 
in the spectral range of 4000-675 cm-1 with a resolution of 4 cm-1 over 64 scans.  
 
6.2.2.4. Preparation of structured ACP 
The ACP structured in microparticles (mACP) or sponges (sACP) were prepared 
from plain ACP swollen in Milli-Q water. The microparticles were obtained by shearing in 
an Ultra-Turrax T25 homogenizer (IKA Labortechnik, Staufen, Germany) at 18,000 rpm 
by 20 minutes, according to Shimojo et al. (2013). The sponges were initially placed in 
polystyrene 24-well microplates (TPP®, Trasadingen, Switzerland), frozen at -20°C and 
lyophilized at temperature of approximately -30°C for 48 hours. 
 
6.2.2.5 Characterization of structured ACP 
HA structured in sponges (sHA) and fluid HA (fHA) were characterized like the 
structured ACP and used as control as necessary. 
123 
 
 
Morphology and pore size. The morphology of ACP sponges was evaluated by 
scanning electron microscopy (SEM) using an LEO 440i Electron Microscopy/Oxford 
(Cambridge, England) operated at 5 kV accelerating voltage. The scaffolds were gold 
coated using a sputter coater POLARON SC7620, VG Microtech (Uckfield, England) for 
180 s at a current of 3 mA. Pore size (n=20) was measured using Image J 1.47t. 
 
Mechanical Properties. Mechanical compression tests of ACP sponges (𝑛 = 3) 
were performed using a Universal Testing Machine, MTS model 810-Flex Test 40 (MTS 
Systems Corporation, Eden Prairie, MN, USA) up to 60% strain, according to Correia et 
al. (2011). The testing machine was equipped with a 1.5 kN load cell, and the loading 
rate was 5 mm/min. Young’s modulus was calculated in the initial linear section of the 
stress-strain curve, when the strain was lower than 10%.  
 
Degradation time. The gravimetric method described by Tang et al. (2007) was 
used to estimate the degradation time of the structured ACP through measurements of 
remaining weight. The assay was carried out with the ACP microparticles and ACP 
sponges in phosphate buffer saline solution (PBS, pH 7.2) (LB Laborclin, Pinhais, PR, 
Brazil) at 37°C. 
 
Average diameter. The average diameter was measured for the ACP 
microparticles suspended in water. The measurements were performed in a Malvern 
Mastersizer S laser diffraction (Malvern Instruments Ltd, Malvern, UK). The standard 
deviation was calculated from ten consecutive measurements. 
 
Rheology. Rheological measurements were performed in steady and oscillatory 
regimes at 25°C using a parallel plate geometry of 20 mm. Steady shear measurements 
were obtained at shear rates of 0.1-50 s-1. Oscillatory measurements were conducted in 
the linear region with a stress of 1.188 Pa and in the frequency range of 0.01 to 10 Hz. 
All rheological measurements were performed using the swollen ACP microparticles 
equilibrated in Milli-Q on a rheometer Haake RheoStress 1 (Haake, Karlsruhe, 
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Germany). 
 
Extrusion force. Initially the ACP microparticles were loaded in 1-mL plastic 
syringes with 30-gauge needles. Afterward, the force required to extrude was measured 
in a MTS 810 Servo-hydraulic Universal Testing Machine (MTS Systems Corporation, 
Eden Prairie, MN, USA) (Load Cell 1.5 kN) at 25°C at a 5.0 mm/min extrusion rate. 
 
Swelling ratio. Swelling measurements of the ACP microparticles were performed 
in PBS at 25°C after 72 h of incubation, according to Shu et al. (2004). The swelling ratio 
(SR) was calculated using the following Equation (1). 
 
𝑆𝑅 =
𝑊𝑠
𝑊𝑑
                                                                                                            Equation (1) 
 
where 𝑤s and 𝑤d are the weights of the scaffolds in the swelled state and the dry state, 
respectively. 
The swelling measurements of the ACP sponges was determined by swelling the 
freeze-dried ACP sponges (with known weights) in PBS at 37°C for 24 hours. The 
swollen ACP sponges were weighed after the removal of excess of water by keeping the 
surfaces on a filter paper. The swelling ratio (SR) was also calculated using Equation 
(1). 
 
Porosity. The porosity (ε) of the ACP sponges was determined according to the 
protocol used by Wang et al. (2011), and calculated by Equation (2). 
 
𝜀 (%) =  
𝑉𝑚−(
𝑊𝑚
𝜌
)
𝑉𝑚
 . 100                                                                                      Equation (2) 
 
where Vm is the total volume of ACP sponges (cm3), ρ is the density of non-porous HA 
(1.0016 g/cm3) and 𝑤m is the weight of sponges (g). Values are expressed as the mean 
± standard deviation (n=3). 
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Cell compatibility. The compatibility of the structured ACP with h-AdMSCs cells 
was carried out by exposing them to cell culture at 37°C for 24 hours. Then, cell viability 
was evaluated by using an MTT assay (3-[4,5-dimethyl-thiazol-2-yl]-2,5-
diphenyltetrazolium bromide) (MTT, Molecular Probes), according to modified Mosmann 
method (1983). The MTT assay is a colorimetric test based on the reduction of yellow 
tetrazolium salt into a purple formazan product in presence of cells (Gümüsşderelioğlu & 
Aday, 2011). 
 
6.2.2.6. Preparation of PRP  
PRP rich in platelets and poor in leukocytes (P-PRP) was prepared according to 
Perez et al. (2014). Briefly, whole blood (WB) was collected into 3.5 mL vacuum tubes 
(Vacuette®, Campinas, SP, Brazil) containing sodium citrate 3.2% (w/v) as 
anticoagulant. WB was initially centrifuged in a Rotina 380R centrifuge (Hettich® 
Zentrifugen, Tuttlingen, Germany) at 100  g for 10 minutes, at 25°C, After the formation 
of three layers (a bottom layer composed mainly of red blood cells (RBCs); an upper 
layer composed of plasma, platelets and some WBCs; and an intermediate layer, or 
buffy coat, composed mostly of WBCs), only the upper layer was collected to obtain P-
PRP. The concentration of platelets, WBCs and RBCs in WB and P-PRP was 
determined using the ABX Micros ES 60 hematology analyzer (HORIBA ABX 
Diagnostics, Montpellier, France). 
 
6.2.2.7. Preparation of activated P-PRP (aP-PRP) 
aP-PRP was prepared via the activation of P-PRP with autologous serum (Ser) 
and 10% (w/v) CaCl2 solution as agonists using the following proportions: agonist/P-
PRP=20% (v/v); Ser/CaCl2 volumetric ratio=9. Ser was prepared by collecting 5 mL of 
WB in tubes without anticoagulant. After 30 minutes for clot formation, WB was 
centrifuged at 2000  g for 10 minutes (Perez et al., 2013).  
 
6.2.2.8 Preparation of composite scaffolds 
For preparation of the composite scaffolds, immediately after activation, aP-PRP 
was mixed with the ACP microparticles or embedded by dripping into the ACP sponges, 
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both in 48-well microplates. In all biological assays performed in this work, the following 
proportions of aP-PRP to structured ACP were used: aP-PRP: microparticles = 200 
µL:100-200 mg and aP-PRP: sponges = 200 µL:10-20 mg in order to guarantee the 
same proportion PRP to HA. 
 
6.2.2.9. Characterization of composite scaffolds 
Release of growth factors. The release of platelet-derived growth factor AB 
(PDGF-AB) and transforming growth factor β1 (TGF-β1) was performed after a 1 hour 
gelation of composite scaffolds in the presence of the culture medium Dulbecco's 
Modified Eagle's Medium with low glucose concentration (DMEM-LG, Gibco, Grand 
Island, NY, USA) in 48-well microplates. The microplates were maintained in an 
incubator with 5% CO2 over the assays. After sampling, the volume was replaced with 
fresh medium at 3, 6, 12, 48 and 72 hours without removing the hydrogels from the 
wells. The samples were stored at -80°C until all samples were collected. The 
concentrations of the released GFs were measured using enzyme-linked 
immunosorbent assay (ELISA) kits (R&D Systems, Minneapolis, MN, USA) according to 
the manufacturer’s instructions and specifications. 
 
h-AdMSCs-seeding in the composite scaffolds. The pre-cultured h-AdMSCs were 
trypsinized and resuspended in P-PRP to a final cell concentration of 1 x 104 cells/ mL. 
P-PRP containing h-AdMSCs was activated and immediately pipetted onto the surface 
of the microparticles or embedded into the sponges, both in 24-well tissue culture plates. 
The composite scaffolds were kept at room temperature for 45 minutes for consolidation 
of the fibrin network. The cells seeded in fHA or in sHA were used as controls.  
 
h-AdMSCs cultivation in the composite scaffolds. Cultivation of the h-AdMSCs 
was carried out in 24-well tissue culture plates, by adding 1 mL of the culture medium 
(DMEM) to the seeded composite scaffolds (n=4). The culture was maintained at 37°C 
over 10 days. Cell proliferation was quantified using the thiazolyl blue tetrazolium 
bromide (MTT) assay. At 3, 5, 7 and 10 cultivation days, the substrates were removed 
and transferred to 24-well plates. MTT (1 mL of 1 mg/mL) was then added, and the 
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cultivation proceeded at 37°C for 4 hours. The MTT solution was then discarded, and 1 
mL of DMSO was added to dissolve the purple formazan crystals. The samples were 
shaken at 120 rpm for 30 min to ensure homogeneous dissolution of the formazan dye, 
and then 200 µL of each sample was transferred to a 96-well plate. Optical density was 
measured at 595 nm using a microplate reader (FilterMax F5 Molecular Devices, 
Sunnyvale, CA, USA). The cell concentration was obtained from the previously built 
calibration curve. 
 
Images of the cell-seeded composite scaffolds. Images of cell-seeded composite 
scaffolds were obtained by scanning electron microscopy (SEM) after 5 days of h-
AdMSCs proliferation. The substrates were fixed in a solution of 4% paraformaldehyde 
and 2.5% glutaraldehyde in PBS, for 2 hours. The samples were than dehydrated in 
ethanol for 15-min intervals in aqueous 50%, 70%, 95% and 100% ethanol solutions 
(2x) and dried at the critical point dryer BAL-TEC CPD 030 (BAL-TEC®, Schalksmühle, 
Germany). After gold coating in a Sputter Coater POLARON, SC7620 (VG Microtech, 
Ringmer, UK), the samples were visualized with a scanning electron microscope 
Leo440i (LEO Electron Microscopy/Oxford, Cambridge, UK) with an accelerating voltage 
of 20 kV. 
 
Induction of osteogenic differentiation. h-AdMSCs-seeding composite scaffolds 
were induced to differentiate into the osteogenic lineage by providing the osteogenic 
medium containing DMEM-LG supplemented with 10% fetal bovine serum (FBS), 1% β-
glycerol-phosphate (Sigma-Aldrich, St. Louis, MO, USA), 1% L-ascorbic acid (Sigma-
Aldrich, St. Louis, MO, USA), 1% dexamethasone (Sigma-Aldrich, St. Louis, MO, USA) 
and 1% Penicillin/Streptomycin solution (Gibco, Grand Island, NY, USA). The medium 
was changed every 7 days.  
 
Alkaline phosphatase activity (ALP). The level of alkaline phosphatase (ALP) 
activity of h-AdMSCs was determined on day 14. Two hundred microliters of the 
supernatant was collected and mixed with 200 μL of p-nitrophenyl phosphate 
(SIGMAFAST™ p-Nitrophenyl phosphate Tablets, Sigma, Saint Louis, MI, USA) as 
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substrate and incubated at room temperature for 30 minutes. Absorbance was read 
immediately on a spectrophotometer at 405 nm. 
 
6.2.2.10. Statistical analysis 
Each experiment was carried out in triplicate unless otherwise specified. All 
results are presented as the mean ± standard deviation (SD). The experimental data 
from all the studies were analyzed using Analysis of Variance (ANOVA). Statistical 
significance was set to p-value ≤ 0.05.  
 
6.3. Results 
 
6.3.1. Characterization of ACP  
The IR spectra from ACP (Figure 28) shows peaks between 1000 and 850 cm-1, 
corresponding to deformation out of the plane of the OH group, which is related to the H-
bonds; between 1250-1080 cm-1, corresponding to the asymmetrical stretching CC(=O)-
O and CHO; at approximately 1400 cm-1, corresponding to the deformation of COH 
bond; and in the region of 1800-1700 cm-1, which is attributed to the stretching vibration 
of C=O of carboxylic acyl groups (~1725 cm -1) and ester groups (1780-1760 cm-1) 
(Schanté et al., 2011; Silverstein et al., 1974). 
These results ensured the auto-crosslinking and its unique feature that no foreign 
bridge molecules are present between the crosslinked HA chains. 
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Figure 28. ATR-FTIR spectra of ACP with 5% of carboxylic groups esterified.  
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6.3.2. Characterization of ACPs structured scaffolds 
The rheological behavior determined by oscillatory and steady measurements of 
the ACP structured in microparticles in relation to 1% fHA is shown in Figure 29(a) and 
29(b), respectively. The microparticles exhibited the gel-like behavior, as analyzed by 
the storage (G’) and loss moduli (G”), where G’ is higher than G” in all studied frequency 
ranges and the curves are parallel to the frequency axis, indicating crosslinking. The 1% 
fHA showed crossover (G’=G”) around 1 Hz indicating concentrated solution behavior, 
as expected. Moreover, mACP exhibited behavior typical of so-called weak gels with tan 
δ (G”/G’)=0.19 in 1 Hz (Ikeda & Nishimari, 2001; Clark & Ross-Murph, 1987).  
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Figure 29. (a) Oscillation spectrum and (b) flow curve of (■) ACP Microparticles and (▲) 
fluid HA (1% wt.). G’ (closed symbol) and G” (open symbol).  
 
The flow curve (Figure 29b) showed a shear thinning behavior characteristic of 
pseudoplastic fluids for mACP and the microparticles were more resistant to shearing 
(up to1 s-1) than 1% fHA.  
Moreover, the microparticles showed G’ (~300 Pa) values between 100-700 Pa, 
which are adequate for injectable application (Kablik et al., 2009). 
In addition to the beneficial rheological properties and microparticle size, the 
injectable scaffolds must have an extrusion force to allow for their easy injection through 
an appropriately sized needle and thereby prevent side effects such as pain, bruising, 
crossover 
130 
 
bleeding, and edema (Kablik et al., 2009). 
For injectable applications, extrusion force values must 
 be smaller than 20 N and the mean diameter of particles smaller than 700 µm 
(Shimojo et al., 2013; Kablik et al., 2009). 
In ACP microparticles, we standardized the mean diameter to values smaller than 
200 µm by adequate conditions of shearing. Thus, the ACP microparticles showed 
extrusion forces around 20N, which is adequate for injectable applications (Table 3). 
Moreover, the extrusion force of the microparticles was five times higher than the 
1% fHA, indicating crosslinking and improvement of mechanical properties.  
 
Table 3. Properties of fHA, sHA, and structured ACP (microparticles and sponges). 
Scaffold Extrusion Force 
(N) 
Young’ s moduli 
(kPa) 
Swelling ratio 
(SR=ws/wd) 
Porosity 
(%) 
ACP microparticles 20 ± 1 - 61 ± 8 - 
fHA (1% w/v) 4.3 ± 0.1 - - - 
ACP sponges - 30 ± 0.1 91 ± 5 97.6 ± 0.2 
sHA - < 10 - 97.8 ± 0.3 
 
The Young’s modulus of ACP sponges (Table 3) was approximately 3 times 
higher than for the sHA with similar porosity (~97%). This result is evidence of the 
improvements to mechanical resistance imparted by ACP, which is one of the most 
important requirements for scaffolds in tissue engineering.  
The capacity to hydration is also an essential factor for cell migration inside the 
scaffolds. The 5% auto-crosslinking did not greatly affect the capacity for hydration of 
the structured ACP. Although the hydration capacity is directly linked to the functional 
groups capable of forming H-bonds with water, in this case, the higher hydration 
capacity of the ACP sponges (~90%) can be attributed to the porous structure of the 
scaffold, which retains greater amount of unbound water. For the ACP microparticles, 
the swelling was ~60%, due to a smaller porous size structure. 
The porosities of the ACP sponges and sHA were similar, which evidence the 
superiority of the ACP sponges as a scaffold, when associated to its mechanical 
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resistance. The porosity values of ACP sponges and sHA ranged around 97%, which 
are adequate for tissue engineering. 
Different aggregations of the HA chains in ACP sponges or sHA are shown in 
Figure 30. In both cases, highly porous structures were formed, confirming the 
determined values for porosity in Table 2. However, the structure of ACP sponges has 
more round pores [Figure 30(a)], whereas the sHA has a leaf structure [Figure 30(b)].  
 
  
(a) (b) 
Figure 30. Figure 4. SEM micrographs of cross-sectional of (a) ACP sponges and (b) 
HA sponge. 
 
The proliferation of h-AdMSCs results, as assayed by MTT, shown in Figure 
31(a) indicated that the structured ACP, sHA and fHA could be considered compatible to 
the cells, by comparison with the positive toxicity control (PTC).  
We also observed that the proliferation of h-AdMSCs on ACP sponges was 
significantly higher than the negative control (p<0.05).  
Moreover, ACP microparticles showed lower cell proliferation compared to fHA, 
while there were no significant differences between the cell proliferation of ACP sponges 
and sHA. 
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Figure 31. (a) Viability of h-AdMSCs exposed to the structured ACP or HA (fluid and 
sponge). Negative control (NTC) = DMEM with 10% FBS; positive control (PTC) = 
DMEM with phenol 0.5%. Mean ± standard deviation n = 3. The population means are 
significantly different from the positive control at *p<0.05. (b) The weight remaining of 
the structured ACP under the time course of degradation (at 37°C, in PBS). (■) ACP 
microparticles and (▲) ACP sponges.  
 
Figure 31(b) shows the degradation kinetics of the structured ACP in PBS in 
terms of remaining weight. Most of the weight reduction, around 40% was observed in 
the first day for both structures. Scaffolds for regenerative medicine applications should 
degrade over the course of tissue regeneration to allow complete repair by host tissue. 
Therefore, degradation must be adjusted to release GFs and allow for cell proliferation.  
 
6.3.3. Characterization of the composite scaffolds 
Figure 32 shows the release kinetic of PDGF-AB and TGF-β1 from the composite 
scaffolds. The GFs were from aP-PRP containing average platelet concentration 
407,000 pq/mm3. The fibrin network from activated aP-PRP alone was used as control.  
133 
 
0 10 20 30 40 50 60 70 80
0
1000
2000
3000
4000
5000
6000
7000
8000
9000
 
 
p
g
 o
f 
P
D
G
F
-A
B
/ 
m
L
 o
f 
P
R
P
Time (hours)  
0 10 20 30 40 50 60 70 80
0
2000
4000
6000
8000
10000
12000
14000
 
 
p
g
 o
f 
T
G
F
-
1
/ 
m
L
 o
f 
P
R
P
Time (hours)
 
(a) (b) 
Figure 32. Growth factor release profiles from P-PRP combined with HA and ACP 
structured scaffolds. (a) PDGF-AB and (b) TGF-β1. (●) ACP microparticles; (▲) fHA; (■) 
P-PRP alone; (Ο) ACP sponges and (Δ) sHA. The concentration of platelets in P-PRP 
was 407,000 pq/mm3. 
 
Controlled release of GFs was achieved from the composite scaffolds. The 
curves show parallel diffusive profiles. The bulk of the GFs were released in the first 12 
hours. For both GFs, the initial release rate was higher in aP-PRP alone and aP-PRP-
ACP sponges, followed by aP-PRP-ACP microparticles, aP-PRP-fHA and aP-PRP-sHA. 
Subsequently, the release rates reduced and different amounts of the GFs were 
released from the scaffolds over the 72 hours assay.  
The release of the most of the GFs occurred in concert with the degradation time 
(12 hours) of the structured ACP [Figure 31(b)]. 
The structured ACP promoted proliferation of h-AdMSCs (Figure 33), which was 
evidence of the benefits of the porous structure, swelling and mechanical properties on 
cell adhesion and migration. 
The importance of the stability of the porous structures for cultivation is clear from 
comparing the performances of aP-PRP-ACP microparticles and aP-PRP-ACP sponges.  
The aP-PRP-ACP sponges showed better cell proliferation compared to aP-PRP 
alone. The effect was similar to aP-PRP-sHA [Figure 33(b)]. However, aP-PRP-ACP 
microparticles [(Figure 33(a)] showed reduced cell proliferation related to aP-PRP alone 
and fHA showed no cell proliferation attributed to the very small pore size and to high 
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viscosity.  
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(a) (b) 
Figure 33. The proliferation profiles of h-AdMSCs cultured in structured HA and ACP 
composite scaffolds as a function of time. (a) Microparticles (concentration of platelets in 
P-PRP = 393,000 pq/mm3) and (b) sponges (concentration of platelets in P-PRP = 
472,250 pq/mm3). Activated P-PRP alone was used as control.  
The micrographs of the composite scaffolds after 5 days of cultivation with h-
AdMSCs are shown in Figure 34. The fibrin network formed on the surfaces of the 
microparticles [Figure 34(a)] and in the pores of the sponge [Figure 34(c)], providing a 
large area covered by fibrin fibers for cell adhesion and proliferation. The porous 
structure of the microparticles could not be observed because they collapsed under the 
dehydration necessary to obtain the images.  
 
  
(a) (b) 
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(c) (d) 
Figure 34. Scanning electron microscopy images of HA and ACP composite scaffolds 
after 5 days of cultivation of h-AdMSCs. (a) ACP microparticles; (b) fluid HA; (c) ACP 
sponges and (d) HA sponge. Original magnification is ×5,000 and the scale bar 
represents 3 µm. 
 
 
Osteogenic differentiation of h-AdMSCs was investigated after HA and ACP 
composite scaffolds induction at days 14. ALP activity, an early marker of osteogenic 
differentiation, was measured and shown in Figure 35. ALP activity was significantly 
higher in the sponges and in ACP microparticles compared with the fHA (control) 
suggesting stimulation of osteogenic differentiation. 
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Figure 35. Alkaline phosphatase (ALP) activity of h-AdMSCs-seeded cultured in the HA 
and ACP composite scaffolds on day 14. Blank = the reagents used in the assay only. 
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Statistically significant differences from blank, n=3, *p<0.05. The concentration of 
platelets in P-PRP was 473,500 pq/mm3. 
 
6.4. Discussion 
In this study, we prepared novel composite scaffolds by associating aP-PRP to 
3D-ACP structured in microparticles or sponges.  
ACP is a crosslinked derivative of hyaluronic acid biocompatible, obtained by 
organocatalyzed auto-esterification (Bellini et al., 2001). ACP was used to increase the 
residence time at the site of application and improve the physicochemical and 
mechanical properties of free HA, reducing the need for repeated applications. 
The auto-esterification reaction of HA was performed with the quaternary 
ammonium salt of HA (HA-TBA) as the intermediate. CMPI was used as activating agent 
of the carboxyl groups of HA according to Magnani et al. (2000). The anhydrous organic 
solvent DMSO was used to minimize CMPI hydrolysis. CMPI reacts with a carboxyl 
group of HA, forms a pyridinium intermediate and releases a chloride ion, which is 
neutralized by tetrabutylammonium. Triethylamine neutralizes the released iodide ion. 
When no amine is added to the reaction medium, esterification occurs as the CMPI-
activated HA reacts with its own hydroxyl groups, forming an ester crosslink between the 
HA chains. The product is the auto-crosslinked HA, usually called ACP. 
The ACP ensures that only the HA, a naturally occurring molecule that has a 
biologic role, is released and eliminated through a known metabolic pathway during its 
degradation in the organism (Mensitieri et al., 1996). According Koçak et al. (1999), ACP 
is slowly resorbed within 2 weeks and is excreted within 40 days by the kidneys. 
In this work, ACP was structured in microparticles and sponges to create 
injectable or solid scaffolds, respectively. Furthermore, aiming ensure better stability of 
the fibrin network from PRP and control the release of GFs, we associate PRP with 
structured ACP. 
P-PRP was obtained by centrifugation to about twice the concentration relative to 
WB. Haynesworth et al. (2002) showed that the proliferation and differentiation of adult 
mesenchymal stem cells are directly related to the platelet concentration. Platelet 
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concentrations ranged from 0.8 to 1.2 x 106 platelets/µL have been proposed to be 
effective for in vivo applications by Weibrich et al. (2004) and Fennis et al. (2005). In our 
biological assays, we used around 0.5 x 106 platelets/µL due to the platelet 
concentration factor (2x) inherent to the process used to obtain PRP. 
P-PRP was activated with autologous serum and Ca+2 in specific conditions to 
obtain fibrin network architectures with thin fibers with an average radius of 
approximately 65 nm. This type of fiber favors proliferation of h-AdMSCs due to its 
paracrine nature for the cells (Ye et al., 2013)  
The composite scaffolds were obtained by mixing the microparticles or 
embedding the sponges with immediately activated P-PRP to ensure that the fibrin 
network was gelled in the scaffold.  
The structured ACP were characterized by physicochemical and mechanical 
properties.  
The effect of ACP structured on biological performance of aP-PRP/ACP was 
evaluated by the kinetics of growth factor release (PDGF-AB and TGF-β1), h-AdMSCs 
proliferation and osteogenic differentiation by marker ALP. 
Beyond that, the scaffolds structured in sponges were characterized in terms of 
porosity, pore shape and interconnectivity, because these aspects are determinant for 
cellular colonization in vitro since they affect the diffusion of physiological nutrients and 
cells through the scaffold (Leong et al., 2003; Liu & Ma, 2004). In addition, the high 
porosity (>90%) and the interconnectivity of pores compromised the mechanical and 
structural stability of the scaffolds. According to Loh & Choong (2013), these aspects 
must be evaluated in accordance with the application and degradation rate of materials 
used. For order to guide tissue regeneration, the mechanical properties of scaffolds 
must maintain the spaces required for cell in-growth and matrix elaboration during in 
vitro cultivation (Leong et al., 2003). The ACP sponges presented morphological 
properties adequate to tissue engineering, whereas the mechanical properties indicated 
application for soft tissues (Hollister, 2005).  
The scaffolds structured in microparticles were characterized by rheological and 
mechanical properties, which allowed injectable applications (Kablik et al., 2009). The 
average diameter of the microparticles of 190 ± 5 µm was supported by our previous 
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work on viscoelasticity and injection force (Shimojo et al., 2013). 
Moreover, we observed that h-AdMSCs cultured in ACP structured scaffolds 
proliferated ensuring the non-cytotoxicity. 
It is well known that growth factors greatly contribute to wound healing and tissue 
regeneration at various stages of cell proliferation and differentiation (Stocum, 1997). 
Moreover, the fibrin converted from fibrinogen works in concert with these GF in 
promoting of tissue regeneration. 
However, the release of most of these growth factors from PRP occurs within the 
first hours after platelet activation and the gradual release of GF is essential for cascade 
of events involved on regeneration process (McCarrel & Fortier, 2009).  
Tsay et al. (2005) showed in their in vitro study that PRP gels had a burst release 
of 80% of PDGF-AB and 82% of TGF-β1 in the medium after 24 h and a sustained 
release for another 14 days. Thus, to protect the GFs against proteolysis and to extend 
its activity, Tabata (2003) suggested combining the functions of scaffolds with controlled 
release technology.  
Scaffolds can be an interesting alternative to gradual release of GFs increasing 
the effectiveness of PRP, and therefore, the regeneration of tissues.  
Aside from the barrier of the ACP structures, the interactions among GFs and the 
scaffolds also play an important role in the controlled release.  
In order to control the release of growth factors into scaffolds, chemical bonding 
(covalent and non-covalent) or physical interaction have been used (Tabata, 2003; King 
& Krebsbach, 2012). However, the physical interactions using hydrophilic polymers has 
been the most commonly used approach to incorporate growth factors into scaffolds 
(King & Krebsbach, 2012). Increasing the magnitude of these electrostatic interactions 
decreases the initial burst release.  
The increase of the concentration of charge on scaffold is the common technique 
to increase the electrostatic attraction between growth factors and scaffolds. Although, 
some studies reported that specific intermolecular interactions may be more effective at 
minimizing the initial burst release of growth factors when compared to non-specific 
electrostatic interactions because these interactions are stronger and localized (Gao et 
al., 2001; Jha et al., 2009; Lee et al., 2011). 
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Because growth factors are generally basic proteins (isoelectric point > 7), in 
physiological pH, they will have positive charge interacting ionically with the acidic 
species. (Hokugo et al.,2005; Okuda et al., 2003) 
Thus, when a scaffold is prepared from a biodegradable polymer with negative 
charges, such as hyaluronic acid and ACP, the growth factors with a positively charged 
site interact electrostatically with the polymer and can be physically immobilized. If 
environmental changes, such as increasing in ionic strength, occurs, the immobilized 
growth factor will be released. However, if such an environmental change does not take 
place, degradation of the scaffolds will be responsible for growth factors release.  
Hokugo et al. (2005) and Tabata & Ikada (1998) reported the controlled release 
of TGF-β1 and PDGF from the hydrogel of acidic gelatin and demonstrated successful 
bone regeneration in rabbit and monkey skull defects, in marked contrast to defects 
treated with free TGF-β1. According theses authors, TGF-β1 and PDGF are sorbed into 
the acidic gelatin hydrogel mainly due to electrostatic interaction between the gelatin 
and GFs molecules. The immobilized growth factors were released from the hydrogel 
since hydrogel degradation occurs. 
Scaffold degradation plays an important role in controlled release in scaffolds that 
strongly interact with growth factors. Generally, growth factor released from these 
scaffolds has been correlated to the rate of degradation of material after the initial burst 
release period (King & Krebsbach, 2012).  
In vivo, it is known that the growth factors are normally stored in the body ionically 
bound to the acidic polysaccharides of the ECM. These bounds protects growth factors 
against denaturation and enzymatic degradation in vivo. In this case, the growth factors 
are released from the ECM complex due to polysaccharide degradation according to the 
need (Tabata, 2003). 
Growth factor released from degradable scaffolds can be tuned by controlling 
either factor diffusion or degradation. Fast degradation will lead to rapid release of 
growth factors, while slowing degradation will retard release of factors (Fournier et al., 
2003).  
Despite the controlled release compared to aP-PRP alone, we observed that the 
initial burst of release within 12 hours occurred in concordance with higher degradation 
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of scaffolds. After this first step, both release and degradation rate are reduced, 
indicating that the GFs release is governed mainly by degradation of scaffolds. 
Van der Dolder et al. (2006) and Lucarelli et al. (2003) showed that PRP had a 
stimulating effect on the initial cell growth and differentiation of osteoblast-like cells and 
stromal cells. 
Moreover, according to Okuda et al. (2003), PRP modulates the cell proliferation 
by PDGF- and/or TGF-β1 mediated-mechanisms.  
Although controversial, it is known that these effects are dependent of PRP 
concentration. Choi et al. (2005) and Arpornmaeklong et al. (2004) showed in their 
studies that the cell viability, proliferation and differentiation were affected by PRP 
concentrations. The results obtained by Choi et al. showed that the viability and 
proliferation of alveolar bone cells were suppressed by high PRP concentrations, but 
were stimulated by low PRP concentrations (1–5%). In contrast, Arpornmaeklong et al. 
(2004) showed that a high concentration of PRP inhibited osteoblastic differentiation and 
increased the proliferation of pre-osteoblast-like cells or osteoblast precursor cells. PRP 
in low concentration did not show a marked effect on cell proliferation or differentiation. 
We found that despite the high concentration of PRP (20% v/v) used in the 
assays, the presence of aP-PRP in the scaffolds was benefic on cell proliferation and 
differentiation.  
We also verified that the differences on structuration of scaffolds in microparticles 
or sponges produced a more prominent effect on cell proliferation of the composite 
scaffolds compared to stimulating of osteogenic differentiation.  
 
6.5. Conclusions 
 
We have demonstrated that the composite scaffolds released PDGF-AB and 
TGF-β1 from platelets mainly during the first 12 h. The released amounts depended on 
the architecture of the structures and on the interactions of the GFs and HA. We also 
showed the composite scaffolds in microparticles or sponges promoted h-AdMSCs 
proliferation and stimulated osteogenic differentiation as evaluated by ALP activity. 
Thus, our results provide evidence that composite scaffolds with superior mechanical 
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properties are promising biomaterials for future clinical use in osteoarthritis therapies. 
The flexibility to obtain injectable formulations (microparticles) or solid sponges opens 
perspectives to use the ACP-derived biomaterials in non-surgical applications, for 
surgical implants or even for wound healing. 
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Abstract. Nowadays, high molecular weight hyaluronic acid (HA) has been widely used 
associated with platelet-rich plasma (PRP) in regenerative medicine. This study aimed 
to investigate in vitro the association of HA crosslinked with 1,4-butanediol diglycidyl 
ether (BDDE), structured in microparticles (mHA-BDDE) and sponges (sHA-BDDE), with 
PRP as composite scaffolds for growth factors release, proliferation of human adipose-
derived mesenchymal stem cells (h-AdMSCs) and differentiation by osteogenic marker 
alkaline phosphatase (ALP). The reason for using BDDE is to increase the residence 
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time in vivo, improve the mechanical stability of free HA (fHA) and provide a larger 
surface area for cell proliferation and differentiation in a new tissue. PRP was obtained 
via controlled centrifugation of whole blood and activated with autologous serum and 
calcium. The results showed that structuration benefited the physicochemical and 
mechanical properties compared to fHA. Both structures were non-cytotoxic. The 
release of GFs from PRP was lower than fHA but higher than the fibrin network. The 
effects on the proliferation of seeded mesenchymal cells were not intense. However, a 
remarkable activity of the osteogenic marker alkaline phosphatase was observed. We 
concluded the structuration of HA provides injectable (mHA-BDDE) or solid (sHA-BDDE) 
formulations with better properties compared to fHA, which associated to PRP may be 
promising for regeneration of bone tissue. 
 
Keywords: Platelet-rich plasma; hyaluronic acid; 1,4-butanediol diglycidyl ether; 
microparticles; sponges. 
 
7.1. Introduction 
 
Platelet Rich Plasma (PRP) is an autologous product prepared from whole blood, 
consisting of a concentrate of platelets, leukocytes, protein and other components 
dispersed in a small fraction of plasma (Marx et al., 1998; Marx, 2004). Platelets and 
leukocytes are sources of growth factors (GFs) which promote wound healing and tissue 
regeneration, through proliferation and differentiation of specific cells.  
In the last decade, PRP has been widely used in medical practice in various 
therapies, especially in orthopedics and sports medicine. This is mainly due to its ability 
to regenerate bone lesions, tendons and cartilage, often avoiding surgical interventions 
(Lana et al., 2014). 
Pure PRP, named as P-PRP, is rich in platelets and poor in leukocytes, according 
to the classification of Ehrenfest et al. (2009). 
Preparation of PRP is composed of two main steps: concentration and activation. 
The fibrin network is formed by the activation of platelets and the breakdown of 
fibrinogen from plasma. The fibrin network is also a weak gel, which acts as a barrier for 
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release of growth factors and also as a natural scaffold for proliferation and 
differentiation of mesenchymal cells.  
However, the fibrin network is fragile, has low viscosity and viscoelasticity, and 
also undergoes rapid degradation in a biological environment. In addition to this, the 
released GFs have a half-life of only few hours.  
In order to overcome these limitations, in the last decade the PRP has been used 
in orthopedics, associated with free hyaluronic acid (HA) of high molecular weight (Pak, 
2012; De Angelis et al., 2012; Chen et al., 2014). Clinical studies in literature have 
shown that tissue regeneration with free HA associated with PRP is greater than HA or 
PRP alone (Pak, 2012; De Angelis et al., 2012). Furthermore, the presence of the HA in 
the formulation is responsible for the reduction of pain resulting from inflammation 
caused by injury in the application of PRP (Fathi, 2012; Chen et al., 2014). 
In our previous studies, we observed that free HA, when combined with PRP, 
interacted with fibrin network improving their mechanical and viscoelastic properties and 
promoting the gradual release of GFs. However, the low mechanical stability of the free 
HA and the need for repeated injections in vivo have limited their application in 
regenerative medicine. 
Thus, aiming to overcome these limitations, we structured HA in microparticles or 
sponges, which were chemically crosslinked by 1,4-butanediol diglycidyl ether (BDDE) 
for stabilization. The microparticles must meet the requirements of injectable 
formulations while the sponges works as solid scaffolds.  
Our hypothesis is that by improving the structural and mechanical properties of 
the fibrin network we benefit the proliferation and differentiation of h-AdMSCs, thereby 
increasing the efficiency of the PRP in tissue regeneration.  
HA crosslinked by BDDE has been widely used in medical and cosmetic area, 
mainly as dermal fillers on tissue augmentation and regeneration (Allemann & 
Baumann, 2008; Andre, 2004; Beasley et al., 2009; Falcone & Berg, 2008) and also as 
a viscosupplement for joint diseases (Schanté et al., 2011; Malson & Lindqvist, 1987).  
HA can be crosslinked by BDDE under alkaline conditions, in which it reacts with 
the deprotonated hydroxyl group of HA to form a stable covalent ether linkage between 
HA and the epoxide groups of the crosslinker (Kenne et al., 2013; Malson & Lindqvist, 
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1986; Garg & Hales, 2004; Schanté et al., 2011). Its ability to crosslink is attributed to 
the reactivity of the epoxide groups present at the two ends of the molecule (De Boulle 
et al., 2013).  
Besides the biodegradability and stability of the ether bond relative to the ester or 
amide bond, BDDE shows lower toxicity (rat oral LD50=1134 mg/kg) compared to others 
crosslinkers (Yeom et al., 2010). 
La Gatta et al. (2013) obtained HA sponges for soft tissues regeneration by 
lyophilization and then reacted with BDDE in heterogeneous conditions. The scaffolds 
showed promising physicochemical and mechanical properties, good cellular viability, 
high stability in cell culture and for enzymatic degradation.  
Zawko et al. (2009) engineered novel dual-crosslinked hyaluronic acid hydrogel 
scaffolds with photopatterned anisotropic swelling using BDDE and glycidyl 
methacrylate, but only the physicochemical and mechanical properties were evaluated. 
Besides the limited number of studies with HA-BDDE, as far as we know, there is 
none report in the literature on the use of HA-BDDE associated to PRP for applications 
in tissue regeneration.  
  
 
7.2. Experimental Section  
 
7.2.1. Materials 
HA in sodium form (MW = 2 x 106 Da) was obtained from Spec-Chem Ind. 
(Nanjing, China). 1,4-Butanediol diglycidyl ether (BDDE) was obtained from Aldrich 
Chemical Co. (Milwaukee, WI, USA). All other reagents were purchased from Synth® 
(Diadema, SP, Brazil) unless specified otherwise. PRP was prepared from whole blood 
(WB) of donors, who were healthy individuals aged between 30 and 40 years old and 
previously assessed through clinical examinations. The human adipose tissue-derived 
mesenchymal stem cells, h-AdMSCs, were provided by Haematology and Hemotherapy 
Center, Umbilical Cord Blood Bank, University of Campinas. All biological experiments 
were approved by the Ethics Committee of the Medical Sciences School of the 
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University of Campinas (UNICAMP; CAAE: 0972.0.146.000-11). 
 
7.2.2. Methods 
7.2.2.1. Preparation and characterization of HA crosslinked with BDDE 
The plain hydrogel of HA/BDDE was prepared in a 1:1 ratio by weight, according 
to the methodology described by Wang (2005). Sodium hyaluronate was dissolved in 
0.25 mol.L-1 NaOH aqueous solution in a stirrer vessel at room temperature for 4 hours. 
BDDE was added to the solution under stirring, and then the solution was kept at 50°C 
for four hours. Then, phosphate buffer saline solution (PBS, pH 7.4) (LB Laborclin, 
Pinhais, PR, Brazil) was added to the stirrer vessel to wash and hydrate the obtained 
gel. After 2.5 days, washing with six changes of fresh PBS, the gel was centrifuged to 
remove free PBS. The HA-BDDE crosslinking was characterized by Fourier-transform 
infrared (FTIR) in a Thermo Scientific Nicolet model 6700 (Thermo Scientific Nicolet™, 
Waltham, MA, USA). Measurements were made in the ATR mode with accessory 
SMART OMNI-SAMPLER, in the spectral range of 4000-675 cm-1 with a resolution of 4 
cm-1 over 64 scans.  
 
7.2.2.2. Preparation of structured HA-BDDE 
The HA-BDDE structured in microparticles (mHA-BDDE) or sponges (sHA-BDDE) 
were prepared from HA-BDDE plain hydrogel swollen in Milli-Q water. The 
microparticles were obtained by shearing in an Ultra-Turrax T25 homogenizer (IKA 
Labortechnik, Staufen, Germany) at 18,000 rpm by 20 minutes (Shimojo et al., 2013). 
The sponges were initially placed in polystyrene 48-well microplates (TPP®, 
Trasadingen, Switzerland), frozen at -20°C and lyophilized at controlled temperature of 
approximately -30°C for 48 hours (Shimojo et al., 2015). Non-crosslinked sponges (sHA) 
was also prepared as control, as well as fluid HA (fHA).  
 
7.2.3. Characterization of the structures 
Degradation time. The gravimetric method described by Tang et al. (2007) was 
used to estimate the degradation time in PBS at 37°C of the structured HA-BDDE 
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through measurements of remaining weight. 
 
Cell compatibility. The compatibility of the structured HA-BDDE with h-AdMSCs 
cells was carried out by exposing them to cell culture at 37°C for 24 hours. Then, cell 
viability was evaluated by using an MTT assay (3-[4,5-dimethyl-thiazol-2-yl]-2,5-
diphenyltetrazolium bromide) (MTT, Molecular Probes), according to modified Mosmann 
(1983) method. The MTT assay is a colorimetric test based on the reduction of yellow 
tetrazolium salt into a purple formazan product in presence of cells (Gümüsşderelioğlu & 
Aday, 2011). 
 
7.2.3.1. mHA-BDDE 
Average diameter. The average diameter was measured for the mHA-BDDE 
suspended in water. The measurements were performed in a Malvern Mastersizer S 
laser diffraction (Malvern Instruments Ltd, Malvern, UK). The standard deviation was 
calculated from five consecutive measurements. 
 
Rheology. Rheological measurements of mHA-BDDE were performed in steady 
and oscillatory regimes at 25°C using a parallel plate geometry of 20 mm. Steady shear 
measurements were obtained at shear rates of 0.1-50 s-1. Oscillatory measurements 
were conducted in the linear region with a stress of 1.188 Pa and in the frequency range 
of 0.01 to 10 Hz. All rheological measurements were performed using the swollen mHA-
BDDE equilibrated in Milli-Q on a rheometer Haake RheoStress 1 (Haake, Karlsruhe, 
Germany). 
 
Extrusion force. Initially the mHA-BDDE were loaded in 1 mL plastic syringes with 
30 gauge needles. Afterward, the force required to extrude was measured in a MTS 810 
Servo-hydraulic Universal Testing Machine (MTS Systems Corporation, Eden Prairie, 
MN, USA) (load cell 1.5 kN) at 25°C at a 5.0 mm/min extrusion rate. 
 
Swelling ratio (SR). Swelling measurements of the HA-BDDE microparticles were 
performed in PBS at 37°C after 72 h of incubation, according to Shu et al. (2004). SR 
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was calculated using the following Equation (1). 
 
SR =
Ws
Wd
                                                                                                            Equation (1) 
 
where ws and wd are the weights of the scaffolds in the swelled state and the dry state, 
respectively. 
 
7.2.3.2. sHA-BDDE 
Morphology and pore size. The morphology of sHA-BDDE was evaluated by 
scanning electron microscopy (SEM) using an LEO 440i Electron Microscopy/Oxford 
(Cambridge, England) operated at 5 kV accelerating voltage. The sponges were gold-
coated using a sputter coater POLARON SC7620, VG Microtech (Uckfield, England) for 
180 s at a current of 3 mA. Pore size (n=20) was measured using Image J 1.47t. 
 
Swelling ratio (SR). The swelling measurements of the HA-BDDE sponges was 
determined by swelling the freeze-dried HA-BDDE sponges (with known weights) in 
PBS at 37°C for 24 hours. The swollen HA-BDDE sponges were weighed after the 
removal of excess of water by keeping the surfaces on a filter paper. The swelling ratio 
was also calculated using Equation (1). 
 
Porosity. The porosity (ε) of the sHA-BDDE was determined according to the 
protocol used by Wang et al. (2003), and calculated by Equation (2). 
 
ε (%) =  
Vm−(
Wm
ρ
)
Vm
 . 100                                                                                      Equation (2) 
 
where 𝑉m is the total volume of sHA-BDDE (cm3), ρ is the density of HA (1.0016 g/cm3) 
and wm is the weight of sHA-BDDE (g). Values are expressed as the mean ± standard 
deviation (n=3). 
 
Mechanical Properties. Mechanical compression tests of sHA-BDDE (𝑛 = 3) were 
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performed using a Universal Testing Machine, MTS model 810-Flex Test 40 (MTS 
Systems Corporation, Eden Prairie, MN, USA) up to 60% strain, according to Correia et 
al. (2011). The testing machine was equipped with a 1.5 kN load cell, and the loading 
rate was 5 mm/min. Young’s modulus was calculated in the initial linear section of the 
stress-strain curve, when the strain was lower than 10%.  
 
7.2.4. PRP preparation and activation 
The P-PRP (rich in platelets and poor in leukocytes) was prepared according to 
Perez et al. (2013). Briefly, whole blood (WB) was collected into 3.5 mL vacuum tubes 
(Vacuette®, Campinas, SP, Brazil) containing sodium citrate 3.2% (w/v) as an 
anticoagulant. WB was initially centrifuged in a Rotina 380R centrifuge (Hettich® 
Zentrifugen, Tuttlingen, Germany) at 100  g for 10 minutes, at 25°C, After the formation 
of three layers (a bottom layer composed mainly of red blood cells (RBCs); an upper 
layer composed of plasma, platelets and some WBCs; and an intermediate layer, or 
buffy coat, composed mostly of WBCs), only the upper layer was collected to obtain P-
PRP. The concentration of platelets, WBCs and RBCs in WB and P-PRP was 
determined using the ABX Micros ES 60 hematology analyser (HORIBA ABX 
Diagnostics, Montpellier, France). 
Autologous serum (Ser) and 10% (w/v) CaCl2 solution were used as agonists to 
activate the PRP preparations (aP-PRP). The Ser was prepared by collecting 5 mL of 
WB in tubes without anticoagulant. After 30 minutes for clot formation, WB was 
centrifuged at 2000  g for 10 minutes The conditions of agonist/PRP=20%; Ser/CaCl2 
volumetric ratio=9 were used for getting an architecture of the fibrin network composed 
of thin fibers (average radius 65 nm), according to Perez et al., 2014).  
 
7.2.5. Release of growth factors  
Immediately after activation, aP-PRP was mixed with the mHA-BDDE or 
embedded by dripping into the sHA-BDDE, both in 48-well microplates. In all biological 
assays performed in this work, the following proportions of aP-PRP to structured HA-
BDDE were used: aP-PRP: microparticles = 200 µL:100 mg and aP-PRP: sponges = 
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200 µL:10 mg in order to guarantee the same proportion PRP to HA. After 1 hour of 
gelation, 1.5 mL of Dulbecco's Modified Eagle's Medium (DMEM) (Gibco, Grand Island, 
NY, USA) with low glucose concentration was added to the composed hydrogels. The 
microplates were maintained in an incubator with 5% CO2 over the assays. After 
sampling, the volume was replaced with fresh medium at 3, 6, 12, 48 and 72 hours 
without removing the hydrogels from the wells. The samples were stored at -80°C until 
all samples were collected. The concentrations of the released GFs, platelet-derived 
growth factor AB (PDGF-AB) and transforming growth factor beta 1 (TGF-β1), were 
measured using enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, 
Minneapolis, MN, USA) according to the manufacturer’s instructions and specifications. 
 
7.2.6. Association of mHA-BDDE or sHA-BDDE with P-PRP and h-
AdMSCs-seeding 
The pre-cultured h-AdMSCs were trypsinized and resuspended in P-PRP to a 
final cell concentration of 1 x 104 cells/mL. P-PRP containing h-AdMSCs was activated 
and immediately pipetted onto the surface of the microparticles or embedded into the 
sponges, both in 24-well tissue culture plates. The plates were kept at room temperature 
for 45 minutes for consolidation of the fibrin network. The cells seeded in fHA or in sHA 
were used as controls.  
 
7.2.7. h-AdMSCs cultivation 
Cultivation of the h-AdMSCs was carried out in 24-well tissue culture plates, by 
adding 1 mL of the culture medium (DMEM) to the seeded structures (n=4). The culture 
was maintained at 37°C for 10 days. Cell proliferation was quantified using the thiazolyl 
blue tetrazolium bromide (MTT) assay. At 2, 4, 7 and 10 cultivation days, the substrates 
were removed and transferred to 24-well plates. MTT (1 mL of 1 mg/mL) was then 
added, and the cultivation proceeded at 37°C for 4 hours. The MTT solution was then 
discarded, and 1 mL of DMSO was added to dissolve the purple formazan crystals. The 
samples were shaken at 120 rpm for 30 min to ensure homogeneous dissolution of the 
formazan dye, and then 200 µL of each sample was transferred to a 96-well plate. 
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Optical density was measured at 595 nm using a microplate reader (FilterMax F5 
Molecular Devices, Sunnyvale, CA, USA). The cell concentration was obtained from the 
previously built calibration curve.  
 
7.2.8. Images of the cell-seeded composite scaffolds 
Images of cell-seeded composite scaffolds were obtained by scanning electron 
microscopy after 5 days of h-AdMSCs proliferation. The substrates were fixed in a 
solution of 4% paraformaldehyde and 2.5% glutaraldehyde in PBS for 2 hours. The 
samples were than dehydrated in ethanol for 15 min intervals in aqueous 50%, 70%, 
95% and 100% ethanol solutions (2x) and dried at the critical point dryer BAL-TEC CPD 
030 (BAL-TEC®, Schalksmühle, Germany). After gold coating in a Sputter Coater 
POLARON, SC7620 (VG Microtech, Ringmer, UK), the samples were visualized with a 
scanning electron microscope Leo440i (LEO Electron Microscopy/Oxford, Cambridge, 
UK) with an accelerating voltage of 20 kV. 
 
7.2.9. Induction of osteogenic differentiation 
The seeded h-AdMSCs were induced to differentiate into the osteogenic lineage 
by providing the osteogenic medium containing DMEM-LG supplemented with 10% 
FBS, 1% β-glycerol-phosphate (Sigma-Aldrich, St. Louis, MO, USA), 1% L-ascorbic acid 
(Sigma-Aldrich, St. Louis, MO, USA), 1% dexamethasone (Sigma-Aldrich, St. Louis, 
MO, USA) and 1% Penicillin/Streptomycin solution (Gibco, Grand Island, NY, USA). The 
medium was changed every 7 days.  
 
7.2.10. Alkaline phosphatase activity (ALP) 
The level of alkaline phosphatase (ALP) activity produced by h-AdMSCs was 
determined as an osteogenic marker on day 14 under differentiation conditions. Two 
hundred microliters of the supernatant was collected and mixed with 200 μL of p-
nitrophenyl phosphate (SIGMAFAST™ p-Nitrophenyl phosphate Tablets, Sigma, Saint 
Louis, MI, USA) as substrate and incubated at room temperature for 30 minutes. 
Absorbance was read immediately on a spectrophotometer at 405 nm. 
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7.2.11. Statistical analysis 
Each experiment was carried out in triplicate unless otherwise specified. All 
results are presented as the mean ± standard deviation (SD). The experimental data 
from all the studies were analyzed using Analysis of Variance (ANOVA). Statistical 
significance was set to p-value ≤ 0.05.  
 
7.3. Results and Discussion 
 
7.3.1. Experimental design 
In this study, we associated P-PRP to HA-BDDE structured into microparticles or 
sponges. First, the synthesized HA-BDDE was characterized by FT-IR to guarantee the 
absence of toxics non-bound chemicals before building the microparticles or sponges. 
Secondly, the structural and mechanical properties of the structured HA-BDDE were 
characterized and evaluated for cell compatibility. The association was obtained by 
mixing the microparticles or embedding the sponges with immediately activated P-PRP 
in a 24 well microplates. P-PRP was obtained by centrifugation to about twice the 
concentration relative to WB. Activation of P-PRP was performed by Ca+2 and 
autologous serum to obtain fibrin network architectures with thin fibers and an average 
radius of approximately 65 nm. This type of fiber favors proliferation of h-AdMSCs due to 
its paracrine nature for the cells. The release of the GFs (PDGF-AB and TGF-β1) was 
evaluated in DMEM culture medium. Cell seeded in the fibrin network alone or 
associated with HA-BDDE structured into microparticles or sponges was obtained by 
adding pre-cultured h-AdMSCs to P-PRP before activation. An in vitro examination of 
kinetics of h-AdMSCs proliferation was determined after 10 days of cultivation, whereas 
ALP activity as an osteogenic marker was evaluated under differentiation conditions 
after 14 days of cultivation. 
 
7.3.2. Chemical modifications  
The chemical modifications of HA crosslinked with BDDE were identified in FTIR 
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spectra of the HA-BDDE by the characteristic peak for BDDE appearing in 1310 cm-1, 
which was attributed to the stretch ether (νC-O, 1320-1100 cm-1) and in 1460 cm-1 
attributed to CH2 deformation (Silverstein et al., 1974; Kim et al., 2014). These results 
ensure the absence of free BDDE before structuring in microparticles or sponges. 
 
7.3.3. Physicochemical and mechanical properties of HA forms  
At physiological pH, the HA and its derivatives are hydrated extensively by water 
because the water forms hydrogen bonds with the N-acetyl and carboxyl groups. The 
dipole attraction of the hydrogen bond to the carboxyl group results in HA’s affinity for 
retaining water. The swelling capacity is dependent upon concentration, crosslinking 
density, and the processes used for hydration.  
The crosslinking reduced the water swelling in the HA-BDDE structures providing 
stability to HA (highly soluble), although they still exhibit high levels of water uptake, as 
shown in Table 4 by the SR values: 43.2 ± 0.7 (sHA-BDDE) and 28 ± 2 (mHA-BDDE). 
The larger hydration capacity of the sponges was attributed to its porous structure, 
which can retain unbound water (Collins & Birkinshaw, 2008; Shimojo et al., 2014).  
 
Table 4. Physicochemical and mechanical properties of HA in the forms: free (fHA), 
structured in sponge (sHA), crosslinked with BDDE and structured in sponges (sHA-
BDDE) or microparticles (mHA-BDDE). 
HA form* SR Young’s moduli 
(kPa) 
G’ (Pa) 
at 1 Hz 
Extrusion force 
(N) 
Pore Size 
(µm) 
Porosity (%) Particle size 
(µm) 
fHA - - * 4.3 ± 0.1 - - - 
sHA - <10 - - - 97.8 ± 0.3 - 
sHA-BDDE 43.2 ± 0.7 14 ± 5 - - 218 ± 24 97.4 ± 0.1 - 
mHA-BDDE 28 ± 2 - 3181 78 ± 7 - - 160 ± 18 
*Forms prepared from 1% fHA. 
**Newtonian behavior. 
 
The stability in PBS of the structures was studied by means of gravimetric 
analyses in terms of remaining weight up to 14 days incubation [Figure 36(a)]. Most of 
the weight reduction (~40%) of HA-BDDE sponges was observed until the seventh day, 
whereas most of the weight reduction (~40%) of HA-BDDE microparticles was observed 
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in the third day. The sHA did not retain their shape during incubation becoming a 
viscous gel.  
We also evaluated the cytotoxicity of HA-BDDE structures by MTT method 
[Figure 36(b)]. The results showed that the HA-BDDE structures exhibit a good 
compatibility to the cells, not only because the proliferation was greater than the positive 
toxicity control (PTC), but it was also significantly higher than positive control NTC 
(p<0.05). 
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(a) (b) 
Figure 36. (a) The weight remaining of the HA-BDDE structures under the time course 
of degradation (At 37°C, in PBS). (■) sHA-BDDE and (□) mHA-BDDE. (b) Viability of h-
AdMSC exposed to the HA-BDDE structures, sHA and fHA for 24 hours. Negative 
control (NTC) = DMEM with 10% FBS; positive control (PTC) = DMEM with phenol 
0.5%. Mean ± standard deviation n = 3. The population means are significantly different 
from positive control at p<0.05.  
Due to the nature of the assay, the higher cell number for mHA-BDDE could be 
justified due to their greater surface area available for cell adhesion compared to fHA. 
Moreover, the fewer number of cells for sHA-BDDE may indicate limitations in cell 
migration due to the porous structure created by the crosslinking. 
 
7.3.3.1. mHA-BDDE  
The mHA-BDDE [Figure 37(a)] exhibited typical gel-type mechanical spectra, with 
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G’ higher than G” in all studied ranges and both moduli lying parallel to the frequency 
axis (Ikeda & Nishimari, 2001).  
The shear viscosity spectra of HA-BDDE showed a pseudoplastic behavior 
[Figure 37(b)], while fHA 1% is a Newtonian fluid. The pseudoplastic behavior is an 
important parameter in injectable applications, where the flow viscosity should be lower 
than the rest viscosity.  
0.1 1 10
1
10
100
1000
10000
 
 
G
' 
a
n
d
 G
"
 (
P
a
)
Frequency (Hz)
 
0.1 1 10
0.1
1
10
100
1000
10000
 
 
V
is
c
o
s
it
y
 (
P
a
.s
)
Shear rate (s
-1
)
 
 
(a) (b) 
Figure 37. (a) Oscillation spectrum of mHA-BDDE and mHA-BDDE/aP-PRP. (■) aP-
PRP; (▲) mHA-BDDE; ( ) mHA-BDDE/aP-PRP 2:1; (●) mHA-BDDE/aP-PRP 1:1; (♦) 
mHA-BDDE/aP-PRP 1:2. G’ (closed symbol) and G” (open symbol). (b) Shear viscosity 
spectra of (▲) fluid HA (1% wt.) and (■) mHA-BDDE. 
 
The microparticles showed a mean diameter (Table 4) around 160 μm, which is 
adequate for an injectable application (<700 μm) (Shimojo et al., 2013; Kablik et al., 
2009).  
G’ values were around 3000 Pa in 1 Hz that are out of the adequate range (100-
700 Pa) for injectable application. Therefore, they should be dispersed in a fluid phase 
or to have the crosslinking degree decreased to fit in the required range (Shimojo et al., 
2013; Kablik et al., 2009). 
In addition to viscoelasticity, the injectable scaffolds must have an extrusion force 
to allow their easy injection through an appropriately sized needle (27-30 g needle) and 
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thereby prevent side effects such as pain (Shimojo et al., 2013; Kablik et al., 2009). The 
crosslinking increased the extrusion force of HA-BDDE (78 ± 7 N) compared to fHA 1% 
(4.3 ± 0.1 N) as expected (Table 4), however, it was not adequate for injectable 
applications (<20 N) (de Melo et al., 2012; Öhrlund et al., 2010).  
Thus, the G’ and extrusion force values obtained indicated the need to adjust the 
formulation for injectable application by adding a fluid phase and/or decreasing the 
degree of crosslinking (Shimojo et al., 2013). 
In this work, we utilized aP-PRP in different volumetric ratio as fluid phase. We 
observed that the addition of the activated P-PRP maintained the pseudoplastic gel-type 
behavior of composite and adequate the rheological properties with reduction of G’, as 
required. The volumetric ratio mHA-BDDE/aP-PRP 1:2 was more suitable for fit the 
requirements for injectable application. (G’ in 1Hz = 503 Pa). This volumetric ratio was 
maintained in the biological assays. 
 
7.3.3.2. sHA-BDDE  
The results of compression test (Table 4) showed that the crosslinking improved 
to mechanical resistance of the sHA-BDDE compared to non-crosslinked sHA. The 
Young’s modulus value (~14 kPa) was higher for the sHA-BDDE than for the sHA with 
the same porosity (~97%).  
The porosity is also an important aspect of cell migration and proliferation, 
guiding and promoting the formation of new tissue. A porosity higher than 90% and pore 
interconnectivity are basic requirements for scaffolds in tissue engineering because they 
affect the diffusion of physiological nutrients and gases to and the removal of metabolic 
waste and by-products from cells that have penetrated the scaffold (Leong et al., 2003; 
Liu & Ma, 2004). The porosity values of sHA-BDDE and sHA obtained in this study, both 
around 97%, are adequate for tissue, engineering, particularly for bone tissue. 
The cross-section morphologies of sHA-BDDE and sHA obtained by SEM are 
shown in Figure 38. In both cases, highly porous structures were formed, confirming the 
determined values for porosity in Table 4. However, the structure of HA-BDDE sponges 
has more open round pores [Figure 38(a)], whereas the sHA has a leaf structure [Figure 
38(b)].  
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(a) 
 
 (b) 
Figure 38. Scanning electron micrographs. Cross-section morphologies of (a) HA-BDDE 
scaffold and (b) sHA.  
 
Although there is a large distribution of sizes, sHA-BDDE showed pores around 
200 μm, which is adequate for regeneration of hard tissues (Salgado et al., 2004). 
Moreover, because human adipose tissue-derived mesenchymal stem cells (h-AdMSCs) 
exhibit a spindle-like shape and are 80–100 μm in diameter and ~200 μm in length, the 
range of pore sizes in sHA-BDDE allows cells to migrate freely into the scaffolds, 
favoring the formation of a new tissue (Chavez-Munoz et al., 2013). 
These values were slightly larger than the ones reported by La Gatta et al. (2013) 
(70-130 µm) for the matrices crosslinked with comparable equivalents of BDDE. This 
difference may be due to the differences in processing conditions that used 
heterogeneous conditions for preparation. 
 
7.3.4. Effects of the association with P-PRP  
7.3.4.1. SEM images 
SEM images (Figure 39) shows the activated P-PRP associated to HA-BDDE 
form a composite scaffold with the fibrin network formed inside the microparticles or 
sponges.  
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Figure 39(b) also shows a cluster of cells on the fibrin fibers.  
  
(a) (b) 
  
(c) (d) 
Figure 39. Scanning electron microscopic images of aP-PRP/HA-BDDE scaffolds after 
5 days of cultivation of h-AdMSCs. Microparticles: (a) magnification of 2,500X and (b) 
magnification of 10,000X. Sponges: (c) magnification of 1,000X and (d) magnification of 
10,000X.  
 
 
7.3.4.2. Release of growth factors 
The release kinetics of PDGF-AB and TGF-β1 from the structured HA associated 
with activated P-PRP in DMEM are shown in Figure 40.  
The curves show parallel diffusive profiles, indicating no collapse of the structure 
during the assays. The maximum TGF-β1 and PDGF-AB release was not observed up 
to 72 hours of assay.  
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For PDGF-AB, we observed a slower release from P-PRP/HA-BDDE than from P-
PRP alone for the first 48 hours. For TGF-β1, we did not observe significant differences 
in the release profiles during the assay time. 
The release of the most of GFs occurred in agreement with the degradation time 
of the scaffolds as could be observed in Figure 40 and Figure 36(a).  
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Figure 40. Growth factor release profile from PRP combined with HA-BDDE scaffolds. 
PDGF-AB (a) and TGF-β1 (b). (■) PRP activated with serum/Ca+2 was used as control; 
(●) sHA-BDDE; (▲) mHA-BDDE. The GFs were measurements from activated P-PRP 
containing average platelet concentration 495,000 pq/mm3.  
 
7.3.4.3. Proliferation of h-AdMSCs and ALP activity 
The kinetic profiles of proliferation were determined for h-AdMSCs cultured in the 
presence of composite scaffolds in 10 days, in comparison with fHA and the activated 
PRP alone [Figure 41(a)].  
At a macroscopic observation, the scaffolds appeared homogeneously colored 
after the MTT treatment at each tested time thus supporting the presence of living and 
metabolically active cells. The cell number per well determined after 2 days exceeded 
the number of seeded cells (1.4 x 104 cells/ well) in the structures associated to PRP, 
meaning that the cells kept in the matrices retained their viability.  
Although the cell proliferation was not intense in the composite scaffolds, it was 
higher than in fHA. The association of PRP with the structures reduced cell proliferation, 
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compared with the fibrin network (activated PRP alone), mainly for the crosslinked mHA-
BDDE and sHA-BDDE. 
In counterpart, the structured HA promoted the ALP activity [Figure 41(b)], an 
early osteoblastic marker, which reflected both the population of viable cells and the cell 
differentiation. The ALP activity was remarkable in mHA-BDDE. Although the necessity 
of determining other factors, the ALP activity points out to the structured HA associated 
to PRP is promising for osteogenic regeneration. 
These results point to the opposite directions of the proliferation and ALP activity, 
which require more detailed studies regarding its mechanisms in the presence of growth 
factors and the composite scaffolds. 
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Figure 41. (a) Kinetic proliferation profiles of h-AdMSCs seeded in aP-PRP/HA-BDDE 
scaffolds structured in sponges and microparticles. aP-PRP was used as control. The 
concentration of platelets in P-PRP was 273,000 pq/mm3. (b) ALP activities of cells 
cultured on aP-PRP/HA-BDDE scaffolds structured in sponges and microparticles 
(statistically significant differences from blank, n=3, *p<0.05). Blank = the colorimetric 
reagent used in the assay only. The concentration of platelets in whole blood donors 
(average of 2 donors) was 468,500 pq/mm3. 
 
7.4. Conclusions 
 
Novel composite scaffolds were prepared from hyaluronic acid crosslinked with 
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1,4-butanediol diglycidyl ether and structured in sponges and microparticles, in 
association with activated platelet-rich plasma. The crosslinked structures improved the 
physicochemical, mechanical and biological properties as compared to free hyaluronic 
acid. Thus, our results provide evidences that the composite scaffolds are promising 
biomaterials for future clinical use in tissue engineering, with perspectives for osteogenic 
regeneration. The flexibility to obtain injectable formulations (microparticles) or solid 
sponges expands their applications.  
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Abstract. This work aimed to evaluate the effects of UV irradiation, plasma radiation, 
steam and 70% ethanol treatments on the sterilization and integrity of auto-crosslinked 
hyaluronic acid (HA-ACP) structured in microparticles or sponges. The integrity of the 
microparticles was characterized by rheological behavior, while for the sponges it was 
characterized by scanning electron microscopy, Fourier transform infrared spectroscopy 
and differential scanning calorimetry. The effectiveness of the sterilization treatment was 
verified by count of microorganism colonies in the samples after the treatments. In 
conclusion, plasma radiation was the best treatment for the sponges, while steam 
sterilization in autoclave at 126°C (1.5 kgf/cm2) for 5 minutes was the best one for the 
microparticles. 
 
Key Words: auto-crosslinked hyaluronic acid, sterilization, plasma radiation, steam, UV 
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irradiation, ethanol treatment. 
 
8.1. Introduction 
Hyaluronic acid (HA) and its crosslinked derivatives have been widely used as 
scaffolds for tissue engineering (Collins and Birkinshaw, 2013; Unterman et al. 2012). 
Sterilization is of fundamental importance for storage as well as for in vitro and in vivo 
applications. 
Several sterilization methods have been used for the sterilization of natural 
polymers structured as scaffolds for cell culture. These methods use dry heat, high-
pressure vapor, ethylene oxide gas, supercritical carbon dioxide or radiation treatments 
(Danillof et al. 2009). An efficient treatment must provide sterility to the scaffold 
preserving its structure (Faraj et al. 2011). 
HA and its crosslinked derivatives are heat-sensitive and sensible to γ-rays, 
presenting chemical degradation and depolymerisation with a decrease of molecular 
weight average (Rehakova et al. 1994). Besides degrading effects, the porous structure 
of scaffolds can be destroyed because of plastic deformation from the heat treatment 
(Plikk et al. 2006). 
Moreover, since scaffolds usually have a porous structure, a sterilization method 
must penetrate materials without leaving residues (Siritientong et al., 2011; Plikk et al. 
2002). 
In this study, we evaluated the effects of different treatments (70% ethanol; UV 
irradiation; plasma radiation and steam) on sterilization and the integrity of auto-
crosslinked hyaluronic acid (HA-ACP) structured in microparticles or sponges. The 
integrity of the microparticles was characterized by rheological behavior, while for the 
sponges it was characterized by scanning electron microscopy, Fourier transform 
infrared spectroscopy and differential scanning calorimetry. The effectiveness of the 
sterilization method was verified by colonies counts of microorganisms after the 
treatments. 
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8.2. Materials and Methods 
8.2.1. Materials 
HA in sodium form (MW = 2 x 106 Da) was obtained from Spec-Chem. Ind. 
(Nanjing, China). All other reagents were purchased from Synth® (Diadema, SP, Brazil) 
unless specified otherwise.  
 
8.2.2. Methods 
8.2.2.1. Preparation of the HA-ACP scaffolds  
HA-ACP preparation. The auto-crosslinked HA was prepared by an 
autoesterification reaction according to protocol described by Bellini et al. 2001. HA-TBA 
(tetrabutylammonium hyaluronate) with a molecular weight of approximately 2 x 106 Da 
and corresponding to 10 mEq of monomeric units was solubilized in 50 mL of 
dimethylsulfoxide (DMSO) at 25°C. Triethylamine (0.5 mEq) was added and the 
resulting solution was agitated for 30 minutes. A solution of 2-chloro-1-methyl pyridinium 
iodide (CMPI) (0.5 mEq) (Sigma-Aldrich, St. Louis, MO, USA) in 15 mL of DMSO was 
slowly added drop by drop over 1 hour and the mixture was kept at 30°C for 15 hours. A 
solution of sodium chloride 2.5% (w/v) was then added and the resulting mixture was 
poured slowly into 150 mL of acetone, maintaining continual agitation. The formed 
precipitate was centrifuged at 10,000 rpm for 10 minutes, washed three times in 100 mL 
of 5:1 acetone: water and three times with 100 mL of acetone and vacuum-dried for 24 
hours at 30°C.  
 
Preparation of structured HA-ACP scaffolds. The HA-ACP scaffolds structured in 
microparticles (mHA-ACP) or sponges (sHA-ACP) were prepared from plain HA-ACP 
swollen in Milli-Q water. The microparticles were obtained by shearing in an Ultra-Turrax 
T25 homogenizer (IKA Labortechnik, Staufen, Germany) at 18,000 rpm by 20 minutes, 
according to Shimojo et al. 2013. For preparation of the sponges, the microparticles 
were initially placed in polystyrene 48-well microplates (TPP®, Trasadingen, 
Switzerland), frozen at -20°C and lyophilized at controlled temperature of approximately 
-30°C for 48 hours. 
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8.2.2.2. Sterilization Treatments 
HA-ACP microparticles were submitted to UV-irradiation, plasma radiation, 
steam, 70% ethanol treatments, aiming sterilization or disinfection. HA-ACP sponges 
were submitted to the same treatments except to steam. Non-treated scaffolds were 
used as control. 
 
Ethanol Treatment. The HA-ACP scaffolds were disinfected with 70% (v/v) 
ethanol, according to Faraj et al. 2011. They were washed with 70% ethanol at ambient 
temperature for 3×1 h and 1×16 h. Thereafter, three short washings with sterile 
phosphate buffered saline (PBS) (pH 7.4) were performed with changes of washing fluid 
directly after one another, and finally 5×1 h and 1×16 h washings with PBS were 
performed. All washing changes were performed in a laminar flow cabinet. sHA-ACP 
was re-frozen at -20°C and lyophilized again.  
 
Plasma Irradiation. The scaffolds were evacuated and then, a pressure of 1 Torr 
was established with the introduction of argon (Ar) gas that combined with an electrical 
potential difference (EPD) create Ar plasma inside the chamber. This treatment was 
performed along 5 minutes. 
 
UV Irradiation. Irradiation was carried out with an ultraviolet lamp (Germetec, Rio 
de Janeiro, RJ, Brazil) at 254-nm wavelength at a distance of 5 cm (UV1) and at a 
distance of 60 cm (UV2). HA-ACP microparticles and HA-ACP sponges were irradiated 
for a total time of 30 min and were turned over halfway through the treatment to irradiate 
the top and bottom surfaces.  
 
Steam. Steam treatment was applied to the microparticles only. The treatment 
was achieved by wet heating at 126°C, under a vapor pressure of 1.5 kgf/cm2 for 1, 2.5, 
5, 10 and 15 minutes in autoclave. 
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8.2.2.3. HA-ACP sponges characterization 
Fourier-transform Infrared (FTIR). FTIR was used to identify possible chemical 
modifications on scaffolds resulting from sterilization processes. Infrared spectra were 
obtained using a Thermo Scientific Nicolet model 6700 (Thermo Scientific Nicolet™, 
Waltham, MA, USA). Measurements were made in the ATR mode with accessory 
SMART OMNI-SAMPLER, in the spectral range of 4000 – 675 cm-1 with a resolution of 4 
cm-1 over 64 scans.  
 
Scanning electronic microscopy (SEM). The morphology of HA-ACP sponges 
sterilized was evaluated by scanning electron microscopy (SEM) using an LEO 440i 
Electron Microscopy/Oxford (Cambridge, England) operated at 5 kV accelerating 
voltage. The scaffolds were gold-coated using a sputter coater POLARON SC7620, VG 
Microtech (Uckfield, England) for 180 s at a current of 3 mA.  
 
Differential scanning calorimetry (DSC). The thermal characterization of the 
scaffolds was achieved by DSC using a Mettler-Toledo DSC1 (Mettler Toledo Co., 
Zürich, Switzerland) module under a nitrogen atmosphere (nitrogen flow rate 50 mL/min) 
with a sample mass around 10 mg and a heating rate of 10°C/min.  
 
8.2.2.4. HA-ACP microparticles characterization 
Rheological properties. HA-ACP microparticles sterilized were evaluated by 
rheological properties. The measurements were performed on a Rheometer Haake 
model RheoStress 1 (Haake, Karlsruhe, Germany). The properties of the scaffolds were 
characterized in the steady and oscillatory regimes at 25oC, using a parallel plate 
geometry of 20 mm. Oscillatory measurements were conducted in the linear region, at a 
stress of 1.188 Pa and in the frequency range of 0.01 to 10 Hz. Steady shear 
measurements were obtained at shear rates of 0.1-50 s-1.  
 
8.2.2.5. Sterility Tests  
All the scaffolds were tested for sterility for heterotrophic bacterial, molds and 
yeasts, immediately following the treatments using a standard assay (Method 61, USP – 
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2012).  
 
8.3. Results and Discussion 
 
8.3.1. Effects of the treatments on physicochemical properties of the HA-
ACP sponges 
The effects of the treatments on HA-ACP sponges were evaluated by scanning 
electron microscopy (SEM), Fourier transform infrared spectroscopy (FTIR) and 
differential scanning calorimetry (DSC).  
The micrographs of sponges obtained by SEM (Figure 42) showed that except to 
ethanol disinfection [Figure 42(e)], the scaffolds remained their porous structure without 
major differences in morphology, regardless the treatments. Ethanol disinfection 
reduced substantially the porosity of HA-ACP sponge. Moreover, we observed loss in 
the scaffold shape by swelling after washing with PBS. 
   
(a) (b) (c) 
  
(d) (e) 
Figure 42. SEM cross-section images of HA-ACP sponges. (a) Unsterile; (b) UV (5 cm); 
(c) UV (60 cm); (d) Plasma and (e) Ethanol disinfection. Bar = 100 µm. 
 
Figure 43(a) shows the FT-IR spectra of HA-ACP sponges. The spectra showed 
bands at 1617 and 1413 cm−1 attributed to the asymmetric (C=O) and symmetric (C-O) 
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stretching modes of the planar carboxyl groups in the hyaluronate. The absorption 
bands at about 1650, 1561, and 1320 cm−1 are characteristic of the amide I, II, and III 
band, respectively. The weak absorption band around 1740 cm−1 was attributed to the 
stretching vibration of ester groups. The three signals centered at 1150, 1072, and 1040 
cm−1 were assigned to C-O-C (O-bridge), C-O (exocyclic), and C-OH group, 
respectively. The band at 945 cm-1 was assigned to asymmetrical out-of-phase ring 
vibration. 
The spectra of HA-ACP disinfected with 70% ethanol showed a band at 990 cm-1 
attributed to C-O of primary alcohols indicating ethanol residual in the structure. 
Therefore, except for the HA-ACP disinfected with 70% ethanol, the spectra were 
very similar indicating that their chemical structure did not change significantly with the 
treatments. 
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Figure 43. (a) FT-IR spectra and (b) DSC of HA-ACP sponges after the different 
treatments. (1) Unsterile; (2) UV irradiation (5 cm); (3) UV irradiation (60 cm); (4) plasma 
radiation and (5) ethanol disinfection. 
 
The effects of treatments on the thermal behavior of the sponges are shown in 
Figure 43(b). All the scaffolds showed the presence of a broad endothermic peak 
between 150 and 160°C associated with the loss of moisture remaining after the drying 
procedure. In addition, significant sharp exothermic peaks around 220 and 245°C were 
observed, which probably represent decomposition (Collins & Birkinshaw, 2008). We 
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consider, none significant changes in the thermal profiles after the treatments.  
 
8.3.2. Effects of the treatments on physicochemical properties of HA-ACP 
microparticles 
Initially, we evaluated the influence of the steam treatment in autoclave, at 126°C, 
under a vapor pressure of 1.5 kgf/cm2, on the rheological properties of HA-ACP 
microparticles. The rheological behavior determined by oscillatory and steady 
measurements are shown in Figure 44(a) and 44(b), respectively.  
We observe that until 5 minutes of steam treatment, the microparticles 
maintained the gel-like behavior, as analyzed by the storage (G’) and loss moduli (G”). 
(Ikeda & Nishimari, 2001). Moreover, considering the Ostwald de Waele power law 
(η=K.γn-1), the flow indices (n) indicate a viscoelastic behavior that is an important 
parameter in injectable applications where the flow viscosity should be lower than the 
rest viscosity. According to the curves, we should consider no significant differences on 
rheological behavior of the microparticles up to 5 minutes of autoclave.  
After the first 5 minutes of treatment, the mechanical spectra showed a crossover 
and due to very low viscosity, it was not possible to determine the flow curve using the 
parallel plate geometry previously used. Thus, these results indicate rheological 
behavior of solution and degradation of the structure.  
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Figure 44. Rheological characterization of HA-ACP microparticles after treatment in 
autoclave at 126°C, under a vapor pressure of 1.5 kgf/cm2 for: (■) 0 minute; (●) 1 
179 
 
minute; (▲) 2.5 minutes; (♦) 5 minutes; ( ) 10 minutes and ( ) 15 minutes. (a) 
Oscillation spectrum and (b) flow curves. G’ (closed symbol) and G” (open symbol) 
moduli. 
 
Figures 45a and 45b show the rheological behavior of the microparticles under 
UV1, UV2, plasma and 70% ethanol treatments. The G’ and G” profiles show that only 
the UV1 treatment, in which the ultraviolet lamp was at a distance of 5 cm from the 
sample, affected the rheological behavior of the microparticles [Figure 45(a)]. Moreover, 
there was a drastic decreased of shear viscosity [Figure 45(b)]. This behavior was 
attributed to degradation of HA by the high UV intensity due to the very small distance 
between the lamp and the sample. 
0.1 1 10
0.01
0.1
1
10
100
1000
10000
 
 
G
' 
a
n
d
 G
"
 (
P
a
)
Frequency (Hz)
 
0.1 1 10 100
1
10
100
1000
 
 
V
is
c
o
s
it
y
 (
P
a
.s
)
Shear rate (s
-1
)
 
(a)  (b) 
Figure 45. Rheological characterization of HA-ACP microparticles after the treatments: 
(■) untreated; (●) UV1; (▲) UV2; (♦) plasma and ( ) ethanol disinfection. (a) Oscillation 
spectrum and (b) flow curves. G’ (closed symbol) and G” (open symbol) moduli. 
 
8.3.3. Sterility evaluation  
Tables 5 and 6 show the results of the sterility test for the sponges and the 
microparticles, respectively. The counts of colonies indicated that 70% ethanol 
disinfection and UV2 treatment were the least effectives, while plasma radiation and 
UV1 were the most effective treatments for the sponges (Table 5). 
 
crossover 
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Table 5. Results of heterotrophic plate count (bacteria) and fungal count (molds and 
yeasts) obtained after treatment of HA-ACP sponges. 
 Heterotrophic Plate Count Fungal Count  
Treatment  Bacteria 
(CFU/mL) 
Molds 
(CFU/mL) 
Yeasts 
(CFU/mL) 
UV (1) - - - 
UV (2) ++ - ++ 
PLASMA - - - 
70% ETHANOL  + - + 
UNSTERILISED ++ + ++ 
*CFU=colony-forming units 
− no growth (detection limit=10 CFU/mL), + amount of microorganism below 1×104 CFU/mL, ++ amount of microorganism 
between 1×104 and 1×106 CFU/mL, +++ amount of microorganism between 1×106 and 1×108 CFU/mL. 
 
The results in Table 6 indicate that only steam sterilization in autoclave was 
effective for sterilization of the microspheres. 
 
Table 6. Results of heterotrophic plate count (bacteria) and fungal count (molds and 
yeasts) obtained after sterilization of HA-ACP microparticles.  
 Heterotrophic Plate Count 
 
Fungal count 
Time (minute) Bacteria 
(CFU/mL) 
Molds 
(CFU/mL) 
Yeasts 
(CFU/mL) 
S 
T 
E 
A 
M 
1 - - - 
2.5 - - - 
5 - - - 
10 - - - 
15 - - - 
UV (1) ++ + ++ 
UV (2) ++ ++ + 
PLASMA ++ ++ + 
70% ETHANOL  + - - 
UNSTERILISED ++ + ++ 
*CFU=colony-forming units. 
− no growth (detection limit=10 CFU/mL), + amount of microorganism below 1×104 CFU/mL, ++ amount of microorganism 
between 1×104 and 1×106 CFU/mL, +++ amount of microorganism between 1×106 and 1×108 CFU/mL. 
 
Comparing the effects of the treatments on the sterilization and physicohemical 
properties of the sponges and microparticles, our results showed that sterilization by 
plasma radiation was the most efficient treatment for sterilizing the auto-crosslinked 
hyaluronic acid sponges because it ensures the sterility and preserve their chemical 
composition and 3-D morphology. In contrast, the steam treatment in autoclave (at 
126°C, 1.5 kgf/cm2) up to 5 minutes was the method most adequate for sterilization of 
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the auto-crosslinked hyaluronic acid microspheres, because it did not change their 
rheological properties.  
 
8.4. Conclusion 
The sterilization by plasma radiation was the most efficient treatment for 
sterilizing the auto-crosslinked hyaluronic acid sponges, while the steam treatment in 
autoclave (at 126°C, 1.5 kgf/cm2) during 5 minutes was the most efficient treatment for 
the microspheres. Thus, these methods can be used for sterilization of ACP structured 
scaffolds. 
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CAPÍTULO 9 – CONCLUSÕES 
 
9.1. Conclusões 
 
Neste trabalho foram preparados e caracterizados os seguintes scaffolds 
compósitos de quitosana (CHT) e/ ou ácido hialurônico (AH) estruturados em esponjas 
(aP-PRP/PCHTs, aP-PRP/SPCHTs, aP-PRP/ACPs, aP-PRP/HA-BDDE e aP-
PRP/PECs) e micropartículas (aP-PRP/iCHT-TPPs, aP-PRP/ACPs, aP-PRP/HA-BDDE 
e aP-PRP/PECs).  
A efetividade in vitro dos scaffolds compósitos, foi avaliada através da cinética de 
liberação de fatores de crescimento (PDGF-AB e TGF-β1) do P-PRP em meio DMEM, 
proliferação e diferenciação de h-AdMSCs através do marcador osteogênico fosfatase 
alcalina (ALP). 
O desempenho individual dos scaffolds foi apresentado nos artigos e na patente 
que compõem este trabalho. 
Os resultados obtidos permitem as seguintes conclusões gerais:  
 Os polímeros naturais CHT e AH podem ser estruturados em esponjas ou 
micropartículas que atuam como scaffolds para o PRP em formulações sólidas 
(esponjas) ou fluidas injetáveis (micropartículas), com diferentes propriedades 
físico-químicas e mecânicas.  
 As esponjas apresentaram elevada porosidade (>90%), alto grau de 
intumescimento adequados para a migração e proliferação celular e resistência 
mecânica adequada ao manuseio e cultivo celular. 
 As micropartículas apresentaram propriedades reológicas e mecânicas 
adequadas para a injeção.  
 Para os scaffolds de CHT estruturados em esponjas, a estabilidade em termos 
de perda de massa com o tempo em PBS foi atribuída à presença de acetato 
residual, enquanto que nas micropartículas foi atribuída ao grau de reticulação. 
Nos scaffolds de AH, a estabilidade refletiu somente do grau de reticulação.  
 Todos os scaffolds preparados neste trabalho não apresentaram citotoxicidade. 
 Nas esponjas a rede de fibrina formou-se preferencialmente no interior dos 
poros, enquanto que nas micropartículas a partição da rede de fibrina entre o 
interior e a superfície das partículas foi dependente da sua rigidez, a qual é 
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função do grau de reticulação. 
 A liberação dos fatores de crescimento (PDGF-AB e TGF-β1) foi 
predominantemente difusiva em todos os scaffolds. A maior parte dos fatores 
(~80%) foi liberada nas primeiras 12 horas em concordância com a estabilidade 
dos scaffolds. 
 A proliferação de h-AdMSCs foi maior ou igual a do PRP para as esponjas de 
ambos os polímeros, exceto quando reticuladas com TPP (CHT) ou BDDE (AH). 
Nas micropartículas, a proliferação foi menor em relação ao PRP e dependente 
da dureza e grau de reticulação. 
 A capacidade das h-AdMSCs para a produção do marcador de diferenciação 
osteogênica ALP foi favorecida nas micropartículas em relação às esponjas.  
 A capacidade de diferenciação osteogênica apresentou uma tendência oposta à 
proliferação celular.  
 A radiação por plasma foi o processo mais adequado para a esterilização por 
das esponjas de ACP, enquanto que o tratamento com vapor em autoclave 
(126°C, 1,5 kgf/cm2), até 5 minutos foi o processo mais eficaz para as 
microesferas de ACP. 
Embora a reprodutibilidade de produção dos scaffolds e o cultivo celular possam 
ser bem controlados pelas condições operacionais, a comparação precisa do 
desempenho dos vários scaffolds é complexa por contemplar os fatores inerentes ao 
PRP, tais como a variabilidade da concentração de plaquetas e fatores de crescimento 
de diferentes doadores nos vários ensaios.  
Assim, concluímos que os scaffolds compósitos preparados neste trabalho são 
promissores para engenharia de tecidos, particularmente para a cicatrização e 
regeneração óssea, no âmbito da medicina regenerativa. 
 
9.2. Trabalhos Futuros 
 
 Minimização da variabilidade do PRP para uma precisa comparação do 
desempenho dos scaffolds. 
 Produzir e caracterizar scaffolds com diferentes tamanhos e formatos para 
ensaios pré-clínicos. 
 Estender os estudos realizados com P-PRP para o L-PRP (plasma rico em 
plaquetas e em leucócitos). 
 Estudar a influência das esponjas e micropartículas na ativação do PRP.  
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 Caracterizar as interações moleculares entre a rede de fibrina e os scaffolds. 
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ANEXO 1 
 
COMPOSIÇÃO E FORMULAÇÃO DE SCAFFOLDS DE ÁCIDO HIALURÔNICO E 
QUITOSANA PARA ASSOCIAÇÃO COM PLASMA RICO EM PLAQUETAS E SEUS 
USOS EM TERAPIA REGENERATIVA  
 
A presente invenção refere-se a scaffolds compostos de ácido hialurônico (AH) e 
quitosana (CHT) em formulações sólida ou fluida (injetável), para associação com 
plasma rico em plaquetas (PRP), em aplicações no campo da medicina regenerativa, 
mais especificamente no campo da ortopedia. Nas formulações sólidas os polímeros 
são estruturados em esponjas e nas formulações fluidas em micropartículas. A 
invenção baseia-se no fato de que a associação de PRP ao ácido hialurônico livre tem 
sido amplamente usado na clínica, em tratamento de lesões musculoesqueléticas. 
Ensaios in vitro mostraram que a estruturação do AH autorreticulado ou de quitosana 
estabilizada em esponjas ou micropartículas, promoveu a liberação gradual dos fatores 
de crescimento provenientes do PRP, estimulou a proliferação de células tronco 
mesenquimais humanas de tecido adiposo, assim como a osteogênese. A associação 
do PRP com os scaffolds melhorou a estabilidade da rede de fibrina, e a estruturação 
em esponjas ou micropartículas melhorou as propriedades mecânicas em relação aos 
polímeros livres. Entretanto, a elevada densidade de carga negativa do AH reduz a 
adesão celular que interfere na regeneração tecidual, enquanto que a elevada carga 
positiva da CHT pode resultar em danos celulares in vivo. Nesse contexto, a presente 
invenção que trata de scaffolds de AH autorreticulado e quitosana para associação com 
PRP evidencia que esses scaffolds constituem biomateriais para uso clínico que 
beneficiam as aplicações do PRP em terapia regenerativa.  
 
